AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 1 of 146 
CLINICAL TRIAL PROTOCOL  
Trial Title : Phase III, open -label, single -dose, multi -center multinational trial 
investigating a serotype 5 adeno- associated viral vector containing the 
Padua variant of a codon- optimized human factor IX gene (AAV5 -hFIXco -
Padua, AMT -061) administered to adult subjects with severe or moderately 
severe hemophilia B  
Short Title: Phase III  trial of AMT -061 in s ubjects with s evere or moderately severe 
hemophilia B . 
Protocol Identification:  CT-AMT -061-02 
EudraCT  No.: 2017 -004305 -40 
Name of Investigational Product:  AMT -061 ( AAV5 -hFIXco-Padua ; etranacogene dezaparvovec ) 
IND N o. 
Indication Studied:  Hemophilia  B 
Developmental Phase of Trial:  III 
Name of the Sponsor/Company:  CSL Behring LLC  
1020 First Avenue  
King of Prussia  
Pennsylvania 19406, USA  
Name of the Monitor ing CRO : Medpace  (with oversight by uniQure biopharma B.V.)  
Coordinating Investigator:  
Protocol Version and Date:  Version 8.0 (Amendment 7.0)  07 Feb 2022  
Version 7.0 (Amendment 6.0) 28 Jun 2021  
Version 6.0 (Amendment 5.0) 04 Feb 2021  
Version 5.0 (Amendment 4.0) 15 Oct 2020  
Version 4.0 (Amendment 3.0) 30 Aug 2019  
Version 3.0 (Amendment 2.0) 07 Dec 2018  
Version 2.0  (Amendment 1.0) 02 Apr 2018  
Version 1.0 (Original) 16 Feb 2018  
This trial, including the archiving, will be conducted in compliance with Good Clinical Practice (GCP) according 
to the International Council for Harmoni sation (ICH) Harmoni sed Tripartite Guideline (CPMP/ICH/135/95)  
Confidentiality statement  
This CSL Behring  document is confidential. The information within this document may not be reproduced or 
otherwise disseminated without approval of CSL Behring . CSL Behring 
PPD
CCI
AMT-061 (AAVS-hFIXco-Padua; etranacogcne dezaparvovec) 
Protocol ID: CT-AMT-061-02 CSL Behring 
CLINICAL TRIAL PROTOCOL SIGNATURE PAGE 
Sponsor's Approval 
--
Signature: 
 
 
, Clinical Development 
Venion: 8.0 CONFIDENTIAL 
Page 2 of 146 Date: 
Date: 07 Feb 2022 
PPD
PPD
PPD
PPD
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 3 of 146 
INVESTIGATOR’S ACKNOWLEDGEMENT  
I have read this  
Protocol ID : CT-AMT -061-02 
Title: Phase III, open- label, single -dose, multi- center multinational trial investigating a serotype 
5 adeno -associated viral vector containing the Padua variant of a codon-optimized human factor 
IX gene (AAV5 -hFIXco -Padua, AMT-061) administered to adult subjects with severe or 
moderately severe hemophilia B.  
I have fully discussed the objective s of this tr ial and the contents of this protocol with the 
Sponsor’s representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the trial, without written authorization from the Sponsor. It is, however, permissible to provide the information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this trial according to this protocol an d any trial specific manuals , to comply 
with its requirements, to subject to ethical and safety considerations and guidelines, and to 
conduct the trial in accordance with Inte rnational Council for Harmonisation guidelines on Good 
Clinical Practice and with  the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to termination of my participation as an Investigator for this trial.  
I understand that the Sponsor may decide to suspend or prematurely terminate the trial at any time for whatever reason; such a decision will be communicated to me in writing. Conversely, should I decide to withdraw from execution of the trial, I will communicate my intention 
immediately in writing to the Sponsor.  
Investigator Name, Address, and 
Telephone Number: 
(please handwrite, print or type)   
 
 
 
 
 
Signature:  
  
Date:   
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 4 of 146 
SUMMARY OF CHANGES  (PROTOCOL HISTORY)  
Current Protocol Amendment  
Summary of Change(s) Since Last Version of Approved Protocol : See Section  13.2 
Amendment Number:  
7.0 (Version 8.0)  Amendment Date:  
07 Feb  2022 Global/Country/Site -Specific:  
Global 
 
List of All Previous Amendments  
Summary of Change(s) for Previous Amendments: See Section  13.3 
Amendment Number  Date of Amendment  Global/Country/Site -Specific  
6.0 (Version 7.0)  28 Jun 2021  Global  
5.0 (Version 6.0)  04 Feb 2021  Global  
4.0 (Version 5.0)  15 Oct 2020  Global  
3.0 (Version 4.0) 30 Aug 2019  Global  
2.0 (Version 3.0)  07 Dec 2018  Global  
1.0 (Version 2.0)  02 Apr 2018  Global  
0.0 (Version 1.0)  16 Feb 2018  Global  
 
List of All Addendum  
Date of Addendum  Global/Country/Site -Specific  
27 Mar 2019  Germany  
27 Feb 2019  France  
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 5 of 146 
EMERGENCY CONTACT INFORMATION  
In the event of a serious adverse event ( SAE ) or an adverse event ( AE) qualifying for special 
notification , the Investigator must complete  the Clinical Trial Serious Adverse Events Form  in 
the electronic case report form ( eCRF ) within 24 hours of becoming aware of the event. In case 
the eCRF is temporarily unavailable, the back -up paper SAE form should be completed and 
submitted to CSL Behring within 24 hours of becoming aware of the event. 
CSL Global Clinical Safety & Pharmacovigilance : 
Email:   
Fax: USA :  
AUS:  
GER:  
 
For protocol- or medical -related issues during normal business hours as well as outside of normal 
business hours, the Investigator must contact both the Med pace and uniQure : 
Medpace : uniQure : 
 
 
 
  
 
 
 
 CSL Behring 
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 6 of 146 
TABLE OF CONTENTS  
1 INTRODUCTION  ...................................................................................................................................... 35 
1.1 Condition Background and Current Treatment  ...................................................................................... 35 
1.2 Gene Therapy Therapeutic Concept  ....................................................................................................... 36 
1.3 Investigational Product Background  ....................................................................................................... 36 
1.3.1  Preclinical Information  ..................................................................................................................... 36 
1.3.2  Preliminary Clinical Information for AMT -061 and Clinical Information for AMT -060 ................ 39 
1.3.2.1  Preliminary Clinical Evidence for Efficacy and Safety of Components of AMT -061 .............. 39 
1.3.2.2  Results of Clinical Trial- AMT -060-01 ..................................................................................... 43 
1.3.2.3  Interim Results for CT -AMT -061-01 ........................................................................................ 43 
1.4 Rationale for the Trial ............................................................................................................................. 44 
1.5 Risk/Benefit Considerations  ................................................................................................................... 46 
1.5.1  Risk of Infusion -related Toxicity  ...................................................................................................... 46 
1.5.2  Risk of Immune Mediated Neutralization of the AAV5 Gene Therapeutic Vector  .......................... 46 
1.5.3  Risk of Immune Mediated Liver Toxicity  ........................................................................................ 47 
1.5.4  Risks to Third Parties and the Environment Related to Shedding via Body Fluids  .......................... 48 
1.5.5  Risk of Vector DNA Integration into the Host Genome  ................................................................... 48 
1.5.6  Risk of Germ -line Transmission of Vector DNA  ............................................................................. 48 
1.5.7  Risk of Off -target  Expression of the Transgene ................................................................................ 49 
1.5.8  Risk of Inhibitor Formation to Protein Expressed from the Transgene  ............................................ 49 
1.5.9  Risk of Breakthrough Bleeding......................................................................................................... 49 
1.6 Accommodations Due to the COVID -19 Pandemic  ............................................................................... 50 
2 TRIAL OBJECTIVES  ............................................................................................................................... 51 
2.1 Primary Objective  ................................................................................................................................... 51 
2.2  
2.3 Safety Objectives  .................................................................................................................................... 51 
3 TRIAL DESIGN  ......................................................................................................................................... 52 
3.1 Overall Trial Design  ............................................................................................................................... 52 
3.1.1  Considerations Due to the COVID -19 Pandemic  ............................................................................. 54 
3.2 Trial Design Rationale  ............................................................................................................................ 54 
3.3 Trial Endpoints  ....................................................................................................................................... 55 
3.3.1  Primary Endpoint  .............................................................................................................................. 55 
3.3.2  Seco ndary Endpoints  ........................................................................................................................ 56 
3.3.3  Sub-study Endpoints  ......................................................................................................................... 60 
3.4 Sample Size ............................................................................................................................................ 60 
3.5 Sites and Regions  ................................................................................................................................... 60 
4 TRIAL POPU LATION .............................................................................................................................. 61 
4.1 Inclusion Criteria  .................................................................................................................................... 61 
4.2 Exclusion Criteria  ................................................................................................................................... 61 
4.3 Reproductive Potential  ........................................................................................................................... 63 
4.4 Restrictions  ............................................................................................................................................. 63 
4.5 Withdrawal of Subject from Therapy or Assessment  ............................................................................. 63 
4.5.1  Reasons for Discontinuation  ............................................................................................................. 64 
4.5.2  Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit  ............................................................. 64 
5 TRIAL TREATMENT  .............................................................................................................................. 65 
5.1 Treatment(s) Administered  ..................................................................................................................... 65 
5.1.1  Investigational Medicinal Product  .................................................................................................... 65 
5.1.2  Non-Investigational Medicinal Product  ............................................................................................ 65 
5.2 Identity of Investigational Medicinal Product  ........................................................................................ 65 
5.3 Dosing and Administration  ..................................................................................................................... 66 
5.4 Randomization and Blinding  .................................................................................................................. 66 
5.5 Labeling, Packaging, Storage, and Handling  .......................................................................................... 66 
5.6 Prior and Concomitant Medication/Therapy  .......................................................................................... 66 
5.6.1  Prior Medication/Therapy  ................................................................................................................. 66 
5.6.2  Concomitant Medication/Therapy  .................................................................................................... 66 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 7 of 146 
5.6.3  Guidelines for Use of Factor IX for Subjects Undergoing Major Surgery  ....................................... 68 
5.6.4  Guidelines for Transaminase Elevations  ........................................................................................... 68 
5.7 Treatment Compliance and Drug Accountability  ................................................................................... 69 
6 TRIAL SCHEDULE AND ASSESSMENTS  ........................................................................................... 71 
6.1 Trial Schedule  ......................................................................................................................................... 71 
6.1.1  Screening (Visit S)  ............................................................................................................................ 71 
6.1.2  Lead -in Phase (Visit L1 to L -Final)  .................................................................................................. 73 
6.1.3  IMP Dose Administration (Visit D)  .................................................................................................. 75 
6.1.3.1  Pre-IMP Dose Administration (Baseline, Day 1)  ...................................................................... 75 
6.1.3.2  IMP Dose Administration  ......................................................................................................... 75 
6.1.3.3  Post-IMP Dose Administration (3 hours)  .................................................................................. 75 
6.1.4  Post-Treatment Follow -up (Visit F1 to F- Final [Week 1 to Week 52/Month 12])  ........................... 75 
6.1.4.1  Early Discontinuation  ............................................................................................................... 77 
6.1.5  Long- Term Follow -up (Visit LTF1 to LTF8 [Month 18 to 60])  ....................................................... 77 
6.1.6  Additional Visits  ............................................................................................................................... 78 
6.1.7  Additional Care of Subjects after the Trial  ....................................................................................... 78 
6.2 Trial Evaluations  .................................................................................................................................... 78 
6.2.1  Demographic and Other Baseline Characteristics  ............................................................................. 78 
6.2.1.1  Demographics  ........................................................................................................................... 78 
6.2.1.2  Medical History and Concomitant Illnesses  .............................................................................. 79 
6.2.1.3  Prior and Concomitant Medication/Therapy  ............................................................................. 79 
6.2.1.4  Hemophilia B Status and History  .............................................................................................. 80 
6.2.1.5  History of Bleeding and Factor IX Use  ..................................................................................... 80 
6.2.1.6  Factor IX Gene Sequencing  ...................................................................................................... 81 
6.2.2  Efficacy Evaluations  ......................................................................................................................... 81 
6.2.2.1  Factor IX Replacement Therapy  ............................................................................................... 81 
6.2.2.2  Bleeding Episodes  ..................................................................................................................... 82 
6.2.2.3  Factor IX Activity Levels and Factor IX Protein Concentration ............................................... 83 
6.2.2.4   
6.2.2.5   
6.2.2.6  Patient Reported Outcomes, Burdens, and Experiences (PROBE) Questionnaire  .................... 86 
6.2.2.7  Musculoskeletal Ultrasound (MSKUS)  .................................................................................... 87 
6.2.3  Safety Evaluations  ............................................................................................................................ 88 
6.2.3.1  Adverse Events  ......................................................................................................................... 88 
6.2.3.2  Vital Signs  ................................................................................................................................. 88 
6.2.3.3  Physical Examination (Including Height and Weight)  .............................................................. 89 
6.2.3.4  Abdominal Ultrasound  .............................................................................................................. 89 
6.2.3.5  Anti- Factor IX Antibodies  ........................................................................................................ 90 
6.2.3.6  Factor IX Inhibitors  ................................................................................................................... 90 
6.2.3.7  Factor IX Recovery  ................................................................................................................... 90 
6.2.3. 8 Total (IgG and IgM) and Neutralizing Antibodies to AAV5  .................................................... 91 
6.2.3.9  AAV5 capsid -specific T cells  ................................................................................................... 91 
6.2.3.10  Vector Genome Detection  ......................................................................................................... 91 
6.2.3.11  Inflammatory Markers  .............................................................................................................. 92 
6.2.3.12  Other Safety Laboratory Evaluations  ........................................................................................ 92 
6.2.4  Others  ................................................................................................................................................ 93 
6.2.4.1  Blood Sample for Future Research  ........................................................................................... 93 
6.2.4.2  Liver Sample for Future Research  ............................................................................................ 93 
6.2.5  General Information Regarding Laboratory Sampling and Results  .................................................. 93 
6.2.6  Volume of Blood to be Drawn From Each Subject  .......................................................................... 95 
7 SAFETY DEFINITIONS, REPORTING AND FOLLOW -UP .............................................................. 96 
7.1 Adverse Event  Definitions  ...................................................................................................................... 96 
7.2 Adverse Events Qualifying for Special Notification  .............................................................................. 97 
7.3 Adverse Event Assessment  Definitions  .................................................................................................. 97 
7.3.1  Severity  ............................................................................................................................................. 97 
7.3.2  Relationship to  IMP .......................................................................................................................... 98 CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 8 of 146 
7.4 Reporting of Adverse  Events  .................................................................................................................. 99 
7.5 Prompt Reporting of SAEs and Other Events to CSL Behring  ............................................................... 99 
7.6 Regulatory Reporting Requirements for SAEs and Other  Events  ......................................................... 100 
7.7 Reporting of Pregnancies  ...................................................................................................................... 100 
7.8 Reporting of Occupational  Exposure  .................................................................................................... 101 
7.9 Follow -up on Adverse  Events  ............................................................................................................... 101 
8 DATA MANAGEMENT  ......................................................................................................................... 102 
8.1 Data Collection  ..................................................................................................................................... 102 
8.2 Clinical Data Management  ................................................................................................................... 102 
8.3 Study Data  ............................................................................................................................................ 102 
8.3.1  Clinical Data – CDISC Study Data Tabulation Model (SDTM)  ..................................................... 103 
8.3.2  Analysis Data – CDISC Analysis Data Model (ADaM)  ................................................................. 103 
9 STATISTICAL METHODS  .................................................................................................................... 104 
9.1 Statistical Analysis  ............................................................................................................................... 104 
9.2 Interim Analyses  ................................................................................................................................... 104 
9.3 Final An alysis  ....................................................................................................................................... 104 
9.4 Selection of Subjects to be Included in the Analyses  ........................................................................... 105 
9.5 Subject Disposition  ............................................................................................................................... 105 
9.6 Demographic and Baseline Characteristics  .......................................................................................... 106 
9.7 Investigational Product Exposure  ......................................................................................................... 106 
9.8 Prior and Concomitant Medication ....................................................................................................... 106 
9.9 Efficacy Analyses  ................................................................................................................................. 106 
9.9.1  Primary Efficacy Endpoints  ............................................................................................................ 106 
9.9.2  Secondary Efficacy Endpoints and Order of Testing of Primary and Secondary Endpoints  .......... 108 
9.9.3   
9.9.4  Optional Sub- study Endpoints  ........................................................................................................ 111 
9.10 Safety Analyses  .................................................................................................................................... 111 
9.11 Sample Size Justification  ...................................................................................................................... 112 
9.12 Data Monitoring Committee  ................................................................................................................. 112 
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES  .......................................................... 114 
10.1 Sponsor’s Responsibilities  .................................................................................................................... 114 
10.1.1  Good Clinical Practice Compliance  ................................................................................................ 114 
10.1.2  Indemnity/Liability and Insurance  .................................................................................................. 114 
10.1.3  Public Posting of Trial Information  ................................................................................................ 114 
10.1.4  Submission of Summary of Clinical Trial Report to Competent Authorities of Member States 
Concerned and Independent Ethics Committees  ............................................................................. 115 
10.1.5  Trial Suspension, Termination, and Completion  ............................................................................ 115 
10.2 Investigator’s Responsibilities  .............................................................................................................. 115 
10.2.1  Good Clinical Practice Compliance  ................................................................................................ 115 
10.2.2  Protocol Adherence and Investigator Agreement  ........................................................................... 116 
10.2.3  Documentation and Retention of Records  ...................................................................................... 116 
10.2.3.1  Electronic Case Report Forms  ................................................................................................ 116 
10.2.3.2  Patient Reported Outcomes  ..................................................................................................... 117 
10.2.3.3  Recording, Access, and Retention of Source Data and Trial Documents  ............................... 117 
10.2.3.4  Audit/Inspection  ...................................................................................................................... 117 
10.2.3.5  Financial Disclosure  ................................................................................................................ 117 
10.2.4  Compliance to all Regional, Local, State, and National Controlled -substance, Biohazard and 
Infectious Disease Regulations and Legislation .............................................................................. 1 18 
10.3 Ethical Considerations  .......................................................................................................................... 118 
10.3.1  Informed Consent  ........................................................................................................................... 118 
10.3.2  Institutional Review Board or Independent Ethics Committee  ....................................................... 119 
10.3.3  Subject Treatment Cards  ................................................................................................................. 120 
10.4 Privacy and Confidentiality  .................................................................................................................. 120 
10.5 Publication Policy  ................................................................................................................................. 121 
11 ADMINISTRATIVE ASPECTS  ............................................................................................................. 122 
11.1 Investigator(s)  ....................................................................................................................................... 122 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 9 of 146 
11.2 International Coordinating Investigator  ................................................................................................ 122 
11.3 Clinical Trial  Sites  ................................................................................................................................ 122 
11.4 Vendors  ................................................................................................................................................ 122 
12 REFERENCE LIST  ................................................................................................................................. 123 
13 APPENDICES  .......................................................................................................................................... 127 
13.1 Laboratory Information  ........................................................................................................................ 127 
13.2 Summary of Changes in Current Amendment  ...................................................................................... 128 
13.3 Previous Amendments  .......................................................................................................................... 130 
 
List of In-Text Figures 
Figure  1 Study Overview  .................................................................................................................................... 23 
Figure  2 Study Design  ......................................................................................................................................... 23 
 
List of In-Text Tables 
Table  1 Schedule of Events for Efficacy and Safety Evaluation, for Screening (Visit S), Lead- in (Visit L1 
to L-Final) and Treatment (Visit D) + Post- Treatment Follow -up (Visit F1 to F- Final)  ...................... 24 
Table  2 Schedule of Events for Laboratory Parameters, for Screening (Visit S), Lead -in (Visit L1 to L -
Final) and Treatment + Post -Treatment Follow -up (Visit F1 to F- Final)  ............................................. 28 
Table  3 Schedule of Events for Efficacy and Safety Evaluation, for Long- Term Follow -up (Visit LTF1 to 
LTF8) .................................................................................................................................................... 31 
Table  4 Schedule of Events for Laboratory Parameters, for Long -Term Follow -up (Visit LTF1 to LTF8)  ...... 33 
Table  5 Summary of Published Clinical Experience with Components of AMT -061 ....................................... 39 
Table  6 Components of AMT -061 Drug Product  .............................................................................................. 65 
Table  7 Use of Prednisolone for the Treatment of Transaminase Increase  ........................................................ 69 
Table  8 Half-Life for Infused Exogenous Factor I X Medication by Commercial Name  .................................. 84 
Table  9 Safety Laboratory Parameters Assessed at the Central and/or Local Laboratory  ................................. 92 
Table  10 Timing of Reporting and Follow -up for (Serious) Adverse Events, Adverse Events for Special 
Notification, and Pregnancies  ............................................................................................................... 99 
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 10 of 146 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
List of Abbreviations 
AAV  adeno -associated virus  
AAV5  adeno -associated viral vector serotype 5  
AAV5 -hFIXco  recombinant adeno -associated viral vector serotype 5 containing the 
wild-type human factor IX  gene, codon-optimized for optimal expression in 
humans, under control of a liver -specific promoter (AMT -060) 
AAV5 -hFIXco -
Padua recombinant adeno -associated viral vector serotype 5 containing a 
codon-optimized Padua derivative of human coagulation factor IX  cDNA 
(AMT -061) 
ABR  annualized bleeding rate  
ADaM  Analysis Data Model  
ADR  adverse drug reaction  
AE adverse event  
AFP Alpha -fetoprotein  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
aPTT  activated partial thromboplastin time  
AST  aspartate aminotransferase  
ATMP  advanced therapy medicinal product  
  
CAP  Controlled Attenuation Parameter  
CDISC  Clinical Data Interchange Standards Consortium  
cDNA  complementary deoxyribonucleic acid  
CHMP  Committee for Medicinal Products for Human Use  
Cmax Maximum concentration  
COVID -19 Coronavirus Disease 2019  
CRA  clinical research associate  
CRO  Contract Research Organization  
CRP  c-reactive protein  
CSR  Clinical Study Report  
DILI  Drug Induced Liver Injury  
DMC  Data Monitoring Committee  
eCRF  electronic case report form  
ELISA  enzyme -linked immunosorbent assay  
EMA  European Medicines Agency  
  
EU European Union  
FAS Full Analysis Set  
FDA  Food and Drug Administration  
FIX coagulation f actor IX  
GFP green fluorescent protein  
ɣGT gamma -glutamyl t ransferase  
gc genome copies  CSL Behring 
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 11 of 146 
GCP  Good Clinical Practice  
GEE  generalized estimating equation  
GTWP  Gene Therapy Working Party  
  
HBsAg  hepatitis B surface antigen  
HBV DNA  hepatitis B virus deoxyribonucleic acid  
HCV RNA  hepatitis C virus ribonucleic acid  
  
hFIX  human coagulation factor IX  
HIPAA  Health Insurance Portability and Accountability Act  
  
ICH International Council for Harmoni sation (previously International 
Conference on Harmoni sation)  
IEC Independent Ethics Committee  
IFNγ  interferon gamma  
IgG immunoglobulin G  
IgM immunoglobulin M  
IL-1β interleukin -1beta  
IL-2 interleukin -2 
IL-6 interleukin -6 
IMP investigational medicinal product  
IND Investigational New Drug  
INR International Normalized Ratio  
  
IRB Institutional Review Board  
ISF Investigator Site File  
IU international unit  
IV Intravenous  
IWRS  Interactive Web Response System  
J.A.D.E.  Joint Tissue Activity and Damage Exam  
MCP -1 monocyte chemotactic protein -1 
MedDRA  Medical Dictionary for Regulatory Activities  
MHRA  Medicines and Healthcare Products Regulatory Agency (UK)  
MSKUS  Musculoskeletal Ultrasound  
NAB  Neutralizing antibody  
NHP  non-human primate  
NIAAA  National Institute of Alcohol Abuse and Alcoholism  
PBGD  porphobilinogen deaminase  
PCR  polymerase chain rea ction  
PP Per Protocol  
  
PROBE  Patient Reported Outcomes, Burdens, and Experiences  
  
QP Qualified Person  
qPCR  quantitative (real -time) polymerase chain reaction  
RM repeated measures  CSL Behring 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 12 of 146 
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SARS -CoV -2 Severe acute respir atory syndrome coronavirus 2  
SD standard deviation  
SDTM  Study Data Tabulation Model  
SOC  System Organ Class  
SUSAR  suspected unexpected serious adverse reaction  
TEAE  Treatment -emergent adverse event  
UK United Kingdom  
ULN  Upper limit of normal  
US/USA  United States  of America  
VAS  Visual Analogue Scale  
WFH  World Federation of Haemophilia  
  CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 13 of 146 
CLINICAL TRIAL PRO TOCOL SYNOPSIS 
Protocol Number:   
CT-AMT -061-02 Investigational Medicinal Product:   
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Title of the Trial: Phase III, open -label, single -dose, multi -center multinational trial investigating a serotype 5 
adeno -associated viral vector containing the Padua variant of a codon- optimized human factor IX gene (AAV5 -
hFIXco -Padua, AMT -061) administered to adult subjects with severe or moderately severe hemophilia B  
Planned Number of Subjects:  
At lea st 50 subjects.  
Planned Number of Sites and Site Location(s):  
It is planned to conduct this trial in approximately 50 sites in the United States of America (USA) , the European 
Union (EU), and the United Kingdom  (UK) . 
Coordinating Investigator   
Trial Period ( Planned):  
First Subject Screening : Q2 2018  
Last Subject Last Visit: Q2 2025  Clinical phase:  III 
Indication/Trial Population:  
Male subjects with severe or moderately severe hemophilia B.  
Objectives:  
Primary:  To demonstrate the non-inferiority of AMT -061 (2 × 1013 gc/kg ) during the 52 week s following 
establishment of stable factor IX expression (months 6 to 18) post-treatment (AMT -061) follow -up compared to 
standard of care continuous routine factor IX prophylaxis  during the lead -in phase, as measured by the annualized 
bleeding rate (ABR) . 
Secondary: To demonstrate additional efficacy and safety aspects of systemic administration of AMT -061. 
Rationale:  
Somatic gene therapy for hemophilia B offers the potential for shift of the disease severity from severe to a moderate 
or mild hemophilic phenotype or complete amelioration through continuous endogenous production of factor IX 
protein after a single administration of adeno- associated viral vector particles. Even a small rise in constantly 
circulating factor IX protein can substantially ameliorate the bleeding phenotype.  
Three subjects have been treated with 2 × 1013 genome copies (gc)/kg AMT -061 in an ongoing dose confirmation 
Phase IIb trial (CT -AMT -061-01). The initial treatment phase has been completed in this study and an interim 
analysis based on a minimum of 6 weeks of post -treatment follow -up data  for each subject has been performed. 
The interim analysis data set includes a combined 24 weeks of observation. All 3 subjects had been diagnosed with 
severe hemophilia B, with corresponding circulating factor IX  activity levels <1% of normal. Following t reatment 
with AMT -061, an increased level of factor IX  activity was observed in all 3 subjects with mean ± standard 
deviation [SD] factor IX  activity of 30.6 ± 6.97% (range: 23.9- 37.8%) at Week 6 and  28.5 ± 6.42% (range 20.6 – 
37.8%) across visits. Factor IX activity was measured using the activated partial thromboplastin time (aPTT) assay 
performed at a central laboratory. Two out of three subject s had previously screen- failed another gene therapy study 
due to pre -existing neutralizing antibodies (NABs) to a different AAV vector. All 3 subjects had evidence of pre -
existing NAB  activity against adeno -associated viral vector serotype 5 (AAV5). No bleeding episodes have been 
reported with an ABR of 0; in the year prior to screening, the number of treatment -requiring bleeding episodes 
ranged between 1 and 5 . No subjects required any infusions of factor IX replacement therapy post -AMT -061 
treatment. No deaths, serious adverse events (SAEs) , or treatment- emergent adverse events (TEAEs) resulting in 
early discontin uation from the trial have been reported . There have been 1 3 TEAEs reported in 2 subjects, including 
2 TEAEs assessed as related to study treatment; all TEAEs were mild in severity . One subject  experienced a mild, 
asymptomatic and transient increase in liver enzyme levels  (specifically elevated aspar tate aminotransferase [AST ] 
levels) , which resolved without any additional treatment. No  T cell response was observed in any of the 3 subjects. 
None  of the subjects developed inhibitory antibodies to factor IX . Overall, the dose of 2 × 1013 gc/kg AMT -061 CSL Behring 
I 
PPD
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 14 of 146 
was shown to be safe and well tolerated and resulted in mean factor IX  activity levels approximately 30% of normal 
circulating factor IX  6 weeks after dosing. 
AMT -061 is a derivative of AMT -060, which is being studied in an ongoing Phase I/II clinical trial in male subjects 
with severe or moderately severe hemophilia B. Both AMT -060 and AMT -061 consist of an identical rAAV5 
capsid. While AMT -060 contains the coding sequence for ‘wild-type’ hFIX, a two -nucleotide change has been 
introduced within the hFIX coding sequence in AMT -061, resulting in a single amino acid substitution, where 
Arginine is replaced  by Leucine at position 338 (R338L) of the mature factor IX protein. The intended change in 
the mature protein represents the hFIX -Padua variant and it is responsible for the observed increased factor IX  
activity per unit of dose achieved with AMT -061 as compared to its predecessor AMT -060. The isolated 
modification leading to the representation of the hFIX -Padua variant in AMT -061 is not expected to influence other 
established safety characteristics of AAV5.  
The results with AMT -061 to date are complemented by r obust efficacy and safety data obtained with AMT -060 
in the  ongoing Phase I/II  trial (CT -AMT -060-01) in ten subjects with hemophilia B. These ten subject s have now 
been followed for up to 2.5 years after treatment. The data demonstrate that subject s achieve clinically relevant and 
stable factor IX  activity levels for up to 2.5 years after treatment with AMT -060. In addition, the AMT -060 
treatment remains safe and well -tolerated. Alanine aminotransferase (ALT) increase was reported for 3 out of the 
10 subject s in the study, however the ALT increases did not lead to loss of factor IX  activity and no T -cell response 
was observed in these subjects. There was no loss of factor IX  activity over time, and there wer e no immune 
responses and no development of factor IX  inhibitors for any of the 10 subject s in the study .  
The purpose of this Phase III trial is to demonstrate the efficacy of AMT- 061 in terms of ABR, to further describe 
its efficacy in terms of endogenous factor IX  activity , and to further describe its  safety profile. The efficacy and 
safety results obtained during the Phase IIb study with AMT -061 (CT -AMT -061-01), supplemented with the strong 
efficacy and safety results obtained during the P hase I/II trial with AMT -060 (CT-AMT -060-01), demonstrate 2 × 
1013 gc/kg to be t he optimal dose for use in this pivotal Phase III trial.  
Investigational Medicinal Product, Dose, and Mode of Administration:  
The investigational medicinal product (IMP) is identified as AAV5 -hFIXco -Padua (AMT -061; etranacogene 
dezaparvovec). AMT -061 is a recombinant AAV5 containing the Padua variant of a codon- optimized human factor 
IX complementary deoxyribonucleic acid (cDNA) under the control of a liver -specific promoter. The 
pharmaceutical fo rm of AMT- 061 is a solution for  intravenous  (IV) infusion.  
The single administered dose of AMT -061 will be 2  × 1013 gc/kg.  
Reference Therapy: 
The reference therapy is the prophylaxis f actor IX  replacement therapy used during the lead- in phase, prior to 
treatment with AMT -061. 
Trial Design/Methodology:  
This is an open- label, single -dose, multi -center, multinational trial, with a screening period, a lead -in phase, a 
treatment + post -treatment fo llow-up phase, and a long- term follow -up phase.  
Screening (Visit S)  
At the s creening visit (Visit S), subjects are assessed for eligibility. Subjects will be asked to complete the  
 and the  will be assessed. Screening 
assessments will also include medical history, vital signs, physical examination, and blood sampling. A 
FibroScan™ will be performed with liver fibrosis scores collected during the assessment. If possible, steatosis 
(Controlled Attenuation Parameter) scores should also be collected during the assessment . If a site does not have 
access to FibroScan, a S ponsor -preapproved alternative may be performed. At this visit, subjects will receive their 
electronic diary (e- diary) and the I nvestigator/study nurse will train them in recording of the bleeding episodes and 
use of factor IX  replacement therapy.  From screening onwards, subjects will record their use of factor IX  
replacement therapy and bleeding episodes in th eir dedicated e- diary. The period between the s creening visit up to 
the start of the l ead-in phase (Visit  L1) is considered a training period, after which the Investigator/study nurse will 
review and evaluate any problems with recording of e -diary data with the subject. The e- diary training can be 
repeated at any time during the trial as considered necessary by the I nvestigator/study nurse.  From screening 
onwards, the Investigator or designee will have regular discussions with the subject regarding  the importance of a CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 15 of 146 
healthy liver before and after receiving a liver directed gene therapy, and factors that might impact liver health 
(including  acetaminophen and alcohol intake ). 
Lead -in phase (Visit L1 to L -Final)  
Eligible subjects will enter the lead -in phase. The length of the lead -in phase is a minimum of 6 months (26 weeks), 
ending at or before Visit D. Subjects will remain in the lead -in phase until a minimum of 6 months of lead -in data 
have been collected and it is confirmed that the subjects still meet  all eligibility criteria, with the final visit in this 
phase (Visit  L-Final) occurring approximately four weeks (6 weeks maximum) prior to the planned date of IMP 
dose administration (Visit D).  
Prior to the start of the l ead-in phase (Visit  L1), subjects will undergo a wash out period from their usual factor IX  
product/dose . The wash out period will be 3 days for regular -acting factor IX  products and 10 days for extended 
half-life factor IX  products . At Visit L1, blood sample s for assessment of factor IX  activity and factor IX  protein 
concentration will be taken.  
During the lead -in phase, subjects will record their use of prophylactic factor IX  replacement therapy and bleeding 
episodes in their e -diary. e-diary data will be reviewed on a continuous basis by the I nvestigator/stu dy nurse, with 
alternating monthly clinic visits and follow -up phone calls  (in line with the trial schedule  and with retraining by 
phone as needed ). In addition to the subjects’ reporting of bleeding episodes in the e -diary, the I nvestigator  or 
designee  will assess each bleeding episode as soon as possible but at least within 72 hours after it has been reported 
by the subject. In case the information provided in the e -diary is not sufficient to assess the bleeding, the subject 
must be called and/or visit the site. At the clinic visits during this lead -in phase (occurring every two months), blood 
samples will be taken for assessment of factor IX  activity , transaminases , and AAV5 antibodies. Subjects will be 
asked to complete the  at Visit L3 . 
If the informed consent form (ICF) is revised during the lead- in phase with important new information that must 
be shared with the study subjects, the amended ICF will be presented, as required by the Institutional Review Board 
(IRB)/Independent Ethics Committee (IEC), for review and consideration by the subject, and signed re -consent is 
to be obtained prior to IMP dose administration. During Visit L -Final, the subject’s eligibility will be re -evaluated 
based on assessments during the lead- in period and a t Visit L- Final. Blood samples will be taken and the laboratory 
values obtained at this visit will be used to determine eligibility for dosing and continued participation in the trial. 
At this visit, subjects will be asked to complete the ,  will be assessed, a physical 
examination will be performed, and vital signs will be measured. The baseline abdominal ultrasound should be 
done at Visit L -Final at the latest. Additionally , blood samples for the factor IX recovery assessment will be taken 
before and 30 minutes after ( timed from end of infusion ) subjects have taken their usual factor IX treatment at this 
visit.  
IMP dose administration (treatment; Visit D) + Post- treatment follow -up phase (Visit  F1 to F -Final  [Week 1 to 
Week 52/Month 12] ) 
At Visit D, pre -IMP dose administration, subject’s eligibility will be confirmed, vital sign measurements will be 
taken, a physical examination will be performed,  and blood samples will be tak en for assessment of factor IX 
activity , routine laboratory parameters , transaminases, and AAV5 antibodies . 
Once eligibility is confirmed and all baseline assessments have been performed, subjects will receive a single 
infusion of AMT -061. After IMP administration (post -IMP), subjects will be monitored at the clinical trial site for 
3 hours for tolerance to the IMP and detection of potential immediate adverse events ( AEs). 
Subjects will then be followed for one year (52 weeks) in the p ost-treatment follow -up phase (Visit  F1 to F -Final  
[Week 1 to Week 52/Month 12] ). Subjects will have weekly visits for the first 12 weeks (Visit F1 to F1 2 [Week 1 
to 12]), and monthly visits from Month 4 to Month 12 (Visit F13 to F-Final  [Month 4 to Month 12/Week 52] ). With 
agreement from the Investigator  and Sponsor,  visits that do not include physical examination and/or  
 may be performed at the subject’s home by an appropriately qualified and trained nurse . Each home 
nursing visit is expected to be supplemented by a phone call from the I nvestigator or designee to the subject to 
discuss AEs, concomitant medications, and e -diary compliance. Adjustments to the visit location or schedule may 
be made to accommodate safety concerns an d restrictions due to the Coronavirus Disease 2019 (COVID -19) 
pandemic.  In all cases, subjects will be kept informed , via the site staff,  as much as possible of changes to the study 
and monitoring plans that could impact them.  CSL Behring 
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 16 of 146 
Subject s are permitted to continue their continuous routine factor IX  treatment in the first wee ks after dosing. 
During the post -treatment follow -up visits, endogenous factor IX  activity will be assessed . If the endogenous factor 
IX activity is ≥5%, continuous ro utine factor IX  prophylaxis  will be discontinued and further management will be 
based on I nvestigator’s clinical judgement and subject preference. Continuation or re -initiation of continuous 
routine factor IX  prophylaxis may be considered if the endogenous  factor IX  activity is between 2 and 5% in at 
least two consecutive laboratory measurements, based on the I nvestigator’s clinical judgement  and subject 
preference. If endogenous factor IX  activity is <2%, continuous routine factor IX  prophylaxis must be continued 
or reinstated. Additional on- demand and/or intermittent prophylactic factor IX  treatment may be given after 
treatment with AMT -061, if considered necessary.  
During the post-treatment follow -up phase, subjects will continue to  record their use of factor IX  replacement 
therapy and bleeding episodes in the e -diary, following the same principles as during the lead- in phase. Further 
samples will be taken for safety and efficacy laboratory parameters . Subjects will complete the  
at Visit F15 (Month 6) and Visit F -Final (Month 12), and  will be assessed at Visit F- Final . 
Additionally, an abdominal ultrasound will be performed at Visit F -Final. Use of concomitant medication and 
occurrence of AEs wil l be continuously monitored. The discussions  with the subject on the importance of a healthy 
liver, and factors that might impact liver health (includi ng acetaminophen and alcohol intake ), will continue.  
For ALT level increments of at least 2 -fold baseline (i.e., Visit D, pre -IMP), and /or greater than the  upper limit of 
normal ( >ULN), by local or central laboratory, the Investigator should contact the Medpace and uniQure  Medical 
Director s to discuss to discuss a clinical management plan  on a case- by-case basis, including potential re -tests 
and/or initiation of corticosteroid treatment. In case of AST level increments > ULN, the I nvestigator should contact 
the Medpace and uniQure M edical Directors and a similar discussion should take place . 
The first secondary  endpoint, endogenous factor IX  activity  at 6 months  after IMP administration , will be assessed 
once  the last subject has achieved 6 months after AMT -061 treatment . The second secondary endpoint, endogenous 
factor IX activity at 12 mon ths after IMP administration, will be assessed once the last subject has achieved 
12 months after AMT -061 treatment. After 52  weeks following stable factor IX expression, all available efficacy 
and safety data collected between s creening and 18 months p ost-treatment will be analyzed and reported in a 
Clinical Study Report ( CSR) , including (but not limited to), the primary ABR endpoint, and the previously assess ed 
secondary endpoints related to factor  IX activity at 6 and 12 months . 
Long- term f ollow -up phase (Visit LTF1 to LTF8 [Month 18 to Month 60] ) 
After the post -treatment follow -up phase, subjects will enter a long -term follow -up phase for an additional four 
years to assess sustainability of efficacy and long -term safety. During this phase, subjects do not have to record 
e-diary data, but are expected to document factor IX  usage and bleeding episode information in study -specific paper 
diaries . Subjects are expected to bring their long -term follow -up bleed diaries and long- term follow -up facto r IX 
use diaries to every study visit during the long -term follow -up phase , and site staff will collect the new information 
at each visit. In between study visits, subjects should contact the site staff immediately in case of an experienced 
bleed and/or factor IX use in addition to completing the questions/information requested on the paper diaries to 
capture all information.  Subjects who are on continuous routine factor IX prophylaxis during the long- term 
follow -up phase of the trial are required to contac t the site staff immediately in case of a bleed and/or factor IX use 
different from their routine factor IX prophylaxis, in addition to completing the questions/information requested on 
the paper diaries to capture all information.  
Subjects visit the clinic every half year (6 months) for evaluation of efficacy parameters and safety. Every 6 months 
an abdominal ultrasound will be performed. Every year ( 12 months), s ubjects will complete the  
and  will be assessed . Occurrence of AEs will be continuously monitored, with at least quarterly 
contact between the site staff and subject ; proper completion of the study- specific paper diaries and proper reporting 
of factor IX usage and bleeding episodes will also be monitored a t these quarterly contacts . Adjustments to the visit 
location or schedule may be made  to accommodate safety concerns and restrictions due to the COVID -19 pandemic.  
In all cases, subjects will be kept informed, via the site staff,  as much as possible of changes to the study and 
monitoring plans that could impact them.  
At the end of the trial, all safety and efficacy data from the long -term follow -up will be analyzed and reported in a 
CSR addendum.  CSL Behring 
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 17 of 146 
Please refer to Figure  1 and Figure  2 for an overview of the study and its design and to Table  1 through Table  4 for 
an overview of the assessments and testing performed throughout these different trial phases.  
Optional Patient Reported Outcomes, Burdens, and Experiences ( PROBE ) Questionnaire Sub- study  
Subjects who consent to this sub- study will complete the PROBE questionnaire at the same visits as the other  
. Adjustments to the visit schedule may be made to accommodate safety concerns and restrictions 
due to the COVID -19 pandemic.  
Optional Musculoskeletal Ultrasound (MSKUS) Sub -study 
Subjects who consent to this optional sub- study will undergo musculoskeletal ultrasounds  (MSKUS) at screening  
(Visit S), Visit L -Final, during the post -treatment follow -up at Visit s F15 (Month 6)  and F -Final  (Month 12/Week 
52), and during the long -term follow -up at Visits LTF2, LTF4, LTF6, and LTF8 (Month 24, 36, 48, and 60, 
respectively) . Adjustments to the visit schedule may be made  to accommodate safety concerns and restrictions due 
to the COVID -19 pandemic.  
Trial Assessments:  
Efficacy assessments include the e- diary for recording of bleedings and factor IX  use, several laboratory parameters 
(including factor IX  protein and activity levels), assessment of joint health, and the  on general 
and disease specific . The PROBE questionnaire and MSKUS  will be assessed for subjects 
participating in these sub- studies.  
Safety is assessed by AEs, physical examination , and laboratory parameters . 
Inclusion and Exclusion Criteria:  
Inclusion Criteria:  
1. Male 
2. Age ≥18 years  
3. Subjects with congenital hemophilia B with k nown severe or moderately severe factor IX  deficiency ( ≤2% of 
normal circulating factor IX ) for which the subject is on continuous routine factor IX  prophylaxis*  
4. >150 previous exposure days  of treatment with factor IX  protein  
5. Have been on stable prophylaxis for at least 2 months prior to screening  
6. Have demonstrated capability to independently, accurately and in a timely manner complete the diary during 
the lead -in phase as judged by the I nvestigator  
7. Acceptance to use a condom during sexual intercourse in the period from IMP administration until AAV5 has 
been cleared from semen, as evidenced by the central laboratory from negative analysis results for at least three 
consecutively collected semen samples (this criterion is applicable also for subjects who are surgically 
sterilized)  
8. Able to provide informed consent following receipt of verbal and wr itten information about the trial.  
* Continuous routine prophylaxis is defined as the intent of treating with an a priori defined frequency of infusions (e.g., tw ice 
weekly, once every two weeks, etc.) as documented in the medical records . 
Exclusion Criteria:  
1. History of factor IX  inhibitors  
2. Positive factor IX  inhibitor test at screening and Visit L- Final  (based on local lab oratory results ) 
3. Screening and Visit L- Final laboratory values  (based on central lab oratory results ): 
a. ALT >2 times ULN 
b. AST >2 times ULN 
c. Total bilirubin >2 times ULN (except if this is caused by Gilbert disease) 
d. Alkaline phosphatase (ALP) >2 times ULN 
e. Creatinine >2 times ULN 
4. Positive human immunodeficiency virus (HIV) serological test at screening and Visit L- Final, not cont rolled 
with anti- viral therapy as shown by CD4+ counts ≤200/μL (based on central lab oratory results ) 
5. Hepatitis B or C infection with the following criteria present at screening : 
a. Currently receiving antiviral therapy for this/these infection(s)  
and/or  
b. Positive for any of the following (based on central laboratory results):  CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 18 of 146 
i. Hepatitis B surface antigen (HBsAg), except if in the opinion of the Investigator this is due to 
a previous Hepatitis B vaccination rather than active Hepatitis B infection  
ii. Hepatitis B virus deoxyribonucleic acid (HBV DNA)  
iii. Hepatitis C v irus ribonucleic acid (HCV RNA)  
6. Known coagulation disorder other than hemophilia B  
7. Thrombocytopenia, defined as a platelet count below 50 × 109/L, at screening and Visit L- Final  (based on 
central lab oratory results ) 
8. Known severe infection or any other significant concurrent, uncontrolled medical condition including, but not 
limited to, renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, pulmonary, neurological, 
cerebral or psychiatric disease, alcoholism, drug dependency or any other psychological disorder evaluated by 
the Investigator to interfere with adherence to the protocol procedures or with the degree of tolerance to the 
IMP 
9. Known significant medical  condition that may significantly impact the intended transduction of the vector 
and/or expression and activity of the protein, including but not limited to: a. Disseminated intravascular coagulation  
b. Accelerated fibrinolysis  
c. Advanced liver fibrosis (suggestive of or equal to METAVIR Stage 3 disease; e.g., a FibroScan™ score 
of ≥9 kPa is considered equivalent ) 
10. Known history of an allergic reaction or anaphylaxis to factor IX  products  
11. Known history of allergy to corticosteroids  
12. Known uncontrolled allergic conditions or allergy/hypersensitivity to any component of the IMP excipients  
13. Known medical condition that would require chronic administration of steroids  
14. Previous gene therapy treatment  
15. Receipt of an experimental agent within 60 days prior to screening  
16. Current participation or anticipated participation within one year after IMP administration in this trial in any 
other interventional clinical trial involving drugs or devices
. 
Planned Duration of Subject Involvement in the Trial:  
• Planned duration of screening/enrolment period: approximately 4 weeks  
• Planned duration of lead- in phase: at least 26  weeks (6  months ) 
• Planned duration of treatment: 1 day (single dose)  
• Planned duration of follow -up: 52 weeks, plus long- term safety follow -up until Month 60 
Endpoints and Statistical Analysis:  
Primary efficacy endpoints  
- ABR comparison between AMT -061 and prophylaxis for non- inferiority between the lead -in phase and 
the 52 weeks following stable factor IX e xpression (months 6- 18 post -treatment)  
Secondary efficacy endpoints  
- Endogenous factor IX activity at 6 months  after AMT -061 dosing  
- Endogenous factor IX activity at 12 months  after AMT -061 dosing  
- Endogenous factor IX activity at 18 months  after AMT -061 dosing  
- Annualized consumption of  factor IX replacement therapy during the 52 week s following stable factor  IX 
expression (months 6- 18 post -treatment) , excluding factor IX replacement for invasive procedures , 
compared to the lead -in phase  
- Annualized infusion rate of factor IX replacement therapy during the 52 week s following stable factor  IX 
expression (months 6- 18 post -treatment) , excluding factor IX replacement for invasive procedures , 
compared to the lead -in phase  
- Proportion of subjects remaining free of previous continuous routine prophylaxis during the 52  week s 
following stable factor  IX expression (months 6 -18 post -treatment)  
- Comparison of the percentage of subjects with trough factor IX activity <12% of normal between the 
lead-in phase and after treatment with AMT- 061 ove r the 52 weeks following stable factor  IX expression 
(months 6 -18 post -treatment)  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 19 of 146 
- ABR comparison between AMT -061 and prophylaxis for superiority between the lead -in phase and the 
52 weeks following stable factor  IX expression (months 6- 18 post -treatment)  
- Rate of spontaneous bleeding events during the 52 weeks following stable factor  IX expression (months 
6-18 post -treatment)  compared to the lead-in phase  
- Rate of joint bleeding events during the 52 weeks following stable factor  IX expression (months 6- 18 
post-treatment)  compared to the lead -in phase  
- Estimated ABR – during the 52 weeks following stable factor IX expression (months 6- 18 post -treatment)  
– as a function of pre -IMP anti -AAV5 antibody titers using the luciferase based NAB assay (as a 
“correlation” analysis)  
- Correlation of factor IX activity levels during the 52 weeks following stable factor IX expression (months 
6-18 post -treatment)  with pr e-IMP anti -AAV5 antibody titers using the luciferase based NAB assay  
- Occurrence of (and resolution of ) new  target joints during the 52 weeks following stable factor  IX 
expression (months 6- 18 post -treatment)  and resolution of pre -existing target joints following AMT -061 
dosing  
- Proportion of subjects with zero bleeds during the 52 weeks following stable factor  IX expression (months 
6-18 post -treatment)  
-  
 during the 12  months  following AMT -061 dosing compared with the lead- in phase  
-  
score during the 12 months  following AMT -061 dosing compared with the lead -in phase  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 20 of 146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sub-study e ndpoints  
- PROBE summary scores and individual item responses.  
- MSKUS sub
-study endpoints  
- Joint Tissue Activity and Damage Exam (J.A.D.E.) scores  
Secondary safety endpoints  
- Adverse events  (AEs)  
- Changes in abdominal ultrasound  
- Anti- AAV5 antibodies (total [ IgM and IgG ], NABs ) 
- AAV5 capsid -specific T cell s 
- Anti- factor IX  antibodies  
- Factor IX  inhibitors  and recovery  
- Hematology and serum chemistry parameters  
- ALT/AST levels, and corticosteroid use for ALT/AST increases  
- Vector DNA in blood and semen  
- Inflammatory markers: IL -1β, IL -2, IL- 6, IFNγ, MCP -1 
- Alpha -fetoprotein (AFP)  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 21 of 146 
Analysis Populations  
The Full Analysis Set (FAS) will include all subjects who are enrolled, entered the lead -in phase , were dosed with 
AMT -061, and provide at least one efficacy endpoint  assessment subsequent to AMT -061 dosing. The FAS 
population will be the primary population for all efficacy statistical analyses.  
The PP population will include all subjects from the FAS population who adhere to a stable and adequate 
prophylaxis use during the lead- in phase, who complete at least  18 months of efficacy assessments (52 weeks after 
achieving stable factor IX expression) for the 18- month (data cut) analysis, who complete at least a full year of 
efficacy assessments  for the 12 -month (data cut) analysis, or who complete at least 6 month s of efficacy assessments 
for the 6 -month (data cut) analysis , and who have no major protocol deviations that impact the interpretation of 
efficacy . The PP population will be used for sensitivity analyses . 
The lead-in safety population will consist of all subjects who receive lead -in treatment (i.e. who are enrolled into 
the lead-in period). The post-treatment safety population will consist of all subjects who receive AMT -061, 
irrespective of any protocol deviations. The s afety population will consist of all subjects who are in either the lead -
in safety population or the p ost-treatment safety population.  
Sample Size 
The study sample size is constrained by the non- inferiority analysis of the primary endpoint, ABR. Via simulation 
of ABR under a negative binomial distribution with a yearly rate of 2.4 events for lead- in and 1.9 for post -treatment, 
with a Pearson correlation of 0.05 for the number of events between the two periods, and with a common negative binomial dispersion parameter of 1.5, a sample size of N=50 will demonstrate non- inferiority with a non- inferiority 
margin of 1.8 and a power of 82.0%. Therefore, the study should consist of at least 50 analyzable subjects.  
Statistical Methods  
Primary efficacy analys es 
The primary aim of the trial is  to demonstrate the non- inferiority of AMT- 061 (2 × 1013 gc/kg)  during the 52  week s 
following establishment of stable factor IX expression (months 6 to 18)  post-treatment (AMT -061) follow -up 
compared to standard of care continuous routine factor IX prophylaxis during the lead- in phase, as measured by 
the ABR. 
Single treatment with AMT -061 will be claimed to be non- inferior to factor IX prophylaxis treatment when the 
upper limit of the one -sided 97.5% confidence interval of the rate ratio in ABR between AMT- 061 (post -treatment) 
and factor IX prophylaxis (lead- in) is less than 1.8.  
ABR will be determined for the lead -in period and post -treatment period ( for the 52 weeks following stable 
factor  IX expression [ months 6-18 post -treatment with AMT -061]). Analysis of the number of reported bleeding 
events will be performed using a repeated measures  (RM) generalized estimating equation (GEE) negative binomial 
regression model accounting for the paired design of the trial with an offset parameter to account for the differential 
collection periods. The estimated rate ratio, one -sided 97.5% Wald confidence interval, and corresponding p- value 
will be determined. The upper limit of the resultant confidence interval of the rate ratio will be compared to the non-inferiority margin of 1.8. If the upper limit is less than 1.8, then non -inferiority will be declared.  
The primary efficacy analysis of ABR for the non- inferiority assessment will be completed using the FAS. 
Order of testing of p rimary and s econdary endpoi nts 
Formal statistical testing of the efficacy endpoints will be performed using the closed testing principle  (for Type I 
error control for multiple testing) . Due to the closed testing principle, no correction for multiplicity is necessary. 
All endpoints will be tested for superiority at a one -sided alpha level of 0.025 (except as otherwise noted). 
Superiority and non -inferiority testing will be accomplished u sing the FAS population. Fixed sequential testing will 
be performed using a hierarchical approach and will be continued until a non -significant result is obtained (except 
as otherwise noted). The primary and secondary endpoints will be analyzed in the following order .  
1. ABR comparison between AMT -061 and prophylaxis for non- inferiority between the lead -in phase and 
the 52 week s following stable factor IX expression (months 6- 18 post -treatment ; primary efficacy 
endpoint)  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 22 of 146 
2. Endogenous  factor IX activity at 6 months  after AMT -061 ( first secondary  efficacy endpoint)  
3. Endogenous  factor IX activity at 12 months  after AMT -061 ( second secondary  efficacy endpoint)  
4. Endogenous f actor IX activity at 18 months  after AMT -061 ( third secondary efficacy endpoint)  
5. Annualized consumption of factor IX replacement therapy  during the 52  week s following stable factor IX 
expression (months 6- 18 post -treatment) , excluding factor IX replacement for invasive procedures, 
compared to  the lead -in phase (secon dary efficacy endpoint)  
6. Annualized infusion rate of factor IX replacement therapy  during the 52 week s following stable factor IX 
expression (months 6- 18 post -treatment) , excluding factor IX replacement for invasive procedures, 
compared to the lead -in phase  (secondary efficacy endpoint)  
7. Comparison of the percentage of subjects with trough factor IX activity <12% of normal between the 
lead-in phase and after treatment with AMT- 061 over the 52  week s following stable factor IX expression 
(months 6 -18 post -treatment ; secondary efficacy endpoint ) 
8. ABR comparison between AMT -061 and prophylaxis for superiority between the lead -in and the 52  week s 
following stable factor IX expression (months 6 -18 post -treatment); secondary efficacy endpoint)  
9. Rate of spontaneous bleeding events during the 52  week s following stable factor IX expression (months 
6-18 post -treatment)  compared to the lead -in phase (secondary efficacy endpoint)  
10. Rate of joint bleeding events during the 52 week s following stable factor IX expression (months 6- 18 
post-treatment)  compared to the lead -in phase (secondary efficacy endpoint)  
11.  during the 12 months  following 
AMT -061 dosing compared with the lead -in phase (secondary  efficacy  endpoint)  
12.  during the 12 months  following AMT -061 
dosing compared with the lead -in phase (secondary efficacy endpoint)  
 
 
 
Safety analyses  
Adverse events will be coded using the most recent version of the Medical Dictionary for Regulatory Activities 
(MedDRA ). Total treatment- emergent AEs  (TEAEs), and broken down by relationship, severity, seriousness, will 
be presented descriptively by system organ class and preferred term, presenting number and percentage of subjects 
and number of events.  
All other safety data will be presented using graphical displays, descriptive statistics (including ch ange from 
baseline, if applicable) , and/or individual data listings.  
The number of days until vector DNA can no longer be detected in blood and semen will be tabulated. The number 
of days is calculated using the date of collection of the first of three consecutive sample negative for vector DNA  
for each matrix.  
All safety analyses will be based on the safety population.  
Analyses will be based on central laboratory measurements if results are available from both local and central 
laboratories.  
 CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 23 of 146 
Study Design Schema  
 
 
Abbreviations: IMP = Investigational Medicinal Product  
Figure  1 Study Overview  
 
 
Abbreviations: IMP = Investigational Medicinal Product  
Figure  2 Study Design  
CSL Behring 
.......................................... ll1111111111111111111111111111111111111111111111111111111111111 
Screening Lead-in Phase IMP Dose Post-treatment Follow-up Long Term Follow-up 
Screen ing 
Visit S Administ ration 
Variab le length 
minimum of 6 months 
Visit L1 Visit every 2 months Visit 
(approx . L-Final 
4weeks 
after Visit S) 
Lead-in 
Visit L1 to LX and L-Final Visit every week 
(W1-W12) II llll llll llll 111111111111111111111 
Visit every month Final Visit 
(M4-M11) (M12/WS2) 
IMP Dose 
Adm inistrat ion 
Visit D Post-treatment Follow-up 
Visit Fl to F20 and F-Final Visit every 6 months 
(M18-M60} 
Long Term Follow-up 
Visit L TFl to L TF8 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 24 of 146 
Trial Schedules 
Table  1 Schedule of Events for Efficacy and Safety Evaluation, for Screening (Visit S), Lead -in (Visit L1 to L -Final) and Treatment (Visit D) + 
Post-Treatment Follow -up (Visit F1 to F- Final)  
Trial Period a Screening  Lead -in b, c, d IMP Dose  
Administration d Post-treatment Follow -up d, e, f Addition
al Visits g 
Day / Week / Month  Visit S h 
 Visit 
L1 
(L-
W0)i Visit L2 to LXj 
(every 2 
months, 
starting at L-
M2) Visit  
L-Final  Visit D  
pre-IMP Visit D  
0h Visit D  
post-IMP 
3h Visit F1 to F12  
(every week 
W1 to W12)  Visit F13 to 
F20 (every 
month  
M4 to M11)  Visit  
F-Final  
(M12/W5
2)  
Visit window (days)  -28 0 ±14 j 0 0 ±15 
minutes  ±2 ±5 ±5  
Informed consent  x           
Inclusion/exclusion 
criteria  x   x x k       
Medical history  x           
Administration o f IMP       x      
Hand -out of subject 
treatment card l       x     
Concomitant 
medication  Continuous  (x) g 
Vital signs (b lood 
pressure, pulse, body 
temperature ) x   x x  x x x x (x) g 
Physical examination  x   x x   x: Visit F1, F2, 
F4, F6, F12  
(W1, 2, 4, 6, 12)  x: Visit F13, 
F15, F17, F19  
(M4, 6, 8, 10)  x (x) g 
Height  x           
Body weight  x   x       (x) g 
Fibro Scan™  m x           
Blood and semen 
sampling  
(see Table  2)  x x x x x  x x x x (x) g 
Subject provided e -
diary device and e-diary 
instruction n x           
Recording of e -diary 
data by subject  
(bleeding episodes, 
factor IX  replacement 
therapy)  Continuous   CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 25 of 146 
Trial Period a Screening  Lead -in b, c, d IMP Dose  
Administration d Post-treatment Follow -up d, e, f Addition
al Visits g 
Day / Week / Month  Visit S h Visit 
L1 
(L-
W0)i Visit L2 to LXj 
(every 2 
months, 
starting at L-
M2) Visit  
L-Final  Visit D  
pre-IMP Visit D  
0h Visit D  
post-IMP 
3h Visit F1 to F12  
(every week 
W1 to W12)  Visit F13 to 
F20 (every 
month  
M4 to M11)  Visit  
F-Final
(M12/W5
2) 
Visit window (days)  -28 0 ±14 j0 0 ±15 
minutes  ±2 ±5 ±5 
Review of e -diary data 
by Investigator/study 
nurse  Continuous  (x)g
Collection of e -diary 
device  x 
Subject provided with  
paper diaries and p aper 
diary instruction for 
Long -Term Follow -up 
Phase  x 
Assessment of 
bleeding episode(s) by 
Investigator o Continuous  (x)g
Liver health discussion 
(including 
acetaminophen and 
alcohol intake ) p Continuous  
Abdominal u ltrasound  q x x 
x x: Visit L3  x x: Visit F15 
(M6)  x 
x x: Visit L3  x x: Visit F15 
(M6)  x 
x x: Visit L3  x x: Visit F15 
(M6)  x 
x x: Visit L3  x x: Visit F15 
(M6)  x 
x x: Visit L3  x x: Visit F15 
(M6)  x 
x x: Visit L3  x x: Visit F15 
(M6)  x 
x x x 
PROBE r, s x x: Visit L3  x x: Visit F15 
(M6)  x 
Musculoskeletal 
ultrasound t x x x: Visit F15 
(M6)  x 
Adverse events  Continuous  (x)hCSL Behring 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 26 of 146 
; D: dosing ; h: hour; ; ; ; IMP: 
investigational medicinal product; ; L-M: lead-in month; L
-W: lead-in week; M:  month; PROBE = Patient Reported Outcomes, Burdens, 
and Experiences; ; W: week; 
a. This table shows events for screening, lead -in, and treatment + post -treatment follow -up. Refer to Table  3 for events during the long -term follow -up.
b. Each visit in the l ead-in phase is scheduled in relation to the date of L1 (L -W0), not in relation to the date of its previous visit.
c. The lead-in phase will be a minimum of 6 months, ending at or before Visit D. Visits will occur every 2 months  and between visits, there will be a follow -up telephone call for e- diary
r
eview (alternating months).
d. For subjects on continuous routine prophylactic Factor IX replacement therapy, these visits should take place on the day that routine prophylactic Factor IX replacement treatment is
planned to be administered. At these visits, blood sampling will take place prior to administration of prophylactic Factor IX replacement therapy. If a subject uses addit ional on -dema nd
Fa
ctor IX replacement treatment, his upcoming study visit may need to be re -scheduled (to the extent the visit window allows) so that the visit takes place at the time the subject
resumes his continuous routine prophylaxis schedule. For subjects only using on -demand Factor IX replacement therapy (only applicable after AMT- 061 administration), his upcomin g
s
tudy visit m ay need to be re- scheduled (to the extent the visit window allows) so that the visit does not take place  within 5 half -lives of exogenous Factor IX product use . In case the 
5 half-lives washout extends beyond the protocol allowed visit window, the Medpace and uniQure Medical Directors are to be contacted to discuss how to proceed.
e. Each visit in the post -treatment follow -up is scheduled in relation to the date of IMP dose administration (Visit D), not in relation to the date of its previous vis it.
f. With agreement from the Investigator and Sponsor  during the Post -Treatment Follow -Up period (from Visit D up until Week 52) , visits that do not include physical examination and/or
 may be performed at the subject’s home by an appropriately qualified and trained nurse. Each home nursing visit is expected to be supplemented by a phone call
from the Investigator or designee to the subject to discuss AEs, concomitant medications, and e -diary compliance.
g. An additional visit can be performed at any time during the study (lead -in or follow -up phases) for the purpose of conducting one or more procedures listed in the column “Additional
Visits”, as per the preference of the I nvestigator. Hence, “(x)” refers to a procedure that can be performed, if judged  relevant by the I nvestigator.
h. The approximately 4- week period between the screening visit (Visit S) and the start of the lead -in phase (Visit L1) is considered a training period, after which the I nvestigator/study
nurse will review and evaluate any problems with recording of e -diary data with the subject.  With prior approval from the Sponsor, screening procedures can occur during the duration
of the screening period.
i. Prior to the Visit L1, subjects will undergo a wash out period from their usual factor IX  product/dose. The wash out period will be 3 days for regular -acting factor IX  products and
10 days for extended half -life factor IX  products.
j. Visit window for Visit L -Final is -28 days ( ±7 days) from Visit D.  The time period between Visit LX and Visit L -Final can be less than 2 months as long as the total lead -in period is  a
m
inimum of 26 weeks.
k. Laboratory assessments from Visit L -Final will be used for inclusion/exclusion criteria at Visit D.
l. When all assessm ents at 3 hours post -IMP administration are performed, the subject treatment card will be handed out and the subject may leave the clinic.  If a subject is traveling to a
d
ifferent site for Visit  D, this card should be handed out at the L -Final visit and th e subject should be instructed to bring it with him to Visit D.
m. Liver fibrosis scores will be collected during the FibroScan assessment . If possible, steatosis (Controlled Attenuation Parameter [CAP]) scores should also be collected. I f a site does not 
have access to FibroScan, a Sponsor -preapproved alternative may be performed. The FibroScan should preferably be done at the screening visit or at an alternative time point, however
at L-Final at the latest. If a FibroScan assessment has been performed within the year prior to screening for which CAP scores are available or if a liver biopsy has been performe d
w
ithin the 2 years prior to the screening visit and fibrosis grade was documented, a FibroScan is not necessary.
n. Instruction can be repeated at any visit as deemed necessary by the Investigator or study nurse.
o. The Investigator or designee will assess each bleeding episode as soon as possible, but at least within 72  hours after it has been reported by the subject.
p. From screening onwards, th e Investigator or designee will have regular discussions with the subject regarding the importance of a healthy liver before and after receiving a liver directed
gene therapy, and factors that might impact liver health (includi ng acetaminophen and alcohol intake ). It is recommended that acetaminophen total daily dose per subject  be limited to
≤2 g/day. It is also recommended that subject s on the study should not consume > 20 g of alcohol per day.  While it is recommended that the daily alcohol limit in grams be adhered to 
most stric tly during the first 12 weeks post -IMP, the importance of abstaining from binge- drinking at any point post IMP administration should be reinforced at every visit.
q. The baseline abdominal ultrasound should be done at L -Final at the latest.  For those subjects where Visit F -Final (Month 12) is impacted by COVID -19, abdominal ultrasounds may b e
co
nducted within the following window: up to -1 month prior to the target visit and up to + 1 month after the target visit.  Adjustments to th e visit timing within this window are to be
documented.
r. It is recommended that t he  ( /PROBE] ) are completed by the subject before he is seen by 
the Investigator and/or study nurse for interview and before other (trial specific) assessments are performed  if possible , as well as before the administration of IMP, in order for the 
answers not to be influe nced by the information given by the physician, by the administration of IMP, or by early side -effects of the IMP or (trial related) assessments. During the 
screening  visit, the  are recommended to be completed after ICF signature, but be fore other (trial -specific) assessments are performed.  At each visit, the CSL Behring 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 27 of 146 
questionnaires are to be completed in the same order every time, following the order presented in the protocol.  The questionnaires are to be completed under site supervision at the s ite. 
For those subjects where the Visit F1 5 and Visit F- Final are impacted by COVID -19, the questionnaires may be conducted at the site within the following window: up to -1 month prior 
to the target visit, up to +2 months after the target visit, and at least 4 months after the last assessment. Adjustments to the visit timing within this window are to be documented.  
s. Applicable only for subjects participating in the optional PROBE questionnaire sub -study.  For those subjects where the Visit F15 and Visit F-Final are impacted by COVID -19, the
P
ROBE questionnaire may be conducted at the site within the following window: up to - 1 month prior to the target visit, up to +2 months after the target visit, and at least 4 months after
the last assessment. Adjustments to the visit timing within this window are to be documented.
t. Applicable only for subjects participating in the optional musculoskeletal ultrasound (MSKUS) sub-study.  If it is not possible to obtain the MSKUS  at screening (Visit S), it is allowed
to obtain this first MSKUS  at a later time point (preferably as soon as possible thereafter during one of the lead -in visits). For those subjects where the Visit F1 5 and Visit F -Final ar e
i
mpacted by COVID -19, scans may be conducted within the following window: up to -1 month prior to the target visit, up to +2 months after the target visit, and at least 4 months after
the last MUSKUS. Adjustments to the visit timing  within this window are to be documented.CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 28 of 146 
Table  2 Schedule of Events for Laboratory Parameters, for Screening (Visit S), Lead -in (Visit L1 to L -Final) and Treatment + Post- Treatment 
Follow -up (Visit F1 to F- Final)  
Trial Period a Screening  Lead -in b, c, d IMP Dose  
Administration d Post-treatment Follow -up d, e Addition
al Visits f 
Day / Week / Month  Visit S  Visit 
L1 
(L-
W0)g Visit L2 to LX  
(every 2 
months, 
starting at L-
M2) Visit  
L-FinalVisit D  
pre-IMP Visit D  
0h Visit D  
post-IMP 
3h Visit F1 to F12  
(every week 
W1 to W12)  Visit F13 to 
F20 (every 
month  
M4 to M11)  Visit  
F-Final
(M12/W5
2) 
Visit window (days)  -28 0 ±14 h0 0 ±15 
minutes  ±2 ±5 ±5 
Local Laboratory  
Factor IX : one -stage 
aPTT for factor IX  
activity for local 
monitoring  x x x x x x x x (x)f
Factor IX  inhibitors 
(Bethesda assay or 
Nijmegen modified 
Bethesda assay) for local monitoring and 
eligibility check i x x x x: Visit F6, F12  
(W6, W12)  x: Visit F15 
(M6)  x (x)f
Transaminases 
(AST/ALT) for local 
monitoring  j x x x x x x x (x)f
Central Laboratory  
One-stage aPTT for 
factor IX  activity  x x x x x x x (x)f
Chromogenic Assay  for 
factor IX  activity  x x x x x x x (x)f
Factor IX  protein 
concentration  x x x x x x (x)f
Anti-factor IX  
antibodies x x: Visit F6, F12  
(W6, W12)  x: Visit F15 
(M6)  x (x)f
Factor IX  inhibitors  
(Nijmegen modified 
Bethesda assay) ix x x x: Visit F6, F12  
(W6, W12)  x: Visit F15 
(M6)  x (x)f
Factor IX  recovery k x (x)f
Total (IgM and IgG) 
antibodies to AAV5  x x x x x: Visit F3, F6, 
F9, F12  (W3, 
W6, W9, W12)  x: Visit F15 
(M6)  x (x)f
Neutralizing antibodies 
to AAV5  x x x x x: Visit F3, F6, 
F9, F12  (W3, 
W6, W9, W12)  x: Visit F15 
(M6)  x (x)f
AAV5 capsid -specific 
T cellsx x x x (x)fCSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 29 of 146 
Trial Period a Screening  Lead -in b, c, d IMP Dose  
Administration d Post-treatment Follow -up d, e Addition
al Visits f 
Day / Week / Month  Visit S  Visit 
L1 
(L-
W0)g Visit L2 to LX  
(every 2 
months, 
starting at L-
M2) Visit  
L-FinalVisit D  
pre-IMP Visit D  
0h Visit D  
post-IMP 
3h Visit F1 to F12  
(every week 
W1 to W12)  Visit F13 to 
F20 (every 
month  
M4 to M11)  Visit  
F-Final
(M12/W5
2) 
Visit window (days)  -28 0 ±14 h0 0 ±15 
minutes  ±2 ±5 ±5 
Sampling for vector 
genome detection  
Blood l x x x x x (x)f
Semen l xm x: Visit F6, F12  
(W6, W12)  x: Visit F13, 
F15 (M4, M6)  x (x)f
Inflammatory markers  
IL-1β, IL-2, IL -6, 
IFNγ, MCP -1 x x x x (x)f
Alpha -fetoprotein 
(AFP)  x x: Visit F15  
(M6)  x (x)f
Hematology and 
coagulation parameters 
nx x x x x x (x)f
Serum chemistry 
parameters o x x x x 
(only CRP)  x x x (x)f
HIV, viral load, and 
CD4+  x x 
HBsAg, HBV DNA 
and HCV RNA  x x 
Factor IX  gene 
sequencing p x 
Blood sample for 
future research q x x x: Visit F12 
(W12)  x 
AAV5: adeno -associated viral vector serotype 5; ALT: alanine aminotransferase; aPTT:  activated partial thromboplastin time; AST: aspartate aminotransferase; CRP: C -Reactive Protein; 
DNA:  deoxyribonucleic acid; h: hour; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HCV RNA: hepatitis C virus ribonucleic acid; HIV: human immunodeficiency virus; 
IFNγ: interferon gamma; IgG: immunoglobulin G; IgM: immunoglobulin M; IL: interleukin: IMP: investigational medicinal product; M:  month; MCP- 1: monocyte chemotactic protein -1; 
W: week.  
a. This table shows events for screening, lead -in, and treatment + post -treatment follow -up. Refer to Table  4 for events during the long -term follow -up.
b. Each visit in the l ead-in phase is scheduled in relation to the date of L1 (L -W0), not in relation to the date of its previous visit.
c. The lead-in phase will be a minimum of 6 months, ending at or before Visit D . Visits will occur every 2 months and between visits, there will be a follow -up telephone call for e- diary
r
eview (alternating months).
d. For subjects on continuous routine prophylactic Factor IX replacement therapy, these visits should take place on the day that routine prophylactic Factor IX re placement treatment is
planned to be administered. At these visits, blood sampling will take place prior to administration of prophylactic Factor IX  replacement therapy. If a subject uses additional on- dema nd
Fa
ctor IX replacement treatment, his upcoming s tudy visit may need to be re -scheduled (to the extent the visit window allows) so that the visit takes place at the time the subject
resumes his continuous routine prophylaxis schedule. For subjects only using on -demand Factor IX replacement therapy (only applicable after AMT -061 administration), his upcomin gCSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 30 of 146 
study visit may need to be re -scheduled (to the extent the visit window allows) so that the visit does not take place within 5 half -lives of exogenous Factor IX product use.  In case the 
5 half-lives wa shout extends beyond the protocol allowed visit window, the Medpace and uniQure Medical Directors are to be contacted to discuss how to proceed.  
e. Each visit in the p ost-treatment follow -up is scheduled in relation to the date of IMP dose administration (Visit D), not in relation to the date of its previous visit.  
f. An additional visit can be performed at any time during the study (lead -in or follow -up phases) for the purpose of conducting one or more procedures listed in the column “Addition al 
Visits”, as per the preference of the I nvestigator. Hence, “(x)” refers to a procedure that can be performed, if judged relevant by the Investigator.  
g. Prior to the Visit L1, subjects will undergo a wash out period from their usual factor IX  product/dose . The wash out period will be 3 days for regular -acting factor IX  products and 
10 days for extended half -life factor IX  products .  
h. Visit window for Visit L -Final is -28 days (± 7 days ) from Visit D.  
i. In case of a positive test for factor IX  inhibitors, a re- test should be performed within two weeks to confirm the positive test. The subject should be called in for an additional vis it in 
case no routine visit is scheduled within this two week timeframe.  
j. For ALT level increments of at least 2- fold baseline (i.e., Visit D, pre -IMP) and /or > upper limit of normal (ULN),  by local or central laborator ies, the Investigator  should contact the 
Medpace and uniQure Medical Directors to discuss a clinical management  plan, on a case -by-case basis, including potential re -tests and/or initiation of corticosteroid treatment. In case 
of AST level increments > ULN, the Investigator should contact the Medpace and uniQure Medical Directors and a similar discussion should take place. 
k. At suspicion of factor IX  inhibitor, the factor IX  recovery assessment should be repeated. Blood samples for factor IX  recovery assessment should be drawn prior to administering the 
subject’s continuous routine factor IX  product/dose and at 30 minutes after the factor IX  dose is administered (timed from end of infusion). The same continuous routine factor IX  
product/dose used at the baseline recovery assay should also be used when repeating the assay.  
l. Sampling for the individual subject and for a specific matrix (i.e., blood or semen) is only to be continued until 3 consecut ive negative samples have been detected for the s ubject for 
that particular type of matrix. The sampling schedule (frequency) may be increased as agreed between the Investigator and subject following the notification of a first negative result on 
blood and/or semen, expediting the opportunity to reach th ree consecutive negative samples on the specific matrix.  Based on the wish of the subject, semen samples can be collected at 
home prior to attending the visit (at the visit day or at the day before the visit day). Also, the frequency of semen sampling may be reduced (to be agreed between Investigator and 
subject) as long as the subject uses a condom during sexual intercourse until 3 consecutive negative samples have been detect ed. 
m. Subjects travelling for Visit D may provide their semen sample at Visit L -Final. 
n. For hematology: Hemoglobin, hematocrit, platelet count, red blood cells, white blood cells with differential count (all expressed in % as wel l as in absolute numbers) ; for coagulation:  
aPTT , and PT (INR).  
o. Serum electrolytes (sodium, potassium), creatinine, creatine kinase, gamma -glutamyltransferase ( ɣGT), AST, ALT, alkaline phosphatase (ALP), CRP, albumin, total bilirubin, glucose 
(non- fasting).  
p. Performed for all subjects who have provided separate informed  consent for factor IX  gene sequencing analysis. Preferably at the screening visit, but otherwise at a later time point 
during the subject’s trial participation.  
q. Only if separate informed consent is given by the subject.   CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 31 of 146 
Table  3 Schedule of Events for Efficacy and Safety Evaluation, for Long- Term Follow -up (Visit LTF1 to LTF8) 
Trial Period a Long -Term Follow -up b, c Additional 
Visits d
Visit  LTF1  LTF2  LTF3  LTF4  LTF5  LTF6  LTF7  LTF8  
Month  18 24 30 36 42 48 54 60 
Visit window (weeks)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
Concomitant medication  Continuous  (x)d
Collection of bleeding and factor IX  
use data  e x x x x x x x x (x)d
Physical examination  x x x x x x (x)d
Blood and semen sampling (see 
Table  4) x x x x x x x x (x)d
Abdominal ultrasound  f x x x x x x x x (x)d
x x x x 
x x x x 
x x x x 
x x x x 
x x x x 
x x x x 
x x x x 
PROBE g, h x x x x 
Musculoskeletal Ultrasound i x x x x 
Adverse events j Continuous  
; h: hour; ; ; ; IMP: investigational 
medicinal product; ; PRO BE = Patient Reported Outcomes, Burdes, and Experiences; ; 
a. This table shows events for the long- term follow -up. Refer to Table 1  for events during screening, lead -in, and treatment + post -treatment follow -up.
b. Each visit in the long -term follow -up is scheduled in relation to the date of IMP dose administration (Visit D), not in relation to the date of its previous visit.
c. For subjects on continuous routine prophylactic Factor IX replacement therapy, these visits should take place on the day that routine prophylactic Factor IX replacement treatment is
planned to be administered. At these visits, blood sampling will take place prior to administration o f prophylactic Factor IX replacement therapy. If a subject uses additional on -dema nd
Fa
ctor IX replacement treatment, his upcoming study visit may need to be re -scheduled (to the extent the visit window allows) so that the visit takes place at the time the  subject
resumes his continuous routine prophylaxis schedule. For subjects only using on -demand Factor IX replacement therapy (only applicable after AMT- 061 administration), his upcomin g
s
tudy visit may need to be re -scheduled (to the extent the visit window allows) so that the visit does not take place within 5 half -lives of exogenous Factor IX product use.  In case the 
5 half-lives washout extends beyond the protocol allowed visit window,  the Medpace and uniQure Medical Directors are to be contacted to dis cuss how to proceed.
d. An additional visit can be performed at any time during the study (long -term follow -up phase) for the purpose of conducting one or more procedures listed in the  column “Additional
Visits” as per the preference of the Investigator. Henc e, “(x)” refers to a procedure that can be performed, if judged relevant by the I nvestigator.
e. Subjects will record bleeding episodes and factor IX replacement therapy use in their study -specific paper long -term follow -up bleed diary and paper long-term follow -up factor IX us e
d
iary, which they will bring to every study visit. Site staff will collect the information that is new since the previous visit in the paper diaries . In between study visits, subjects shoul d
co
ntact the site staff immediately in case of an experienced bleed and/or factor IX use in addition to completing the questions/information requested on the  paper diaries.  Subjects wh o
ar
e on continuous routine factor IX prophylaxis during the long- term follow -up phase of the trial are required to contact the site staff immediately in case of a bleed and/or factor IX us eCSL Behring 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 32 of 146 
different from their routine factor IX prophylaxis, in addition to completing the questions/information requested on the paper diaries to capture all information.  The visit frequency is 
every 26 weeks (6 months) in this long- term follow -up phase, however, there should also be at least quarterly contact (±2 weeks) between the site staff and subject to monitor the proper 
completion of the study -specific paper diaries, and proper reporting of factor IX usage and bleeding episodes.  
f. For those subjects where a long-term follow -up visit is impacted by COVID -19, abdominal ultrasounds may be conducted within the following window: up to - 1 month prior to the 
target visit and up to + 1 month after the target visit.  Adjustments to the visit timing within this window are to be documented.  
g. It is recommended that t he  ( ) are completed by the subject before he is seen by the 
Investigator and/or study nurse for interview and before other (trial specific) assessments are performed, as well as before t he administration of IMP, in order for the answers not to be 
influenced by the information given by the physician, by the administration of IMP, or by early side -effects of the IMP or (trial related) assessments.  At each visit, the questionnaires are 
to be completed in the same order every time, following the order presented in the protocol.  The questionnaires are to be completed under site supervision at the site. For those subjects 
where the LTF2 ( Month 24 ), LTF4 ( Month 36 ), LTF6 ( Month 48 ), and/or LTFU8 ( Month 60 ) visits are impacted by COVID -19, the questionnaires  may be conducted at the site within 
the following window: up to -1 month prior to the target visit, up to +2 months after the target visit, and at least 4 months after the last assessment. A djustments to  the visit timing within 
this window are to be documented  
h. Applicable only for subjects participating in the optional  PROBE questionnaire sub -study.  For those subjects where the LTF2 (Month 24), LTF4 (Month 36), LTF6 (Month 48), and/or 
LTFU8 (Month 60) visits are impacted by COVID -19, the PROBE questionnaire may be conducted at the site within the following window: up to -1 month prior to the target visit, up to 
+2 months after the target visit, and at least 4 months after the last assessment. Adjustments to the visit timing within this window are to be documented.  
i. Applicable only for subjects participating in the optional musculoskeletal ultrasound (MSKUS) sub -study.  For those subjects where the LTF2 (Month 24), LTF4 (Month 36), LTF6 
(Month 48), and/ or LTFU8 (Month 60) visits are impacted by COVID -19, scans may be conducted within the following window: up to -1 month prior to the target visit, up to +2 
months after the target visit, and at least 4 months after the last MUSKUS. Adjustments to the visit  timing within this window are to be documented.  
j. The visit frequency is every 26 weeks (6 months) in this long -term follow -up phase, however there should be at least quarterly contact (±2 weeks) between the site staff and subject to 
monitor the occurrence of AEs.  
  CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 33 of 146 
Table  4 Schedule of Events for Laboratory Parameters, for Long -Term Follow -up (Visit LTF1 to LTF8)  
Trial Period a Long -Term Follow -up b, c Additional 
Visits d 
Visit  LTF1  LTF2  LTF3  LTF4  LTF5  LTF6  LTF7  LTF8   
Months  18 24 30 36 42 48 54 60  
Visit window (weeks)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2  
Local Laboratory           
Factor IX: one -stage aPTT for factor I X 
activity for local monitoring  x x x x x x x x (x) d 
Transaminases (AST/ALT) for local 
monitoring e x x x x x x x x (x) d 
Central Laboratory           
One-stage aPTT for factor IX activity  x x x x x x x x (x) d 
Chromogenic Assay for factor IX 
activity  x x x x x x x x (x) d 
Factor IX protein concentration  x x x x x x x x (x) d 
Anti-factor IX antibodies   x  x  x  x (x) d 
Factor IX inhibitors  
(Nijmegen modified Bethesda assay) f  x  x  x  x (x) d 
Factor IX Recovery g         (x) d 
Total (IgM and IgG) antibodies to 
AAV5   x  x  x  x (x) d 
Neutralizing antibodies to AAV5   x  x  x  x (x) d 
Sampling for vector genome detection  x x x x x x x x (x) d 
Blood h x x x x x x x x (x) d 
Semen h x x x x x x x x (x) d 
Alpha -fetoprotein (AFP)   x x x x x x x x (x) d 
Hematology and coagulation 
parameters i x x x x x x x x (x) d 
Serum chemistry parameters j x x x x x x x x (x) d 
AAV5: adeno -associated viral vector serotype 5; ALT: alanine aminotransferase; aPTT: activated partial thromboplastin time; AST: aspartate aminotransferase; IgG: immunoglobulin G; 
IgM: immunoglobulin M;  IMP: investigational medicinal product . 
a. This table shows events for the long- term follow -up. Refer to Table 2  for events during screening, lead -in, and treatment + post -treatment follow -up. 
b. Each visit in the long- term follow -up is scheduled in relation to the date of IMP dose administration (Visit D), not in relation to the date of its previous vis it. 
c. For subjects on continuous routine prophylactic Factor IX replacement therapy, these visits should take place on the day that routine prophylactic Factor IX replacement treatment is 
planned to be administered. At these visits, blood sampling will take place prior to administration of prophylactic Factor IX  replacement therapy. If a subject uses a dditional on -demand 
Factor IX replacement treatment, his upcoming study visit may need to be re -scheduled (to the extent the visit window allows) so that the visit takes place at the time the subject 
resumes his continuous routine prophylaxis schedule. For  subjects only using on- demand Factor IX replacement therapy (only applicable after AMT- 061 administration), his upcoming CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 34 of 146 
study visit may need to be re -scheduled (to the extent the visit window allows) so that the visit does not take place within 5 half -lives of exogenous Factor IX product use . In case the 
5 half-lives washout extends beyond the protocol allowed visit window, the Medpace and uniQure Medical Directors are to be contacted to discuss how to proceed.  
d. An additional visit can be performed at any time during the study (long -term follow -up phase) for the purpose of conducting one or more procedures listed in the column “Additional 
Visits” as per the preference of the Investigator. Hence, “(x)” refers to a procedure that can be performed, if judged relevant by the Investigator.  
e. For ALT level increments of at least 2- fold baseline (i.e., Visit D, pre -IMP) and /or > upper limit of normal (ULN),  by local or central laborator ies, the Investigator  should contact the 
Medpace and uniQure Medical Directors to discuss a clinical management plan, on a case- by-case basis, including potential re -tests and/or initiation of corticosteroid treatment. In case 
of AST level increments > ULN , the Investigator should contact the Medpace and uniQure Medical Directors and a similar discussion should take place.  
f. In case of a positive test for factor IX  inhibitors, a re- test should be performed within two weeks to confirm the positive test. The su bject should be called in for an additional visit in 
case no routine visit is scheduled within this two week timeframe.  
g. At suspicion of factor IX  inhibitor, the factor IX  recovery assessment should be repeated. Blood samples for factor IX  recovery assessme nt should be drawn prior to administering the 
subject’s continuous routine factor IX  product/dose  and at 30 minutes after the factor IX  dose is administered (timed from end of infusion). The same continuous routine factor IX  
product/dose used at the baseline recovery assay should also be used when repeating the assay.  
h. Sampling for the individual subject and for a specific matrix (i.e., blood or semen) is only to be continued until 3 consecut ive negative samples have been detected for the subject for 
that particular type of matrix. The sampling schedule  (frequency)  may be increased as agreed between the Investigator and subject following the notification of a first negative result on 
blood and/or semen, expediting the opportuni ty to reach three consecutive negative samples on the specific matrix. Based on the wish of the subject, semen samples can be collected at 
home prior to attending the visit (at the visit day or at the day before the visit day). Also, the frequency of semen  sampling may be reduced (to be agreed between Investigator and 
subject) as long as the subject uses a condom during sexual intercourse until 3 consecutive negative samples have been detect ed. Semen samples are only to be collected as applicable.  
i. For hematology: h emoglobin, hematocrit, platelet count, red blood cells, white blood cells with differential count (all expressed in % as well  as in absolute numbers ); for coagulation:  
aPTT , and prothrombin time (or INR [International Normalized Ratio]).  
j. Serum electrolytes (sodium, potassium), creatinine, creatine kinase, gamma -glutamyltransferase ( ɣGT), aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline 
phosphatase (ALP), C -Reactive Protein (CRP), albumin, total bilirubin, glucose (non -fasting).  
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 35 of 146 
1 INTRODUCTION 
1.1 Condition Background and Current Treatment 
Congenital hemophilia B is an inherited bleedi ng disorder characterized by an increased bleeding 
tendency due to either a partial or complete deficiency of the essential blood coagulation f actor 
IX (FIX). The deficiency is the result of mutations of the respective clotting factor genes. 
Hemophilia B is an X -linked, recessive condition,  since it occurs a lmost exclusively in ma les.  
Females typi cally a re asymptomatic c arriers . The number of pe ople with hemophilia B 
worldwide is approximately 30,000 and in the United
 States ( US) alone is approximately 4,000 
(World F ederation of Haemophilia [WFH], 2017). Approximately 1 in 20,000 – 50,000 live male 
newborns has hemophilia B. 
The severity of symptoms can var y 
and the severe forms become apparent early in life. About 
one-third
 of individuals with hemophilia B have a severe disorder characterized by functional 
factor IX levels that are less than 1% of nor mal (Kessler & Mariani, 2006 ). Moderate and mild 
hemophilia B, with 1 - 5% or 5 - <40% of nor mal factor IX level, r espectively,  are each obs erved 
in about one-third of patients (Kessler & Mariani , 
2006). 
Bleeding is the main symptom of the disease and usually increases when the infant becomes 
mobile. Mild cases may go unnoticed until later in life, when they occur in response to surgery or 
trauma. In severe or moderate hemophilia internal bleeding may occur anywhere, but bleeding 
into
 joints is most common (National Heart, Lung, and Blood Institute, 2013) . Severe recurrent 
bleedings may lead to severe arthropathy, joint contractures and pseudotumors, resulting in 
chronic pain, disability and reduced  (Bolton-Maggs et al., 2003) . As few
 as 
one to two bleeds can trigger progressive, irreversible joint disease (Gater et al., 2011 ). 
The overall l ife expectancy i n severe hemophilia is 63 years, which is about 15 years lower than 
general male popul ation ( Darby et al., 2007 ). Life expectancy in patients without liver 
complications  (e.g., human immunodeficiency virus [HIV] or he patitis C ) can appr oach t hat o f 
the general male popul ation ( Plug et al, 2006; Osooli et al 2017 ). 
There is no cure for hemophilia B. The primary goals of hemophilia B therapy are the prevention 
of bleeding episodes, rapid and definitive treatment of bleeding episodes (breakthrough bleeds) 
that occur even while on a regular prophylactic regimen and provision of adequate hemostasis 
during surgery a nd emergencies. Currently, these goals are essentially met for hemophilia B 
subjects by intravenous (IV) injections of commercially available recombinant- or  
plasma -derive d factor IX products, e ither at t he time of  a bleed (on -demand) or by regular 
infusions up to s everal
 times a week (prophylactically). The recent approvals of extended half-
life factor IX products allow for reduce d frequency of factor administration  (once every 7 to 14 
days) and maintaining a higher factor IX
 trough level (Taylor and Kruse- Jarres , 2016 ). CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 36 of 146 
1.2 Gene Therapy Therapeutic Concept  
Somatic gene therapy offers the potential for a shift of the disease severity phenotype from 
sever e to a moderate or mild hemophilia phenotype or complete amelioration  through continuous 
production of stable factor IX  levels after a single administration of vector, especially since a 
small rise in circulating factor IX  to at least 1% of normal levels can substantially ameliorate the 
bleeding phenotype and thus improve the  for patients . 
1.3 Investigational Product Background 
AMT -061 has been developed for the treatment of hemophilia B. AMT-061 is a recombinant 
adeno -associated viral vector serotype 5 (rAAV5) containing the coding sequence for the Padua 
variant of the human coagulation factor IX (hFIX-Padua), codon optimized for optimal 
expression in humans, under control of a liver-specific promoter (also known as AAV5- hFIXco -
Padua).  
AMT -061 is a derivative of AMT -060, which has been studied in a Phase I/II clinical trial in 
humans with severe or moderately severe hemophilia B. Both AMT-060 and AMT-061 have the 
same recombinant AAV5 containing the codon- optimized wild -type human factor IX  gene, but 
the latter incorporat es a two -nucleotide change in order to encode the naturally occurring Padua 
variant of human coagulation factor IX . The FIX -Padua protein differs from the ‘ wild-type ’ 
human factor IX  protein by a single amino acid and it is resp onsible for the observed increased 
Factor IX activity per unit of dose achieved with AMT-061 as compared to its predecessor 
AMT -060. 
Both AMT-060 and AMT-061 employ the same AAV5 capsid as vector and liver- specific 
promoter, conferring similar safety and expression profiles. Section  1.3.1 provides a summary of 
the preclinical information for AMT -060 and AMT-061. C linical information for AMT -060 is 
summarized in Section  1.3.2. For the most comprehensive information regarding AMT-060 and 
AMT -061 refer to the mo st recent  Investigator’s Brochure. 
1.3.1 Preclinical Information  
Information for AMT -061 
The AMT -060 and AMT-061 based gene therapy vectors are identical with the exception of a 
two-nucleotide substitution resulting in a single codon change (AGG to CTG) in the coding 
sequence for factor IX  present in AMT-061, corresponding to an Arginine to Leucine 
substitu tion in the transgenic protein. CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 37 of 146 
The R338L substitution, FIX-Padua, represents a naturally occurring variant of factor IX  
showing a gain-of-function, which results in higher factor IX  activity with similar factor IX  
protein expression ( Simioni et al., 2009). This augmentation is thought to be largely caused by 
increased affinity of the activated protein to activated clotting factor VIII (FVIIIa; 
Kao et al., 2013). Both AMT-060 and AMT-061 employ the same vector AAV5 without any 
changes and it is therefore expected that AMT -061 will present a safety profile similar to  that 
observed with AMT-060. 
A non-human primate (NHP) study (NR-061-17-001) was performed to assess 4 different dose 
levels of AMT -061 in direct comparison with AMT-060 with respect to liver transduction, 
circulating factor IX  protein levels, circulating factor IX  activity levels and toxicity, after a single 
IV dose with 13 or 26-week observation period. The study comprised of measurements of circulating hFIX protein levels, total circulating factor IX  activity levels, assessment of vector 
DNA in plasma, b iodistribution including more than 25 different organs/tissues, complete safety 
panel routinely performed in GLP-toxicity studies and monitoring of six different liver enzymes 
and additional coagulation markers throughout the study. The study revealed dose dependent 
plasma vector DNA levels, human factor IX  protein levels and factor IX  activity for AMT-061. 
Clinical signs were unaffected by treatment as well as clinical chemistry and hematology. Coagulation investigations up to 26 weeks revealed a shortening of the activated partial 
thromboplastin time (aPTT) and longer PT clotting times at the highest dose (9.0 × 10
13 genome 
copies [gc]/kg) of AMT-061 only, without an effect on plasma D-dimer and thrombin-
antithrombin levels, suggesting that despite the eff ect on the clotting times, the overall clotting 
cascade is functioning within physiological boundaries. The study clearly showed that at a dose 
of 5 × 1012 gc/kg, plasma exposure, liver distribution, liver cell transduction, and transgene 
expression are similar for both AMT-060 and AMT-061 but the transgene activity is 
approximately 6 times higher per unit protein for AMT-061 compared to AMT-060. Although the study design only included a direct comparison at 5 × 10
12 gc/kg, it can be expected that 
plasma exposure, liver distribution, liver cell transduction, and transgene expression behave similarly at each dose level with a range. As expected the study demonstrated that for the same 
dose, the mean factor IX  protein of AMT-060 (average of 4.89, ranging from 3.17 to 7.61%) and 
AMT -061 (average of 4.85, ranging from 2.92 to 6.17%) was comparable. The confirmation of 
transgene activity being approximately six times higher per unit protein (average of 6.10, ranging 
from 5.41 to 7.47%) can similarly be expected to result in multiple of the already demonstrated 
activity levels of AMT -060 within a range. These results are comparable to the increase in gain -
of-function reported for the Padua factor IX  protein compared with “ wild-type ” factor IX  protein 
in animal models ( Crudele et al., 2015; Monahan et al., 2015).  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 38 of 146 
The observed translation of the NHP for AMT-060 to the clinical Phase I/II for AMT-060 
supports the translation of the NHP study for AMT-061 (NR-061-17-001, Study No. NC1615) to further inform the dose rationale for the dose confirmation trial (CT- AMT -061-01) with 
2 × 10
13 gc/kg AMT-061. At 2  × 1013gc/kg, AMT-061 is predicted to result in mean factor IX  
activity ranges of 40% of normal, with acceptable ranges (between approximately 18- 76%) 
within the expected safety for factor IX  replacement (upper bound of the safety and therapeutic 
target range is 129%). 
The other non- clinical study was a formulation bridging study in wild- type male mice to test 
AMT -061, manufactured as per process used to manufacture the material for the pivotal clinical trial, 
in direct comparison with AMT -060, both tested at 3 different concentrations (formulated with or 
without polysorbate 20). This study showed a similar dose-dependent expression of hFIX protein 
levels in plasma, supporting equal transgene expression mediated by the two products.  
The non- clinical studies with AMT -061 indicated that AMT-061 has a comparable distribution and 
plasma shedding profile to AMT-060, which was not influenced by the addition of polysorbate 20 to 
the formulation. The addition of the polysorbate 20 to the formulation had no effect on the safety 
profile of AMT-060 and AMT -061 in wild -type mice.  
Information for AMT -060 
A range of in vivo  studies in wild -type and hemophilia B mice and in NHPs  have been performed 
to characterize the safety and pharmacology of AMT-060. 
Pharmacology studies in mice and NHPs  showed out that infusion of AMT -060 resulted in 
vector dose-dependent circulating levels of (human) factor IX  protein. 
To verify that AMT -060 mediates expression of biologically active hFIX, and to confirm that the 
hFIX produced and secreted into the circulation can ameliorate the clotting defect inherent to 
factor IX  deficiency, a dose-range study was  performed in a murine model of hemophilia B 
(Study NR-060-13-007 ). Results of this study indicated direct correlation in vivo between 
circulating human factor IX  protein levels and human factor IX  activity.  
In both Rhesus and Cynomolgus macaques injected with various doses of AMT -060, the 
resulting hFIX expression correlated with the dose and was sustained for the duration of the 
6 months follow-up (Cynomolgus macaque; Study 522156 and NR -060-14-006) and 90 days 
follow-up (Rhesus monkey; Study 520665 and NR-060-11-009). 
None of the animals presented elevated liver enzyme levels or other signs of toxicity during the 
whole observation period, and after sacrifice no abnormalit ies were obs erved in the liver. 
These non- clinical data suggest that IV  administration of AMT -060 is able to mediate sustained 
levels of factor IX , and that such administration is not associated with any significant safety 
concerns.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 39 of 146 
1.3.2 Preliminary Clinical Information for AMT -061 and Clinical Information for 
AMT -060 
The combination of an AAV5 vector and the human factor IX  gene (AAV5 -hFIX) had not been 
evaluated in human trials prior to the initiation of the Sponsor’s Phase I/II clinical trial 
CT-AMT -060-01. The AAV5 capsid and the hFIX gene cassette have been tested individually in 
other Phase I/II clinical trials. The results from these trials providing preliminary clinical 
evidence for efficacy and safety of AMT -061 are summarized in Section  1.3.2.1, the results of 
the first in human trial for AMT -060 (CT -AMT -060-01) are summarized in Section  1.3.2.2, and 
the interim results of the first in human tria l for AMT -061 (CT- AMT -061-01) are summarized in 
Section  1.3.2.3. 
1.3.2.1 Preliminary Clinical Evidence for Efficacy and Safety of Components of AMT -061 
In Table 5, the most relevant published data and studies conducted with AAV capsids and hFIX 
that were identified through searches of PubMed and clinicaltrials.gov databases are presented.  
The data outlined below support that administration of AMT-061 will be sa fe, well -tolerated, and 
able to generate sustained endogenous production of factor IX  at clinically meaningful activity 
levels.  
Table  5 Summary of Published Clinical E xperience wi th Components of AMT -061 
Reference  Capsid  Gene  Promotor  Target 
tissue  Key Findings  
D’Avola, 2016  AAV5 -
based  PBGD  -- Liver  - No adverse events associated with 
capsid  
- Capable of transducing hepatocytes in 
vivo  
Rangarajan, 
2017  AAV5  BDD -
FVIII  APOE  
HCR/A1AT  Liver  - Mild asymptomatic transaminase 
increases in 7  subjects  
- Capable of delivery that results in 
clinically relevant transgene 
expression durable to >1 year  
Lu et al, 1993  Retro -viral hFIX  LTR  
N2CMV  Autologous 
skin 
fibroblasts  - Increase in factor IX  activity and 
improved symptoms in 1  subject  
- No safety or toxicity concerns  
Kay, 2000  AAV2  hFIX  CMV  Muscle  - Expression of biologically active 
hFIX  
- No inhibitors to factor IX  
Manno, 2003  AAV2  hFIX  CMV  Muscle  - Safe incorporation of hFIX into 
muscle cells  
- Persistence of vector genome and 
protein expression to 10 months  
- No inhibitors to factor IX  
Jiang, 2006  AAV2  hFIX  CMV  Muscle  - Persistence of vector genome and 
local protein expression at 3.7 years 
post-treatment  
- No inhibitors to factor IX  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 40 of 146 
Reference  Capsid  Gene  Promotor  Target 
tissue  Key Findings  
Manno, 2006  AAV2  hFIX  hAAT -
APOE  Liver  - Transient expression of factor IX  at 
clinically relevant doses by transduced 
hepatocytes  
- Loss of factor IX  expression with 
ALT increase  
- No inhibitors to factor IX  or T-cell 
response to the capsid  
Nathwani, 
2011,  2014 , 
2018  AAV8  hFIXcoa LP1a Liver  - Successful transduction of hepatocytes 
resulting in clinically relevant increases in serum factor IX  activity  
- Clinically relevant increases in 
factor IX activity sustained up to 
approximately 8 years  
- Elevated transaminases in 4  subject s; 
factor IX  expression retained in 2 with 
corticosteroid treatment  
- No inhibitors to factor IX  
- No late toxicity  
George, 2017  Undisclosed  hFIX -
Padua  hAAT -
APOE  Liver  - Clinically relevant increases in factor 
IX activity  sustained to >1 year  
- Elevated transaminases in 2 subjects; 
partial to full factor IX  activity 
retained with corticosteroid treatment  
- No inhibitors to factor IX  
AAV5 /AAV2/AAV8: adeno -associated viral vect or of serotype 5 (or 2 or 8); ALT: alanine aminotransferase; APOE: 
apolipoprotein E; BDD -FVIII: B- domain deleted factor VIII; CMV:  Cytomegalovirus;  hAAT: human α1 -antitrypsin; hFIX: 
human factor IX; LTR: long terminal repeat; PBGD:  porphobilinogen deaminase . 
a  Same transgene expression cassette as is used for AMT -060 
 
AAV5 Capsid  
Two studies of the AAV5 capsid in humans were identified. 
D’Avola et al. (2016) studied the AAV5 -based  vector comprising the capsid shell of AMT-060 
and containing a functional porphobilinogen deaminase (PBGD) gene tested at varying doses 
(5 × 1011 to 1.8 × 1013 gc/kg; single IV infusion) in eight adult subjects  with intermittent acute 
porphyria. One subject  failed screening due to pre-existing AAV5 neutralizing antibodies 
(NABs) . All eight subject s who received AAV5 -PBGD were followed for one year. No 
treatment -related adverse events (AEs) were observed during the infusion or the follow-up 
period. One subject who received the highest dose experienced a mild increase (<3x upper limit 
of normal [ULN]) of liver transaminase levels one week after receiving AAV5 -PBGD, 
coincident with an acute porphyria attack. Levels normalized once the attack resolved. As 
expected, all subject s developed antibody titers against AAV5; no subject s developed antibodies 
against the transgene product. The AAV5 vector was cleared from all bodily secretions by 30 days post- administration. To gether, these findings support good safety and tolerability for the 
AAV5 capsid. Evaluation of liver biopsies at one year post- treatment showed persistence of 
vector genomes and transgene messenger RNA in all six  subject s evaluated, suggesting that the 
AAV5 capsid is able to effectively deliver genetic material to the nuclei of liver cells.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 41 of 146 
Initial results up to 52 weeks post-treatment have also reported by Rangarajan et al (2017)  from a 
Phase I/II trial of an AAV5 -B-domain- deleted factor VIII (FVIII) const ruct in 9 adults with 
hemophilia A. In this report , subject s received doses ranging from 6 × 1011 to 6 × 1013 gc/kg via 
single IV infusion. No serious adverse events ( SAEs ) attributable to treatment were observed. 
The first subject  receiving the highest dose experienced a mild increase in transaminase levels, 
which resolved with a short course of corticosteroids; subsequent subjects  received prophylactic 
steroid treatment, of whom six experienced mild transient increases in their tr ansaminase levels. 
One subject experienced a decline in FVIII activity from 227  IU/dL to 52 IU/dL in conjunction 
with an increase in alanine aminotransferase (ALT) occurring after discontinuation of 
prophylactic steroids. A second course of corticosteroids was initiated and FVIII subsequently 
increased. No clear relationship was observed between corticosteroid use and resolution of 
elevated aminotransferase. All subjects have tapered off corticosteroids and continue to 
demonstrate increased FVIII activity at 1 year.  
Together, these findings support a strong expected safety profile of the AAV5 capsid in humans, 
with no serious safety concerns emerging. Mild, asymptomatic liver transaminase increases are 
the most common event, consistent with reports from othe r liver -targeted AAV serotypes. 
Together, these studies provide evidence that the AAV5 capsid is capable of transducing human hepatocytes in vivo , resulting in detectable, sustained transgene expression. 
Gene cassette  
Gene transfer of the human wild -type f actor IX  gene has been evaluated in three key studies in 
adult subject s with hemophilia B. The most recent reports demonstrate that this construct is 
capable of inducing sustained, clinically relevant increases in factor IX  activity without 
associated safety concerns.  
In three subject s receiving transfer of the wild -type hFIX gene under control of a 
cytomegalovirus (CMV) promotor/enhancer (2 × 1011 gc/kg) into the muscle via AAV2, 
evidence of factor IX  protein expression was seen both in the circulation and through histological 
examination of muscle biopsies ( Kay et al., 2000). Factor IX  consumption was reduced in two  
subject s, providing evidence of biological activity of the secreted protein. Five addi tional 
subject s were then dosed up to 1.8 × 1012 gc/kg. Presence and expression of the transgene was 
demonstrated via polymerase chain reaction ( PCR) and Southern blot in muscle biopsies up to 
month 10 post- injection. No muscle tissue abnormalities were no ted, suggesting the cells were 
not damaged by incorporation of the vector genome ( Manno et al., 2003). Follow -up of one 
subject  3.7 years after injection showed persistence of the vector genome and protein expression 
locally in the muscle ( Jiang et al., 2006).  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 42 of 146 
A subsequent trial examined the effects of the wild -type hFIX under control of a liver- specific 
human ɑ1 -antitrypsin (hAAT) promotor coupled with the apolipoprotein E (APOE) enhancer and 
hepatic control region, packaged into AAV2 vectors and administered via hepatic vein infusion 
to seven subject s at doses up to 2 × 1012 gc/kg ( Manno et al., 2006). No evidence of increased 
circulating factor IX  activity was obtained at 8 × 1010 or 4 × 1011 gc/kg. At the highest dose, both 
subject s showed transient incr eases in circulating factor IX  activity (approximately 12% and 3% 
of normal) which gradually returned to baseline. The high-responding subject demonstrated asymptomatic increases in serum transaminase levels coincident with the decline in factor IX  
activity that subsequently normalized. A second subject  who received the middle dose also 
experienced an asymptomatic increase of serum transaminase levels that normalized without 
intervention. Testing in this subject  indicated that no T-cell response developed to the factor IX  
protein. 
The cassette identical to that incorporated in AMT -060, and forming the basis for the modified 
version incorporated in AMT -061, has been examined in 10 subjects in a trial sponsored by 
St Jude’s and University College of London ( Nathwani et al., 2011; Nathwani et al., 2014; 
Nathwani et al., 2018). Subject s received increasing doses (2 × 10
11 to 2 × 1012 gc/kg; single IV 
infusion) of the LP1-hFIXco construct delivered via AAV8, resulting in a steady state of 1 -6% 
normal factor IX  activity that remained stable at last reported follow -up approximately 8 years 
after administration. Use of exogenous factor IX  replacement was reduced by 92% following 
treatment. Bleeding episodes in the year aft er gene transfer decreased to a median of 1.5, 
compared with 15.5 in the year preceding treatment. Four of the six subject s who received the 
highest dose experienced increases in serum transaminase levels 7 -10 weeks after administration 
and were treated wi th prednisolone, of whom three experienced an associated loss of factor IX  
activity. No subject s developed inhibitors to factor IX  protein. All subject s demonstrated 
evidence of endogenous synthesis of factor IX  from the transgene cassette. No evidence of late 
toxicity has emerged even at approximately 8 years post- treatment.  
Initial results have been published from a single study showing sustained factor IX  expression 
driven by a gene cassette encoding a Padua v ariant factor IX  (George et al., 2017). Ten subjects 
received a single IV dose of 5  × 1011 gc/kg, resulting in mean steady state factor IX  expression of 
approximately 34% at 52 weeks at time of the report. Two subjects experienced increases of liver 
transaminases and were treated with prednisolone, of whom one experienced a partial loss of factor IX  activity. No subjects developed inhibitors. 
Across all three studies, no subject s who had received gene transfer (total N=31) developed 
inhibitors to the transgenic hFIX protein ( Manno et al., 2003; Manno et al., 2006; 
Nathwani  et al., 2014; George et al., 2017).  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 43 of 146 
1.3.2.2 Results of Clinical Trial- AMT -060-01 
Enrollment and dosing in a first- in-human trial with AMT -060 (CT -AMT -060-01) has been 
completed.  Follow-up of up to 2.5 years from all five subjects in the low dose (5 × 1012 gc/kg) 
cohort and 2 years follow-up from all five subjects in the high dose (2 × 1013 gc/kg) cohort are 
currently available (Cohort 1 and 2, respectively; Leebeek et al., 2018; Miesbach et al, 2017). 
The durability of factor IX  protein expression encoded by the codon optimized human 
coagulation factor IX  complementary deoxyribonucleic acid ( cDNA ) obtained at this point in 
time is robust and sustainable. 
There have been no deaths or AEs that have resulted in discontinuation reported in 
CT-AMT -060-01. There were a total of 3 SAEs  assessed as treatment -related  reported , including 
a febrile episode, elevation of liver enzymes, and elevation of ALT . Fourteen treatment -related 
AEs were reported in 6 subject s in the first 3.5 months post- treatment . There were no additional 
treatment -related  AEs reported during this additional follow-up period up to 2.5 years post-
treatment. Three subjects  had mild, temporary ALT elevations 3 to 6 months post- treatment , 
which resolved with tapering courses of prednisolone with no recurrence. None of the observed ALT increases w ere associated with any concurrent loss of endogenous factor IX  activity  or 
capsid -specific T -cell response. No subject devel oped inhibitory antibodies to factor IX  during 
the course of the trial.  
Following administration of AMT -060, stable factor IX  activity and clinically meaningful 
reductions in bleeds and exogenous factor IX use were observed, with disease severity improved in all subject s. The mean of all endogenous factor IX activity values measured post- treatment 
over the course of follow-up was 4.9% of normal in Cohort 1 and 7.4% of normal in Cohort 2. Eight of the nine subjects who had been on factor IX  prophylaxis at the time of trial entry no 
longer require factor IX  prophylaxis after treatment with AMT -060. Annualized exogenous 
factor IX  use was reduced by ≥ 82% in Cohort 1 and ≥ 78% in Cohort 2 compared to pre-
treatment . Mean annualized total bleeds de creased by ≥47% in Cohort 1 and ≥ 62% in Cohort 2. 
1.3.2.3 Interim Results for CT -AMT -061-01 
Enrollment and dosing in an ongoing dose confirmation Phase IIb trial with AMT-061 (CT-AMT -061- 01) has been completed  and three subjects have been dosed with 2 × 10
13 gc/kg 
of AMT -061. A n interim analysis was performed after all subjects had completed 6 weeks of 
post- treatment follow -up and the interim analysis data set includes a combined 24 weeks of 
observation. The interim analysis results from CT -AMT -061- 01 were reviewed by the Data 
Monitoring Committee (DMC; see Section  9.12) who recommended that a single dose of 
2 × 1013 gc/kg of AMT -061 be used in the treat ment phase of this Phase III trial.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 44 of 146 
There have been no deaths, SAEs, or treatment -emergent adverse events (TEAEs) resulting in 
early discontinuation from CT- AMT -061-01 at the time of the interim analysis . Overall, there 
have been 13 TEAEs reported in 2 of 3 subjects , including 2 treatment- related TEAEs reported 
in a single subject (C -reactive protein increased and headache) . All TEAEs  were mild in severity  
and the majority ( 11/13 events) were assessed as not related to study treatment. The system 
organ class ( SOC ) with the most reported events was Nervous System Disorders (4 events) and 
the most common TEAE was headache, reported in 2 subjects , though one subject experienced 6 
separate events of pain . One subject had a mild, asymptomatic, and transient increase in liver 
enzyme levels (specifically, elevated aspartate aminotransferase [ AST ] levels ) which resolved 
without any additional treatment and was not reported as a TEAE.  No T- cell res ponse has been 
observed in any of the 3 subjects. None of the subjects have developed inhibitory antibodies to 
factor IX . 
All 3 subjects had been diagnosed with severe hemophilia B with corresponding circulating 
factor IX  activity levels <1% of normal. A s ingle dose of 2 × 1013 gc/kg of AMT -061 was 
demonstrated to result in factor IX  activity levels of ≥5% as early as 1 week post -treatment with 
mean ± standard deviation ( SD) factor IX  activity of 30.6 ± 6.97% (range: 23.9-37.8%) at Week 
6 and 28.5 ± 6.42% (range 20.6-37.8%) across visits ( factor IX  activity was measured using the 
aPTT assay performed at a central laboratory). Factor IX  activity was 37.1% of normal at ten 
weeks after administration in the first subject , 23.3% of normal at eight weeks following 
administration in the second subject , and 30.0% of normal at six weeks after administration in 
the third subject . The second and third subject s had previously screen- failed another gene 
therapy study due to pre-existing NABs  to a different AAV vector. All 3 subjects had evidence 
of pre -existing NAB  activity against adeno -associated viral vector serotype 5 (AAV5).  
In the year prior to screening the number of treatment-requiring bleeding episodes ranged from 1 
to 5 spontaneous episodes and there was  1 moderate spontaneous bleeding episode in 1 subject in 
the period between screening and dosing. After dosing, there were no bleeding episodes and the estimated annualized bleeding rate ( ABR ) was  0. Additionally, none of the subjects have 
required any infusions of factor IX  replacement therapy post -treatment with AMT -061. 
1.4 Rationale for the Trial 
The current treatment options for hemophilia B have several limitations. Treatment with prophylactic regular IV injections of factor IX  is not curative and very demanding due to the 
need for frequent IV infusions and concomitant risk for infection and thromboses related to the placement of indwelling catheters. Periodic or regular factor IX  infusion results in peaks and 
troughs in plasma factor levels allowing for breakthrough bleeding episodes. Due to these factors, poor adherence to treatment is a concern and a major contributing factor to failure of prophylaxis, associated with increased risk of bleeding and subsequent joint damage, thereby adding to the all-cause mortality rate. There is also a risk of developing NABs  against the 
administered factor IX . The burden of the disease is high, both for the individual subject  and CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 45 of 146 
their families, and for society. Due to (long- term) impairments in mobility and functional status, 
subject s may not be able to fully participate in social activities, such as sports, school, or work. 
Living with hemophilia can have a substantial effect on mental wellbeing, particularly among 
young people and signs of major depressive disorder are not uncommon. The economic burden 
for the society is significant. The cost of severe hemophilia, including indirect costs, is estimated 
at EUR 199,541 per subject  in Europe, ranging from EUR 129,365 to 319,024 
(O’Hara  et al., 2017). Hemophilia subject s are accredited with requiring 2- 3 times the health care 
resources per inhabitant in developed countries ( Schramm & Berger, 2003). Hemophilia  B 
thereby directly impacts the health -related  ( Witkop et al., 2017).  
Somatic gene therapy for hemophilia B offers the potential for shift of the disease severity from 
severe to a moderate or mild hemophilic phenotype or complete amelioration through continuous 
endogenous production of factor IX  protein after a single administration of AAV vector particles. 
Even a small rise in constantly circulating factor IX  protein can substantially ame liorate the 
bleeding phenotype. 
Three subjects have been treated with 2 × 1013 genome copies (gc)/kg AMT-061 in an ongoing 
dose confirmation Phase IIb trial (CT- AMT -061-01). The initial treatment phase has been 
completed in this study and an interim analysis based on a minimum of 6 weeks of post-
treatment follow -up data for each subject has been performed  (see Se ction 1.3.2.3 for an 
overview of the interim analysis results) . Overall, the dose of 2 × 1013 gc/kg AMT-061 was 
shown to be safe and well tolerated  and resulted in mean factor IX  activity levels approximately 
30% of normal circulating factor IX  6 weeks after dosing. 
The results with AMT -061 to date are complemented by robust efficacy and safety data obtained 
with AMT -060 in the ongoing Phase I/II  trial (CT-AMT -060-01) in 10 subjects  with hemophilia 
B who have now been followed for up to 2.5 years after treatment  (see Section 1.3.2.2 for an 
overview of study data). The data demonstrate that subjects achieved clinically relevant and 
stable factor IX  activity levels for up to 2.5 years after treatment with AMT -060. In addition, the 
AMT -060 treatment remains  to be safe and well -tolerated.  
The purpose of this Phase III trial is to demonstrate the efficacy  of AMT -061 in terms of 
endogenous factor IX  activity and ABR , and to further describe its safety profile. The efficacy 
and safety results obtained during the Phase IIb study with AMT-061 (CT- AMT -061-01), 
supplemented with the strong efficacy and safety results obtained during the P hase I/II trial with 
AMT -060 (CT -AMT -060-01), demonstrate 2 × 1013 gc/kg to be the optimal dose for use in this 
pivotal Phase III trial.  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 46 of 146 
1.5 Risk/Benefit Considerations 
Somatic gene therapy for hemophilia B offers the potential benefit of a shift of the disease 
severity from severe to a mild hemophilia phenotype or complete amelioration through 
continuous endogenous production of factor IX  after a single administration of vector.  
The identified risks are considered low and manageable and to  not affect the risk/benefit balance 
in an unfavorable way. The optimized adeno- associated viral vect or (AAV) approach has the 
potential to further limit the risks currently associated with AAV gene therapy approaches. 
The risks as described in the following sections have to be considered . 
1.5.1 Risk of Infusion -related T oxicity 
To date no infusion- related toxi cities have been observed in previous clinical trials of liver -
directed gene transfer, including the CT -AMT -060-01 trial. In CT -AMT -061-01, one subject had 
mild TEAEs of headache and paresthesia reported on Day 1, which resolved the same day; the 
event of headache was assessed as possibly related to study treatment.   
As a precaution , subjects in this trial will be monitored for tolerance to the investigational 
medicinal product ( IMP) and detection of potential immediate AEs at the clinical trial site for 
three hours following infusion.  
1.5.2 Risk of Immune M ediated N eutralization  of the AAV5 G ene Therapeutic Vector  
Pre-exist ence o f antibodies that recognize a gene therapeutic vector can potentially reduce its 
bioavailability and hence its activity.  For this reason, the eligibility criteria for CT -AMT -060-01 
included the absence of detectable levels of circulating AAV5  NABs . Screeni ng for AAV5 
NABs  was performed using a bio-assay based on a green fluorescent protein (GFP) reporter 
gene. In line with previously reported low prevalence for AAV5 NABs  (Boutin et  al., 2010), no 
antibodies were detected and all subjects passed screening. 
Recent availability of a more sensitive bio -assay, based on a luciferase reporter gene prompted 
retrospective analysis of the screening samples from the CT -AMT -060-01 trial and pre- treatment 
samples of some of the nonclinical NHP studies. Retros pective analysis using this more sensitive 
assay revealed the presence of detectable levels of AAV5 NABs  in three out of 10 CT -AMT -
060-01 trial subjects and in all tested animals. However, judging by circulating factor IX  activity 
levels or safety outcomes , these pre-existing AAV5 NAB  levels held no predictive value: the 
CT-AMT -060-01 trial subject showing the highest titer of 1/340 also showed highest circulating 
factor IX  activity levels of this cohort, and in the NHPs  no impact on efficacy was evident at  
titers up to 1/1000, at dose levels down to one-tenth of the low dose level in the CT -AMT -060-
01 trial (i.e., 5 × 1011 gc/kg ver sus 5 × 1012 gc/kg). CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 47 of 146 
These studies suggested that although AAV5 NABs  are prevalent in humans and NHPs , the 
absolute levels at w hich they are present may not suffice to  impact AMT -060 at the infused dose. 
In all subjects who were shown to have AAV5 NABs  prior to treatment, factor IX  activity 
remained  stable , and none of the subjects  showed evidence of liver toxicity or activation of T-
cell responses against the capsid. As pre -existing antibody levels did not seem to preclude 
efficacy, and were not associated with any immune- mediated adverse effect, the proposed trial 
will allow enrolment of  subjects regardless of antibody levels. Nonetheless, AAV5 NAB  levels 
will be measured in all subjects both before and after dosing, in order to allow a retrospective 
analysis to confirm the suggested lack of impact of prevalent titers on the efficacy of A MT-061. 
For this, the more sensitive luciferase- based assay will be used.  
It is of note that after dosing of AMT-061 all subjects will develop antibodies against the capsid proteins and these antibodies are likely to persist. In the ongoing Phase IIb trial, CT -AMT -061-
01, AAV5 NABs  were detected in all 3 subjects  at Screening . As liver transduction will have 
taken place before these responses are fully mounted, these responses are unlikely to impact 
factor IX  expression. However, they may impact the efficacy of any future administration (i.e., a 
second dose) of the same vector, since post-dosing antibody levels may exceed prevalent pre-
existing levels by several orders of magnitude. 
1.5.3 Risk of Immune M ediated L iver Toxicity 
IV administration of a liver -directed AAV vector might lead to transaminase increase. Previous 
clinical trials have shown that increases in liver enzymes respond promptly and normalize after 
administration of glucocorticoids. Subjects  in the trial will be monitored  weekly during the first 
12 weeks after infusion of AMT -061 for the occurrence of transaminase increases, which, in the 
absence of an alternative etiology for the ALT increase, may warrant the initiation of a 
corticosteroid treatment (see Section  5.6.2). 
In the CT- AMT -061-01 trial, there were no subjec ts with  an increase in ALT  after dosing with 
AMT -061. A transient  increase in AST was noted in one su bject with potentially clinically 
significant levels at 2 × baseline at Week 4 but levels were normal at the next clinic visit and this increase was not reported as a TEAE . 
In the CT -AMT -060-01 trial, three subjects (one subject  in the low dose cohort and two subjects  
in the high dose cohort) had mild, asymptomatic increase of ALT.  This is not an unexpected 
finding, as increases of transaminases have been observed in trials associated with gene therapy targeting the liver. It is important to note that in all three subjects  none of the observed ALT 
increases was associated with any concurrent loss of endogenous factor IX  activity. No evidence 
of immune reaction  (e.g., capsid -specific T -cell response)  was associated with t his increase . CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 48 of 146 
1.5.4 Risks to Third Parties and the Environment Related to Shedding via Body Fluids  
The AAV vector will distribute systemically and small amounts of vector DNA have been 
observed in previous non- clinical and clinical studies in blood, urine, saliva, nasal secretion, 
feces  and semen . In CT -AMT -061-01, vector DN A was detected in all 3 subjects after at least 6 , 
8, or 10 weeks of follow-up in blood and after 6 weeks of follow-up in semen. In CT -AMT -060-
01, vector DNA was detected at  78 weeks and later in semen and blood in some subjects . 
Vector DNA measured in these bodily fluids is unlikely to represent infectious particles. In addition, the vector is non-pathogenic and cannot replicate. Therefore, the risk for third parties such as  family and health care personnel is considered marginal. Due to the incapacity of 
replication, the non-infectious nature of the shed DNA and the negligible amounts shed, the risk 
to the environment can be considered negligible. No specific containment or protection measures 
are deemed necessary.  
1.5.5 Risk of Vector DNA I ntegration into the H ost Genome  
Reaction (nr LAM PCR) and subsequent high throughput sequencing on DNA was extracted 
from the livers of both mouse and Cynomolgus macaques after administration of  AMT -060 at 
various doses. There was no preferred integration in genes known to mediate malignant 
transformation or clonal dominance. Both episomal (concatemeric) and integrated forms of AMT -060 were retrieved, but the sequences were present almost exclusively as non -integrated 
episomal forms. The retrieved integrants were randomly distributed throughout the host genome. No specific clustering was seen in Cynomolgus macaque genome, while some lev el of clustering 
around active genes was seen in the mouse. There were no signs of in vivo  clone selection in the 
animals.  
1.5.6 Risk of G erm-line Transmission of V ector DNA  
The risk of germ line transmission is considered negligible for AAV-based vectors due to the marginal integration level of the vector DNA into the host genome. Any potential risk is addressed by requiring the use of a condom during the trial in the period from administration of 
the investigational drug until the AAV5 vector has been cleared from semen, as evidenced by 
negative analysis results for AAV5 vector for at least three consecutively collected semen samples.  
Additionally, s ubjects are asked to inform their partner of their participation in this trial, as well 
as the importance of contraception use to limit the reproductive potential in the period from IMP 
administration until AAV5 has been cleared from the semen. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 49 of 146 
1.5.7 Risk of O ff-target Expression of the T ransgene 
The vector will distribute s ystemically to a ll tissues the reby potentially inf ecting other cells than 
liver c e
lls resulting  in of f-target gene expressi on. This risk is addressed by the use of a liver-
specific promoter in the gene cassette . In other clinical tria ls using similar vector approaches, no 
AEs have been reported that could be  related t o potential of f-t arget expr ession.  
1.5.8 Risk of  Inhibitor  Formation to Protein E xpressed f rom the Transgene 
There is a risk of inhibitor/antibodies development against the expressed f actor IX protein. No 
factor IX inhibitor formation was seen in any  of the previous  clinical trials reported in lite rature 
where s ubjects were exposed t o hFIX gene transfer and  where the express ed levels of  factor  IX 
were measurabl
e (Manno et al., 2003 ; Manno et al., 2006 ; Nathwani et al., 2011 ; 
Nathwani  et al.,  2014 ) or in CT- AMT -060-01. In-silico studies indicate no highe r risk of 
potential immunogenicity for factor IX protein e xpressed f rom AMT -061 following 
incorporati
on of the single amino acid change as compared to the “wild- type” factor IX protein 
expressed from AMT -060. Expression of a Padua transgene product did not result in inhibitors in 
studies conducted in murine and inhibitor-prone canine models (Cantore et al 2012 ; 
Monahan, 2015; Crudele et al 2015). In C T-AMT-061-01, the formation of factor IX inhibitors 
was not detec
ted in any of the 3 subjects at 6 weeks aft er dosing. 
To assist with mini mizing thi s risk, subjects will be s elected  on th e basis of  a low  risk of  factor 
IX inhibitor development by choosi ng subjects with more than 150 exposure days to a factor  IX 
product as w ell as
 omitting  subjects with a previous factor IX inhibitor. S ubjects will be  
regularly monitored for factor  IX inhibitor development. 
1.5.9 Risk of  Breakthrough B leeding 
The scope of  the liver -directed A AV ge ne ther apy approach i s to esta blish a stable and durable 
expression of factor  IX and to convert to mild or  completely a me liorate the  seve re hemophilia 
phenotype.
 Previous  clinical trials w ith similar A AV ve ctors a nd the w ild-type gene cassette 
have shown that stable and years long f actor  IX expression  can b e achieved 
(N
athwani  
et al.,  2018). Nonet heless , there is a risk that breakthrough bleeding may occur, 
particularly if demanding physical activity is unde rtaken. This risk will be managed by the use of 
factor IX replacement as needed throughout the trial. Every effort will be made to avoid 
continuous routine use of prophylactic f actor  IX replacement therapy during the tria l. 
In an ongoing Phase IIb trial with AMT-061 (C T-AMT -061-01), therapeutic levels of factor  IX 
protein and resultant factor  IX activity l evels w ere  seen as e arly  as one w eek. I n a previous trial 
with
 AMT-060, t herapeutic l evels of  factor IX protein and resultant factor IX activity l evels w ere 
seen as e arly as one week af ter treatment. In thi s trial, subjects will be administered a dose of 
their usual factor I X product/dose for the  factor  IX recovery as sessm ent at V isit L -Final and w ill 
be permitted to continue their continuous routine factor  IX treatment in the  first w eek a fter 
dosing. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 50 of 146 
Additional on-demand factor IX  may be given after treatment with AMT -061, if considered 
necessary. Furthermore, subjects  are monitored closely for five years after administration of IMP 
and the need for renewed prophylactic therapy will be clinically assessed by the treating 
physician according to  the local standard of care for hemophilia subjects . 
1.6 Accommodations Due to the COVID-19  Pandemic  
In the first quarter of 2020, a pandemic was announced for Coronavirus Disease 2019 
(COVID -19) which is caused by the virus severe acute respiratory syndrome coronavirus 2 
(SARS -CoV-2). The pandemic impacted the conduct of clinical trials due to quarantines, site 
closures, travel limitations, diversion of resources and general interruptions in study related 
procedures, leading to protocol deviations. This study protocol includes contingency measures to 
manage disruptions due to COVID-19 control measures; see Section  3.1.1 for details on 
measures related to adjustments to visit location/method and schedule, as well as Section  6.2.2.4, 
Section  6.2.2.7, and Section  6.2.3.4 for new visit windows for  questionnaires, 
musculoskeletal ultrasound (MSKUS), and abdominal ultrasound assessments, respectively. The 
impacts of these implemented contingency measures on the outcomes of this study, including 
any protocol deviations that ultimately result from COVID -19 illness and/or COVID- 19 control 
measures will be discussed in the Clinical Study Report (CSR). 
The decision to test a subject  in the study for COVID-19 should be based on the site’s current 
guidelines and at the discretion of the Inves tigator . If a subject  participating in the study is 
identified as a person under investigation, it is mandatory to immediately notify appropriate 
authorities as per site’s regulations and to notify Medpace and uniQure’s Medical Directors. As 
co-infections can occur, all subject s should be considered for COVID-19 virus testing regardless 
of whether another respiratory pathogen is found.  
If a subject  is confirmed positive for COVID-19 at any time during the trial, the medical care, 
isolation , and management, should be according to national, local, institutional, and public health 
guidelines.  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 51 of 146 
2 TRIAL OBJECTIVES 
2.1 Primary Objective 
The primary objective is to demonstrate the non- inferiority of AMT -061 (2 × 1013 gc/kg) during 
the 52 weeks following establishment of stable factor IX expression (months 6 to 18) post-
treatment (AMT -061) follow-up compared to standard of care continuous routine factor IX 
prophylaxis during the lead -in phase, as measured by the ABR . 
 
 
2.3 Safety Objectives 
The safety objectives  include monitoring of AEs , changes in abdominal ultrasound, formation of 
anti-AAV5 antibodies (total immunoglobulin M and immunoglobulin G [IgM and IgG], NABs ), 
AAV5 capsid -specific T cell response, formation of  anti-factor IX  antibodies, formation of factor 
IX inhibitors and recovery , hematology and serum chemistry, shedding of vector DNA in blood 
and semen , inflammatory markers , AST/ALT  increase, use of corticosteroids required to 
preserve factor IX  activity in the context of AST/ALT  increases , and alpha-fetoprotein ( AFP). CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 52 of 146 
3 TRIAL DESIGN  
3.1 Overall Trial Design 
This is an open- label, single -dose, multi- center, multi- national trial, with a screening period, a 
lead-in phase, a treatment plus a post- treatment follow -up phase, and a long- term follow -up 
phase.  Overviews of the trial and its design are presented in Figure 1 and Figure 2. 
At the screening visit (Visit S), subjects will be assessed for eligibility and will be instructed in 
how to record bleeding episodes and use of factor IX  replacement therapy in their dedicated 
electronic diary (e -diary). The approximately 4 week period between screening up to the start of 
the lead -in phase (Visit L1) is considered a training period where subjects will record their use of 
factor IX  replacem ent therapy and bleeding episodes in their dedicated e-diary, with the 
Investigator/study nurse reviewing and evaluating any problems with recording of this data with the subject. The period between screening and the start of the lead-in phase will also be used to wash  out subjects from their exogenous factor IX  for a pre -defined period of 3 days for regular-
acting factor IX  products and 10 days for extended half- life factor IX  products. 
After s creening  (Visit S), eligible subject s will enter a lead -in phas e prior to the start of 
AMT -061 treatment. 
During the lead-in phase, subjects will record their use of factor IX replacement therapy and bleeding episodes in a dedicated e-diary. The length of the lead-in phase is a minimum of 6 months (26 weeks), ending a t or before Visit D. Subjects will remain in the lead -in phase until a 
minimum of 6 months of lead- in data have been collected and it is confirmed that the subject still 
meets all eligibility criteria. The final visit in this phase (Visit L -Final) will occur approximately 
28 days (±7 days ) prior to the planned date of IMP dose administration (Visit D). If the ICF is 
revised during the lead-in phase with important new information that must be shared with the 
study subjects, the amended ICF will be presented, as required by the Independent Ethics 
Committees (IECs)/Institutional Review Boards  (IRBs) , for review and consideration by the 
subject, and signed re-consent is to be obtained prior to IMP dose administration. 
During the lead-in phase, visits are planned as follows: 
- Visit L1 will occur after eligibility is confirmed, approximately 4 weeks after 
screening . 
- Alternating monthly clinic visits and follow -up phone calls until a minimum of 6 
months of lead-in data have been collected and it is confirmed that the subjects still meet all eligibility criteria (i.e., clinic visits every 2 months; Visit L2 to LX) . For 
follow- up phone calls, an email communication is acceptable as an alternative if the 
subject cannot be reached, though reasonable efforts for a phone call should be made. The time period between Visit LX and Visit L -Final can be less than 2 months, as 
long as the total lead -in period is a minimum of 26 weeks. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 53 of 146 
- The final visit (Visit L -Final)  will occur approximately 4 weeks prior to the planned 
date of IMP dose administration (Visit D) . 
After the lead -in phase, subjects will receive a single-dose of AMT-061 at Visit D and will be 
followed for one year (i.e., post- treatment follow -up phase; 52 weeks) to evaluate efficacy and 
safety.  During the post- treatment follow -up, visits are planned as follows:  
- Weekly up to Week 12 (Visit F 1 to F1 2) 
- Every month from Month 4 to Month 11 (Visit F13 to F2 0) 
- Final visit at Month 12/Week 52 (Visit F -Final)  
Following the post- treatment follow -up phase, subjects continue into the long- term follow -up for 
an additional four years. During the long- term follow -up, visits are planned as follows: 
- E very half year  (6 months) from 18 to 60 months (4 years ; Visit LTF1 to LTF8 ); 
however, there should be at least quarterly contact (± 2 weeks) between the site staff 
and subjects to monitor for the occurrence of AEs, proper completion of the study-
specific paper diaries, and proper reporting of factor IX usage and bleeding episodes. 
Six months after IMP administration, the first secondary endpoint, endogenous factor IX  activity 
at 6 months after AMT -061 dosing, will be analyzed once the last subject has achieved 6 months 
after AMT -061 treatment. This assessment will be based on clean data and a partially locked 
database.  
Twelve months after IMP administration, the second secondary endpoint, endogenous factor IX 
activity at 12 months after AMT -061 dosing, will be analyzed and reported via an interim 
analysis once the last subject has achieved 12 months (52 weeks) after AMT -061 treatment. This 
assessment will be based on clean data and a partially locked database.  
Factor IX expression is anticipated to be stable within 6 months post-dose. A fter 52 weeks 
following stable factor IX expression,  
. Data up to that point will be considered locked and will not be changed (with the 
exception of ending dates and outcomes for continuing events and treatments) without explicit 
authorization from the Sponsor. Following the 18 months post-dose assessments, subj ects will be 
followed for an additional 3.5 years for evaluation of efficacy parameters and safety . At the end 
of that 3.5-year period, all safety and efficacy data will be reported in a CSR addendum covering 
the entire study duration, including the later 3.5- year period . 
The overall trial participation will be approximately 5.5 years.   
The end of the clinical trial is defined as the point in time the last subject  has completed the long-
term follow-up observation period of 5 years after administration of the IMP. CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 54 of 146 
3.1.1 Considerations Due  to the COVID-19 Pandemic  
Due to the COVID-19 pandemic, adjustments to the visit location/method  or schedule may be 
made to accommodate safety concerns and restrictions experienced by individual subjects and 
sites. In all cases, subjects will be kept informed, via the site staff,  as much as possible, of 
changes to the study and monitoring plans that could impact them. 
Discontinuation of subjects from the study post- treatment with AMT -061 is not considered to be 
in the best interest of the subject, due to the irreversible nature of the IMP. Wherever possible, 
every effort is to be made to have the subject visit the clinic for the study visits according to schedule. Should a clinic visit not be possible, options that may be considered include site nurses travelling to a subject’s home, local laboratory use, or home nursing services (for certain visits, if 
pre-approved by t he Investigator and Sponsor). These options, if used, will be supplemented with 
a phone call or telemedicine/telehealth safety follow -up call. A (t emporar y) transfer of a subject 
to an alternate clinical trial site may also be considered in order to continue on -site visits, only if 
this does not pose undue burden to the subject and/or "new" site. 
In some instances, it may not be possible to conduct any type of visit at all. Where none of the 
above options are feasible, subject visits may be moved beyond the maximum visit window permitted.  Such  delay s will be assessed on a case by case basis. Until visits are rescheduled, 
supplemental phone calls or telemedicine/telehealth contact between  Investigator/study staff and 
subject are to be arranged . 
Supplemental phone calls or telemedicine/telehealth safety follow -up calls will be used  to 
confirm the subject’s status and wellbeing. At these supplemental phone calls, safety  information 
should be gathered (i.e., AEs, concomitant m edication  use), subjects should be asked about any 
new unreported bleeds or factor IX consumption and confirm their use of the e-diary or paper diaries (as applicable) , and there should be continued discussions with the subject on the 
importance of a healthy liver. These discussions will be documented in the source documents. 
All deviations from the study protocol are to be documented, with rationale. If a protocol 
deviation is due to the COVID-19 pandemic, this will be noted. 
3.2 Trial Design Rationale 
In gene therapy it is common practice to provide a single dose of vector via IV infusion. This 
infusion in a previous trial with AMT -060 was proven to be safe and effective resulting in 
identification of a clin ical dose for AMT-060 to proceed to further clinical studies. Although a 
single administration of AMT -060 at a dose of 2 × 1013 gc/kg resulted in successful conversion 
of clinical phenotype to mild in most subjects  (see Section  1.3.2.2), the desired goal is to achieve 
higher levels of factor IX  activity to allow for a more consistent and meaningful clinical 
response. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 55 of 146 
AMT -061 is a derivative of AMT-060 that produces the hFIX- Padua variant. Based on NHP 
studies with AMT -061, as well as data from subjects with the natural Padua mutation, it is 
expected that, compared to its predecessor, AMT -061 will lead to a higher level of circulating 
factor IX  activity at comparable levels of factor IX  protein, thereby increasing the likelihood of 
alleviating the need for exogenous therapy, including on- demand treatment of traumatic bleeds 
and selective prevention of a bleed (e.g., because of upcoming physical activity, sports, etc.).  At 
2 × 1013gc/kg, AMT-061 is expected to result in mean Factor IX  activity ranges of 40% of 
normal, ranging between approximately 18-76%. Interim analysis data from the ongoing Phase 
IIb trial CT -AMT -061-01 demonstrated that AMT -061 was safe and well tolerated and resulted 
in mean factor IX  activity of approximately 30% of normal at 6 weeks after treatment with a 
dose of 2 × 1013 gc/kg (see Section  1.3.2.3).  
A dose of 2 × 1013 gc/kg for AMT -061 was selected for use in the treatment phase of this study 
based on interim data from CT- AMT -061-01 a nd the recommendation from the DMC (see 
Section  9.12). 
The lead -in phase of the trial is used for assessment of the bleedings occuring during standard of 
care continuous routine factor IX  prophylaxis which is part of the primary efficacy parameter. 
Bleedings and factor IX  use data are recorded  by the subjects  in a dedicated e- diary  after a 
training. The  ongoing evaluation of the e-diary data by the Investigator/study nurse and 
subsequent retraining of the subjects, as necessary, is used to ensure adequate data recording and compliance. 
This trial is conducted at multiple  centers as the prevalence of severe and moderately severe 
hemophilia B subject s is low.  
Due to the nature of the disease in question it is not ethical to perform a placebo- controlled trial 
and no relevant active comparators exist.  Based on this, the trial is designed as an open- label and 
uncontrolled trial. 
3.3 Trial Endpoints 
3.3.1 Primary Endpoint  
The primary efficacy endpoint is  as follows: 
- ABR comparison between AMT-061 and prophylaxis for non-inferiority between the 
lead-in phase and the 52 weeks following stable factor IX expression (months 6-18 
post- treatment)  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 56 of 146 
3.3.2 Secondary Endpoints  
Secondary efficacy endpoints: 
- Endogenous factor IX activity at 6 months after AMT -061 dosing 
- Endogenous factor IX activity at 12 months after AMT -061 dosing 
- Endogenous factor IX activity at 18 months after AMT -061 dosing 
- Annualized consumption of factor IX replacement therapy during the 52 weeks following 
stable factor IX expression  (months 6-18 post- treatment) , excluding factor IX 
replacement for invasive procedures , compared to the lead -in phase 
- Annualized infusion rate of factor IX replacement therapy during the 52 weeks following stable factor IX expression  (months 6-18 post- treatment) , excluding factor IX 
replacement for invasiv e procedures , compared to the lead -in phase 
- Proportion of subjects remaining free of previous continuous routine prophylaxis during the 52 weeks following stable factor IX expression (months 6-18 post- treatment)  
- Comparison of the percentage of subjects with trough factor IX activity <12% of normal 
between the lead -in phase and after treatment with AMT -061 over the 52 weeks 
following stable factor IX expression (months 6-18 post- treatment)  
- ABR comparison between AMT-061 and prophylaxis for superiority betwee n the lead -in 
phase and the 52 weeks following stable factor IX expression (months 6-18 
post- treatment)  
- Rate of spontaneous bleeding events during the 52 weeks following stable factor IX 
expression (months 6- 18 post -treatment)  compared to  the lead -in phase 
- Rate of joint bleeding events during the 52 weeks following stable factor IX expression (months 6-18 post- treatment)  compared to the lead -in phase 
- Estimated ABR – during the 52 weeks following stable factor IX expression (months 6-18 post- treatment)  – as a function of pre- IMP anti -AAV5 antibody titers using the 
luciferase based NAB assay  (as a “correlation” analysis)  
- Correlation of factor IX activity levels during the 52 weeks following stable factor IX expression (months 6- 18 post -treatment)  with pre- IMP anti -AAV5 antibody titers using 
the luciferase based NAB assay  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 57 of 146 
- Occurrence of ( and resolution of ) new  target joints during the 52 weeks following stable 
factor IX expression  (months 6-18 post- treatment)  and resolution of pre-existing ta rget 
joints following AMT-061 dosing 
- Proportion of subjects with zero bleeds during the 52 weeks following stable factor IX 
expression (months 6- 18 post -treatment)  
-  
during the 12 months following AMT-061 dosing compared with 
the 
lead-in phase 
-  during 
the 12 months following AMT-061 dosing compared with 
the lead -in phase 
 CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 58 of 146 
 
 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 59 of 146 
 
 
Secondary safety endpoints  
- AEs 
- Changes in abdominal ultrasound 
- Anti-AAV5 antibodies (total [IgM and IgG], NABs ) 
- AAV5 capsid -specific T cell s  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 60 of 146 
- Anti-factor IX  antibodies 
- Factor IX  inhibitors and recovery  
- Hematology and serum chemistry parameters 
- ALT/AST levels, and corticosteroid use for ALT/AST increases 
- Vector DNA in blood and semen  
- Inflammatory markers: IL -1β, IL -2, IL -6, IFNγ, MCP -1 
- AFP 
3.3.3 Sub-s tudy Endpoints  
- Patient Reported Outcomes, Burdens, and Experiences (PROBE) summary scores and 
individual item responses. 
- MSKUS Sub -study Endpoints 
o Joint Tissue Activity and Damage Exam (J.A.D.E.) scores 
3.4 Sample Size  
The study sample size is constrained by the non-inferiority analysis of the primary endpoint, 
ABR.  Via simulation of ABR under a negative binomial distribution with a yearly rate of 
2.4 events for lead -in and 1.9 for post-treatment, with a Pearson correlation of 0.05 for the 
number of events between the two periods, and with a common negative binomial dispersion parameter of 1.5, a sample size of N=50 will demonstrate non-inferiority with a non- inferiority 
margin of 1.8 and a power of 82.0%. Therefore, the study should consist of a t least 50 analyzable 
subjects . 
Refer to Section  9.11 for further information on sample size justification. 
3.5 Sites and  Regions 
It is planned to conduct this trial in approximately 50 sites in the United States of America (USA) , European Union (EU ), and the United Kingdom (UK) . CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 61 of 146 
4 TRIAL POPULATION  
Subjects will be adult males  with severe or moderately severe hemophilia B. 
4.1 Inclusion Criteria 
The subject cannot be enrolled in the trial before all of the following inclusion criteria are met: 
 Male 
 Age ≥18 years  
 Subjects with c ongenital hemophilia B with known severe or moderately severe factor IX  
deficiency ( ≤2%  of normal circulating factor IX ) for which the subject is on continuous 
routine factor IX  prophylaxis* 
 >150 previous exposure days of treatment with factor IX  protein 
 Have been on stable prophylaxis for at least 2 months prior to screening 
 Have demonstrated capability to independently, accurately and in a timely manner 
complete the diary during the lead-in phase as judged by the Investigator 
 Acceptance to use a condom during sexual intercourse in the period from IMP administration until AAV5  has been cleared from semen, as evidenced by the central 
laboratory from negative analysis results for at least three consecutively collected semen samples (this criterion is applicable also for subjects who are surgically sterilized)  
 Able to provide informed consent  following receipt of verbal and written information 
about the trial. 
* Continuous routine prophylaxis is defined as the intent of treating with an a priori defined frequency of infusions (e.g., twice weekly, once every two weeks, etc.) as documented in the medical records.  
4.2 Exclusion Criteria 
Subjects are excluded from the trial if any of the following exclusion criteria (including local and central laboratory test results , as specified ) are met :  
 History of factor IX  inhibitors 
 Positive factor IX  inhibitor test at screening and Visit L- Final  (based on local laboratory 
results ) 
 Screening  and Visit L- Final  laboratory values (based on central lab oratory results ): 
a. ALT >2 times upper normal limit (i.e., upper limit of normal; ULN) 
b.  AST >2 times ULN  
c. Total bilirubin >2 times ULN (except if caused by Gilbert disease)  
d. Alkaline phosphatase (ALP) >2 times ULN  
e. Creatinine >2 times ULN  1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
1. 
2. 
3. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 62 of 146 
 Positive human immunodeficiency virus (HIV) serological test at screening and Visit L-
Final , not controlled wi th anti- viral therapy as shown by CD4+ counts ≤200/μL (based on 
central lab oratory results) 
 Hepatitis B or C infection with the following criteria present at screening : 
a. Currently receiving antiviral therapy for this/these infection(s) 
and/or 
b. Positive for any of the following (based on central laboratory results): 
i. Hepatitis B surface antigen (HBsAg), except if in the opinion of the Investigator 
this is due to a previous Hepatitis B vaccination rather than active Hepatitis B infection  
ii. Hepatitis B virus deoxyribonucleic acid (HBV DNA) 
iii. Hepatitis C virus ribonucleic acid (HCV RNA)  
 Known coagulation disorder other than hemophilia B 
 Thrombocytopenia, defined as a platelet count below 50 × 109/L, at screening  and 
Visit L- Final  (based on central laboratory results) 
 Known severe infection or any other significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease, 
alcoholism, drug dependency or any other psychological disorder evaluated by the 
Investigator to interfere with adherence to the protocol procedures or with the degree of tolerance to the IMP  
 Known significant medical condition that may significantly impact the intended 
transduction of the vector and/or expression and activity of the protein, including but not 
limited to:  
a. Dissemi nated intravascular coagulation  
b. Accelerated fibrinolysis  
c. Advanced liver fibrosis (suggestive of or equal to METAVIR Stage 3 disease; e.g., a 
FibroScan™ score of ≥9 kPa is considered equivalent)  
 Known history of an allergic reaction or anaphylaxis to factor IX  products 
 Known history of allergy to corticosteroids 
 Known uncontrolled allergic conditions or allergy/hypersensitivity to any component of 
the IMP excipients  
 Known medical condition that would require chronic administration of steroids 
 Previous gene therapy treatment 
 Receipt of an experimental agent within 60 days prior to screening 
 Current participation or anticipated participation within one year after IMP administration 
in this trial in any other interventional clinical trial involving drugs or devices. 4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 63 of 146 
4.3 Reproductive Potential 
Male subjects who participate in this trial acce pt to use a condom during sexual intercourse in the 
period from IMP administration until AAV5 has been cleared from semen, as evidenced by the 
central laboratory from negative analysis results for at least three consecutively collected semen 
samples (this criterion is applicable also for subjects who are surgically sterilized).  
Subjects are being asked to inform their partner of their participation in this trial, as well as the importance of contraception use to limit the reproductive potential in the period from IMP 
administration until AAV5 has been cleared from the semen. 
4.4 Restrictions 
There is one restriction associated with participation in this trial, which is related to reproduction and described in Section  4.3. 
4.5 Withdrawal of Subject from Therapy or Assessment 
A subject may withdraw from the trial at any time , for any reason, without prejudice to their 
future medical care by his/her physician or at the institution. The Investigator or Sponsor may withdraw the subject at any time if it is not in the best interest of the subject to continue participation . Since this is a gene therapy trial in which the IMP is administered to human 
subjects as a one -time only dose, the I nvestigator should make all reasonable attempts to 
maintain the subjects in the trial after IMP administration to allow long -term follow -up on safety. 
Where a subject is withdrawn from the t rial at his own request or based on a decision of the 
Investigator, the safety follow-up should be maintained, conditional to the consent of the subject. The safety follow-up will include periodic review (approximately every 6 months) of medical records to gather information obtained during routine visits from the subject with his treating 
physician for the time until 5 years post- IMP administration . Information on AEs, SAEs, 
concomitant medication use, an d laboratory assessments will be collected as available.  If a 
subject is to withdraw from the trial, the Investigator should make all reasonable attempts to have 
the subject sign the separate ICF in order to maintain the long- term safety follow-up. 
Subject s who withdraw from the trial after being dosed with AMT-061 will be requested  to 
complete the same final evaluations ( see Section  6.1.4.1) as subjects completing the trial 
according to the protocol, particularly safety evaluations in the subject’s interest so that data can 
be recorded in the same way as for subjects who completed the trial. Comments (spontaneous or 
elicited) or complaints made by the subject must be rec orded in the source documents. The 
reason for  (if given) and date of withdrawal, must be recorded on the electronic case report form 
(eCRF) and source documents.  
Subjects who withdraw fro m the trial after enrolling in  the Lead -in Phase but who are not dosed 
will be required to return their e -diary device and will not be requested to complete any final 
evaluations. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 64 of 146 
Sufficient subjects will be enrolled  to ensure a minimum of 50 subjects in the PP population. It is 
estimated that at least 56 subjects on continuous routine prophylaxis may be enrolled to ensure 
there are sufficient subject to achieve this goal.  
4.5.1 Reasons for Discontinuation 
The r easons for discontinuation  from this gene therapy trial include: 
• AE 
• Withdrawal by principal Investigator 
• Withdrawal by subject 
• Lost to follow-up 
4.5.2 Subje cts ‘Lost to Follow- up’ P rior to L ast S cheduled V isit 
At least three documented attempts must be made to contact any subject lost to follow -up at any 
time point prior to the last scheduled contact (office visit or telephone contact). One of these 
documented attempts must include a written communication sent to the subject’s last known 
address via courier or mail (with an  acknowledgement of receipt request) asking that they return 
the e- diary device (if applicable) and return to the site for final safety evaluations. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 65 of 146 
5 TRIAL TREATMENT  
5.1 Treatment (s) Administered 
5.1.1 Investigational Medicinal Product 
The IMP is identified as AAV5 -hFIXco -Padua (hereafter referred as AMT -061; e tranacogene 
dezaparvovec). AMT -061 is a recombinant adeno-associated viral vector of serotype 5 (AAV5) 
containing the Padua variant of a codon-optimized human factor IX  cDNA under the control of a 
liver-specific promoter. The pharmaceu tical form of AMT -061 is a solution for IV infusion. 
Subjects will receive a single IV infusion of 2 × 1013 gc/kg AMT-061. 
5.1.2 Non-Investigational Medicinal Product 
The reference therapy is the prophylaxis factor IX  replacement therapy used during the lead-in 
phase prior to treatment with AMT -061. CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 66 of 146 
5.3 Dosing and Administration 
AMT -061 will be administered at a dose of 2 × 1013 gc/kg as a one-time infusion in a periphera l 
vein. The subjects will be monitored for tolerance to the IMP and detection of immediate AEs 
for three hours after dosing. 
Detailed  instructions for IMP handling e.g., receipt,  storage, preparation, administration , 
cleaning, destruction, and the recordin g of the se critical activities will be described in the IMP 
Handling Manual. 
5.4 Randomization and Blinding  
Not applicable,  as this is an open- label trial with one treatment arm.  
5.5 Labeling, Packaging, Storage, and Handling  
All medication used in this trial will be prepared and labeled according to the rules of Good 
Manufacturing Practice, International Council for Harmonis ation  (ICH) -Good Clinical Practice 
(GCP) ( E6[R2]) and local regulatory requirements. Further details on IMP labeling, packaging 
and handling, e.g., receipt, storage, preparation, administration, cleaning, destruction, 
documentation etc., will be described in the IMP Handling Manual. 
5.6 Prior and Concomitant Medication/Therapy  
5.6.1 Prior Medication/Therapy  
Prior medication/therapy includes medication/therapy (including herbal treatments, vitamins, 
non-pharmacological treatment such as psychotherapy as appropriate) received within 30 days of 
and discontinued prior to the date of s creening . Prior medication/therapy information must be 
recorded on the appropriate eCRF page.  
For this trial, it is not allowed to have received an experimental  agent within 60 days prior to 
screening. In addition, use of previous gene therapy is not allowed. 
5.6.2 Concomitant Medication/Therapy  
Concomitant medication/therapy is defined as any medication/therapy being continued by the 
subject post IMP administration  (Visit D) , and any new medication/therapy received during the 
trial. 
Concomitant treatment taken as of the date of IMP administration  must be recorded on the 
appropriate eCRF page.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 67 of 146 
The following treatments will not be allowed during trial participation: 
- Continuous routine factor IX  prophylaxis post-dose if a subject’s endogenous factor 
IX activity result is above 5%  
- Treatment in another interventional clinical trial involving drugs or devices for one 
year following IMP administration in this trial  
- Another gene therapy treatment  
- Chronic administration of steroids (oral and/or inhaled) 
For any known hepatotoxic medications, other alternatives should be considered. The 
Investigator is expected to review the concomitant medications on an ongoing basis for these 
types of medications. Where possible, subjects should be taken off any known hepatotoxic drugs 
before V isit D.  A searchable, comprehensive list of drugs ranked by Drug Induced Liver Injury 
(DILI) concern (Food and Drug Administration [ FDA ] Drug Induced Liver Injury Rank 
[DILIrank] dataset) is available from the following site: https://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/ucm6
04985.htm. 
Apart from the above listed treatments, no protocol restrictions will apply with respect to 
concomitant medications . 
Subjects are permitted to continue to administer their continuous routine factor IX treatment on 
the day of dosing (after the pre- IMP assessments are completed) and continue their continuous 
routine factor IX  treatment in the first week s after dosing to provide sufficient factor IX coverage 
for the initial days post- treatment . During the post- treatment follow -up visits, endogenous factor 
IX activity will be assessed. If the endogenous factor IX  activity result is ≥5%, continuous 
routine factor IX  prophylaxis will be discontinued and further management will be based  on 
Investigator’s clinical judgement and subject preference.  Continuation or re- initiation of 
continuous routine factor IX  prophylaxis may be considered if the endogenous factor IX  activity 
is between 2 and 5% in at least two consecutive laboratory measurements , based on the 
Investigator’s clinical judgement and subject preference.  If endogenous factor IX  activity is 
<2%, continuous routine prophylaxis must be continued or reinstated . Additional on-demand 
and/or intermittent prophylactic factor IX  treatment may be given after treatment with AMT -061, 
if considered necessary.  
Factor IX infusions are not recommended for subject s with factor IX activity in the 
non-hemophilic ( ≥40% of normal) range especially in subject s with a confirmed COVID-19 
infection, as increased thrombogenic risk is a known complication of COVID-19. Subject s with 
factor IX activity in the non -hemophilic range post- treatment with AMT -061 and infected with 
COVID-19 may potentially be at the same risk of thrombosis as subject s without hemophilia ; 
antithrombotic therapy for these subject s should be considered under the same guidelines 
recommended for those without hemophilia. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 68 of 146 
5.6.3 Guidelines for Use of Factor IX for Subject s Undergoing Major Surgery  
Replacement of factor  IX for subject s undergoing major surgery in this trial will be according to 
established guideline ( Srivastava et al., 2013 ) in terms of factor IX activity level pre - and post-
surgical procedure. The target factor  IX activity level pre - and post- major surgery , regardless of 
whether the regular or extended half -life replacement is administered as per World Federation of 
Hemophilia , is as follows:  
 Factor IX Activity Level  
Pre-operative:  60-80% 
Post-operative:  40-60% Day 1 -3 
 30-50% Day 4 -6 
 20-40% Day 7 -14 
 
For minor surgery, use of factor IX is up to the Investigator but should be discussed with the medical monitor.  
Factor IX infusions are not recommended for subject s with factor IX activity in the 
non-hemophilic ( ≥40% of normal) range especially in subject s with a confirmed COVID-19 
infection, as increased thrombogenic risk is a known complication of COVID-19. Subject s with 
factor IX activity in the non-hemophilic range post- treatment with AMT -061 and infected with 
COVID-19 may potentially  be at the same risk of thrombosis as subject s without hemophilia ; 
antithrombotic therapy for these subject s should be considered under the same guidelines 
recommended for those without hemophilia. 
5.6.4 Guidelines for Transaminase Elevations 
Transaminase levels will be monitored based on the site’s local laboratory results and central 
laboratory results, with local laboratory analysis results arranged , if possible, to be provided on 
the same day or the day after the blood sampl e is collected to allow for rapid detection of any 
elevations in transaminase levels.  
For ALT level increments of at least 2 -fold baseline (i.e., Visit D, pre- IMP) an d/or > ULN, by 
local or central laboratories, the Investigator should contact the Medpace and uniQure M edical 
Directors to discuss a clinical management plan  on a case -by-case basis , including potential re-
tests and/or initiation of corticosteroid treatment. In case of AST level increments > ULN, the 
Investigator should contact the Medpace and uniQure Medical Directors  and a similar discussion 
should take place.  
Investigators should assess potential causes of a transaminase elevation, to rule out if the 
elevation is due to intense exercise, alcohol consumption, or use of concomitant medications. Additional laboratory assessments including creatine kinase assessment and a viral panel are recommended as needed.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 69 of 146 
See Table 7 for a recommended approach to prednisolone treatment. Medications equivalent to 
prednisolone may also be used. A combined immunosuppressant regimen or the use of other products can also be considered in case of prednisolone treatment failure or contraindication. 
Corticosteroid tapering should be discussed among  the Investigator and Medpace and uniQure 
Medical Directors based on changes in and normalization of transaminase levels. 
Investigators should monitor subjects for steroid- related AEs. If use of high dose 
prednisolone/prednisone is prolonged, blood pressure and glucose levels should be monitored at 
each clinic visit, or more frequently if needed, and Investigators should consider starting subject s 
on vitamin D, a proton pump inhibitor, and/or P neumocystis jiroveci  prophylaxis therapy . 
Subjects  who are placed on corticosteroid treatment should be closely monitored for pote ntial 
COVID-19 infection. Where possible and as per site guidelines and at the discretion of the Investigator, subject s should be tested for COVID- 19 at the time of initiating corticosteroid 
treatment. Those on corticosteroid treatment who are positive for COVID -19 might be 
considered for more rapid tapering than outlined in Table 7;  steroid tapering should be discussed 
among the Investigator and Medpace and uniQure Medical Directors.  
Table  7 Use of Prednisolone for the Treatment of Transaminase Increase  
Timeline  Prednisolone dose (mg/day)  
Week 1  60 
Week 2  40 
Week 3  30 
Week 4  30 
Maintenance until transaminase level  returns to baseline level ( Visit 
D, pre-IMP)  20 
After pre -IMP level has been reached  Reduce daily dose by 5 mg/week  
5.7 Treatment Compliance and Drug Accountability 
Investigators will be provided with a subject  pack containing sufficient vials of the IMP  to 
prepare and administer the required dose for each subject . The Investigator or designee will 
acknowledge receipt of the subject  pack  by documenting date of receipt, shipment content, and 
condition. Accurate records of all IMP  prepared, administered, returned, and/or destroyed must 
be maintained as detailed further in this section as well as in the IMP Handling Manual. Investigators will be responsible for implementing a system for subject and product traceability 
at the clinical site. That system should contain sufficient detail to allow  linking of each vial  
delivered to the Investigator to the subject receiving it and vice versa . 
The Investigator has overall responsibility for preparing and administering  the IMP . Where 
permissible, tasks may be delegated to a qualified designee (e.g., a pharmacist) who is 
adequately trained in the protocol and procedures as described in  the IMP Handling Manual and 
who works under the supervision of the Investigator. This delegation must be documented in the 
applicable trial delegation of authority form. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 70 of 146 
The Investigator or his/her designee will administer the IMP only to subjects included in this 
trial, for whom it is confirmed that they are eligible for dosing, following the procedures set out 
in the trial protocol and the IMP Handling Manual. Each subject will be given only the IMP 
carrying his treatment assignment. All dispensing will be documented on the eCRF s and/or other 
IMP record s. 
The Sponsor or its representatives must be permitted access to review the supplies storage and distribution procedures and records. 
Based on entries in the Interactive Web Response System (IWRS) and  drug accountability forms, 
it must be possible to reconcile IMPs delivered  with those used and destroyed if unused. All 
IMPs must be accounted for and all discrepancies  must be investigated and documented to the 
Sponsor’s satisfaction. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 71 of 146 
6 TRIAL SCHEDULE AND ASSESSMENTS  
6.1 Trial Schedule  
For details on the timing and frequency of the assessments and testing during screening (Visit  S), 
lead-in (Visit L1 to L -Final), and Treatment (Visit D) + post- treatment follow -up (Visi t F1 
[Week 1]  to F- Final  [Week 52/Month 12] ) refer to the flow charts in  Table 1 and  Table 2, and for  
the long- term follow -up (Visit LTF1 [Month 18] to LTF8  [Month 60]) refer to  Table 3 and  
Table 4. 
Throughout the study, it will be the aim to draw blood samples at those time points when the 
subject’s factor IX  activity level is expected to be at its trough. See Section  6.2.2.3 for further 
details.  
6.1.1 Screening  (Visit S ) 
Informed consent must be obtained from each subject prior to any of the trial procedures being 
performed (see also Section  10.3.1).  
At this visit, subjects will be asked to complete the  and the  will be 
assessed. It is recommended that each subject should complete the , 
including PROBE if applicable, after ICF signature, but before other (trial- specific) assessments 
are performed. Screening assessments will also include medical history, vital signs, physical 
examination  (including height and weight), MSKUS  (if applicable), and blood sampling. With 
prior approval from the Sponsor, screening procedures can occur during the duration of the 
screening period. 
A Fibro Scan (or suitable alternative) will be performed with liver fibrosis scores collected during 
the assessment. If possible, steatosis (Controlled Attenuation Parameter [CAP]) scores should 
also be collected during the assessment.  The FibroScan should preferably be done at the 
screening visit or at an alternative ti me point, however at Visit L-F inal at the latest.  If a 
Fibroscan  was performed in the year prior to screening for which fibrosis score is available or if 
liver biopsy has been performed within the 2 years prior to screening and fibrosis grade was 
documented, a FibroScan is not necessary . 
At this visit, s ubjects will receive t heir e-diary and the I nvestigator/study nurse will train them in 
recording of the bleeding episodes and use of factor IX  replacement therapy.  From s creening 
onwards, subjects will record their use of factor IX  replacement therapy and bleeding episodes in 
the dedicated e- diary. e -diary data will be reviewed on a continuous basis by the 
Investigator/study nurse. The approximately 4-week period between the s creening visit (Visit S) 
up to the start of the l ead-in phase (Visit  L1) is considered a training period, after which the 
Investigator/study nurse will review and evaluate any problems with recording of e- diary data CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 72 of 146 
with the subject. The e-diary training can be repeated at any time during the trial as considered 
necessary by Investigator/study nurse. 
Eligibility according to the trial in - and exclusion criteria will be evaluated at screening and 
during the period up to start of the l ead-in phase. For a description of the in- and exclusion 
criteria please refer to  Section  4.1 and Section  4.2. 
The overall eligibility will be determined once all screening values and results of other required 
procedures are available. Subjects  who fail to meet inclusion criteria and/or meet at least one of 
the exclusion criteria and did not receive AMT -061 are defined as a screen failure.  
Subjects who meet an exclusion criteri on, or fail to meet an inclusion criterion ( screen failures ) 
may only be re- evaluated  for participation in the trial after con sultation with, and agreement 
from, the Sponsor. 
Separate informed consents are to be taken for blood samples for future research and for factor 
IX gene sequencing analyses. Factor IX  gene sequence analyses will be performed  for all 
subjects that provide consent, even if they already have factor IX  gene mutation information 
available. If the subject provides consent for one or both ICFs, the respective blood samples will be taken during the screening visit. 
Separate informed consents are to be taken for the PROBE sub-study, and for the MSKUS  sub-
study. Assessments will only be performed if the site is participating in the sub-study and the 
subject has provided consent for the sub-study. 
The use of concomitant medication and occ urrence of AEs  will be monitored throughout the trial 
on an ongoing basis. 
From screening onwards, the Investigator or designee will have regular discussions with the 
subject regarding the importance of a healthy liver before and after receiving a liver directed 
gene therapy, and factors that might impact liver health (including acetaminophen and alcohol intake ). It is recommended that the acetaminophen total daily dose per subject be limited to 
≤2 g/day. It is also recommended that subjects on the study should not consume >20 g of alcohol 
per day . It is recommended that the daily alcohol limit in grams be adhered to most strictly 
during the first 12 weeks post- IMP. The following stated limit of amount/frequency may help 
guide the study team to couns el subject s regarding alcohol use in a similar manner across the 
duration of the trial: 
- In the US, one “ standard ” drink (or a “unit” of alcohol) contains roughly 14 g of pure 
alcohol, which is found in 12 ounces of regular beer, 5 ounces of wine or 1.5 ounces of distilled spirits ( Source:  National Institute of Alcohol A buse and Alcoholism 
[NIAAA]). CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 73 of 146 
In Europe, alcohol content in a “standard drink” measure differs between countries. On average, 
they contain between 8 and 13 g of ethanol across Europe. It is recommended that one visits their national consumer information website(s) for further information if nece ssary ( Source: 
https://www.re sponsibledrinking.eu/new- page/ ) . 
While it is recommended that the daily alcohol limit in grams be adhered to most strictly during the first 12 weeks post-IMP, the importance of abstaining from binge-drinking at any point post-IMP administration should be reinforced at every visit. 
6.1.2 Lead -in Phase ( Visit L1 to L -Final ) 
During the lead-in phase, visits are planned as follows: 
- Visit L1 will occur after eligibility is confirmed, approximately 4 weeks after 
screening . 
- Alternating monthly clinic visits and follow -up phone calls until a minimum of 6 
months of lead-in data have been collected and it is confirmed that the subjects still 
meet all eligibility criteria (i.e., clinic visits every 2 months; Visit L2 to LX) . For 
follow- up phone calls, an email communication is acceptable as an alternative if the 
subject cannot be reached, though reasonable efforts for a phone call should be made. The time period between Visit LX and Visit L -Final can be less than 2 months, as 
long as the total lead -in period is a minimum of 26 weeks. 
- The final visit (Visit L -Final) will occur approximately 4 weeks prior to the planned 
date of IMP dose administration (Visit D) . 
The length of the lead-in phase is a minimum of 6 months (26 weeks), ending at or before 
Visit D. Subjects will remain in the lead -in phase until a minimum of 6 months of lead- in data 
have been collected and it is confirmed that the subjects still meet all eligibility criteria, with the 
final visit in this phase (Visit L- Final) occurring approximately 28 days (±7 days ) prior to the 
planned date of IMP dose administration (Visit D) . 
At Visit L1, blood samples for assessment of factor IX  activity and factor IX  protein 
concentration  will be taken. Prior to this visit, subjects must have undergone a wash  out period  
from their usual factor IX  product/dose. The wash out period will be 3 days for regular-acting 
factor IX  products and 10 days for extended half- life factor IX  products. 
During the lead -in phase, subjects will record their use of prophylactic factor IX  replacement 
therapy and bleeding episodes in the e- diary. e -diary data will be reviewed on a continuous basis 
by the Investigator/study nurse, with alternating monthly clinic visits and follow-up phone calls (in line with the trial schedule  and with retraining by phone as needed ). For follow -up phone 
calls, an email communication is acceptable as an alternative if the subject cannot be reached, though reasonable efforts for a phone call should be made. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 74 of 146 
In addition to the subjects’ reporting of bleeding episodes in the e-diary, the Investigator or 
designee will assess each bleeding episode, by describing the reported bleeding episode as soon 
as possible but at least within 72 hours after it has been reported by the subject. In case the 
information provided in the e-diary is not suffi cient to assess the bleeding, the subject must be 
called and/or visit the site.  
At the clinic visits during this lead -in phase (occurring every 2 months), blood samples will be 
taken for assessment of factor IX  activity , transaminases, and AAV5 antibodies. In addition, the 
regular discussions with the subject regarding the importance of a healthy liver before and after 
receiving a liver directed gene therapy, and factors that might impact liver health (including 
acetaminophen and alcohol intake ), will continue. 
Subjects will be asked to complete the  at Visit L3 , including PROBE if 
applicable. 
If the ICF is revised during the lead-in phase with important new information that must be shared 
with the study subjects, the amended ICF will be presented, as required by the IRB/IEC, for 
review and consideration by the subject, and signed re-consent is to be obtained at Visit L -Final 
at the latest.  
During Visit L -Final , the subject’s eligibility will be re -evaluated  based on assessments  during 
the lead -in period and at Visit L -Final  (for an overview of the inclusion and exclusion criteria see 
Section  4.1 and Section  4.2). If a subject, who was previously considered eligible, no longer 
meets the trial inclusion criteria, the subject can be re -evaluated as described in Section  6.1.1. 
The laboratory values obtained at this visit will be used to determine eligibility for dosing  and 
continued participation in the trial. The baseline abdominal ultrasound should be done at Visit 
L-Final at the latest.  
At Visit L -Final, it is recommended that each subject should complete the , 
including PROBE if applicable, prior to the interview by the Investigator and/or study nurse and 
any other trial related procedures.  Other assessments at this visit include the  MSKUS  (if 
applicable), , physical examination (including weight), and vital signs 
evaluation. Additionally , the factor IX  recovery assessment  is done (see Section  6.2.3.7).  
If a subject is travelling to a different site for Visit  D, the treatment card should be handed out at 
the L -Final visit and the subject should be instructed to bring it with him to Visit D. These 
subjects may also provide their semen sample at Visit L -Final instead of Visit D.  CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 75 of 146 
6.1.3 IMP Dose Administration  (Visit D) 
6.1.3.1 Pre-IMP  Dose Administration ( Baseline , Day 1) 
Prior to administration of AMT -061, the Investigator should ensure subject ’s eligibility  (see 
Section  4.1 and Section  4.2). Lab oratory  results  from Visit L -Final will be used to confirm 
eligibility for dosing and continued participation in the trial. If a subject, who was previously 
considered eligible, no longer meets the trial inclusion criteria, the subject can be re- evaluated 
once, as described in Section  6.1.1. 
At this visit, vital sign measurement s will be taken  and a physical examination  will be 
performed. Furthermore, baseline blood and semen samples will be collected for efficacy and 
safety laboratory parameters,  serum chemist ry, and  hematology as detailed in Table 2. Also, for 
subjects who signed the optional ICF, the sample for future research is taken. 
6.1.3.2 IMP Dose Administration  
Subjects will receive a single infusion of AMT-061 according to the procedures described in 
Section  5.3 and in the IMP Handling Manua l. 
6.1.3.3 Post-IMP Dose Administration (3 hours) 
Three hours after completion of the IMP infusion, vital signs are measured and blood samples 
are taken for C -reactive protein (CRP) measurement and vector genome detection. The subject 
may leave the clinic after all Visit D, post-IMP assessments have been performed, and the 
subject has received his subject treatment card.  Subjects who travelled to a different site for 
Visit D should have received their treatment card at the L-Final visit and brought it with them to 
Visit D. 
Subjects are permitted to continue their continuous routine factor IX treatment post-IMP and in 
the first weeks after dosing to provide sufficient factor IX coverage for the initial days post-
treatment.  
6.1.4 Post-Treatment Follow -up (Visit F1 to F-Final [Week 1 to Week 52/Month 12]) 
Subjects are followed for a total duration of 52 weeks, with visits weekly f or the first 12 weeks, 
(Visits F1  [Week 1]  to F12 [Week 12] ), and monthly from Month 4 to Month 12 (Visits F13  
[Month 4] to F- Final  [Month 12] ). With agreement from the Investigator and Sponsor, visits 
during the post-t reatment follow-up period (from Week 1  up until Week 52)  that do not include 
physical examination and/or  may be performed at the subject’s home by an 
appropriately qualified and trained nurse. Each home nursing visit is expected to be 
supplemented by a phone call from the Investigator or designee to the subject to discuss AEs, 
concomitant medications, and e-diary compliance. Options for how visits may occur to 
accommodate safety concerns and restrictions due to COVID-19 are described in Section  3.1.1.  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 76 of 146 
During the post- treatment follow -up phase, subjects will continue to record their use of factor IX  
replacement therapy and bleeding episodes in the e-diary, following the same principles as 
during the lead-in phase, as described in Section  6.1.2. The Investigator or designee will assess 
each bleeding episode, by describing the reported bleeding episode as soon as possible but at 
least within 72 hours after it has been reported by the subject. In case the information provided in 
the e-diary is not sufficient to assess the bleeding, the subject must be called and/or visit the site. 
The discussions with the subject on the importance of a healthy liver and factors that might 
impact liver health (including acetaminophen and alcohol intake), will continue. In addition, use 
of concomitant medication and occurrence of AEs will be continuously monitored. 
Subjects are permitted to continue their continuous routine factor IX  treatment in the first weeks 
after dosing. At Visit F1  (Week 1) , 1 week  after IMP administration, the subjects will visit the 
clinic for endogenous factor IX  activity assessment (by local and central laboratory). During the 
post- treatment follow -up visits, factor IX  activity levels will be monitored throughout the study. 
If the endogenous factor IX  activity result is ≥5 %, continuous routine factor IX  prophylaxis will 
be discontinued and further management will be based on Investigator’s clinical judgement and 
subject preference. Continuation or re-initiation of continuous routine factor IX  prophylaxis may 
be considered if the endogenous factor IX  activity is between 2 and 5% in at least two 
consecutive laboratory measurements, based on the I nvestigator’s clinical judgement and subject 
preference. If endogenous factor IX  activity is <2%, continuous routine prophylaxis must be 
continued or reinstated. Additional on-demand and/or intermittent prophylactic factor IX  
treatment may be given after treatment with AMT -061, if considered necessary. 
Vital signs are measured at each visit in this phase. A physical examination is perfo rmed at 
Visits F1, F2, F4, F6, F12, F13, F15, F17, F19, and F- Final  (Weeks 1, 2, 4, 6, and 12, and Month 
4, 6, 8, 10, and 12 [Week 52]). S amples for efficacy  and safety laboratory parameters  and 
hematology and serum chemistry, are taken at each  visit except for  the samples for factor IX  
antibodies and factor IX  inhibitors ( taken at Visits F6 , F12, F15, and F- Final  [Weeks 6 and 12, 
and Months 6 and 12]), semen sampling for shedding (taken at Visits F6, F12, F1 3, F1 5, and 
F-Final  [Weeks 6 and 12, and Months 4, 6, and 12]), total (IgM and IgG) antibodies and NABs  
to AAV5 (taken at Visits F3, F6, F9, F12, F15, and F- Final  [Weeks 3, 6, 9, and 12, and Months 6 
and 12] ), and the blood sample taken for future research (taken at Visits F1 2 [Week 12]  and 
F-Final  [Week 52/Month 12] ; see also  Table 2).  At Visit F1 5 (Month 6) and Visit F- Final 
(Month 12/Week  52), it is recommended that each subject  should c omplete the  
, including PROBE if applicable, prior to the interview by the trial physician and 
any other trial related procedures.  
For subjects participating in the MSKUS  sub- study, assessments will occur at Visit F15  
(Month 6) and Visit F -Final  (Month 12/Week 52). CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 77 of 146 
Additionally , at Visit F -Final ( Month 12/ Week  52), an abdominal ultrasound is performed, the 
 is evaluated, the e- diary data devices are collected , the study- specific paper 
diaries for the long- term follow -up are provided, and the complete efficacy and safety data are 
analyzed and reported.  
6.1.4.1 Early Discontinuation 
The procedures listed for the final visit (Visit F -Final  [Month 12/Week 52]), with the exception 
of the distribution  of the study- specific paper diaries  for the long- term follow -up, must also be 
performed at early discontinuation (refer also to Section  4.5), but prior to Week 52 . In case a 
subject discontinues after Week 52 but prior to Month 60, he must complete the LTF8 
(Month 60) assessments/procedures.  
6.1.5 Long- Term Follow- up (Visit LTF1 to LTF 8 [Month 18 to 60]) 
During the long- term follow -up, s ubjects  will visit the clinic every 26 w eeks (6 months ± 2 
weeks ). At each visit, the following assessments will be done: review of AEs and concomitant 
medications, collection of bleeding and factor IX  use data, abdominal ultrasound, and sampling 
for efficacy and safety laboratory parameters. It is recommended that the s ubject  complete s the 
, including PROBE if applicable, at Visits LTF2  (Month 24) , LTF4  
(Month 36) , LTF6  (Month 48), and LTF8 (Month 60) , prior to any other trial  procedure is 
performed  at the visit. Evaluation of  and evaluation of the MSKUS  (if 
applicable) will also be performed  at Visit LTF2  (Month 24) , LTF4  (Month 36) , LTF6  (Month 
48), and LTF8 (Month 60). A physical examination will be performed at Visits LTF1  (Month 
18), LTF2  (Month 24) , LTF3  (Month 30) , LTF4  (Month 36) , LTF6  (Month 48), and LTF8 
(Month 60). There should be an additional contact moment between site staff and subject in 
between these routine visits to facilitate at least quarterly (± 2 weeks) monitoring of occurr ence 
of AEs , proper completion of the study-specific paper diaries, and proper reporting of factor IX 
usage and bleeding episodes. Options for how visits may occur to accommodate safety concerns 
and restrictions due to COVID- 19 are described in Section  3.1.1. 
In the long- term follow -up, subjects will document their use of factor IX  replacement therapy 
and bleeding episodes in study- specific paper diaries . Subjects are expected to bring their long-
term follow -up bleed diaries and long- term follow -up factor IX use diaries  to every study visit 
during the long- term follow -up phase. At each visit, site staff will collect the information that is 
new since the previous visit in the paper diaries. In between study visits, subjects should contact 
the site staff immediately in case of a bleed and/or factor IX use in addition to completing the 
questions/information requested on the paper diaries to capture all information. Subjects who are 
on continuous routine factor IX prophylaxis during the long- term follow -up phase of the trial are 
required to contact the site staff immediately in case of a bleed and/or factor IX use different 
from their routine factor IX prophylaxis, in addition to completing the questions /information 
requested on the paper diaries to capture all information. CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 78 of 146 
In total, each subject will be followed for approximately five years after administration of 
AMT -061. This is in line with the European Medicines Agency (EMA) guideline on follow-up 
of subjects  administered with a gene therapy medicinal product 
(EMA/CHMP/GTWP/60436/2007).  
At the end of the long- term follow -up all end of trial procedures, i.e., the LTF8 ( Month 60) 
procedures, as detailed in  Tabl e 3 and  Table 4, should be performed . 
In case of a bleed occurring within 2 weeks of a scheduled LTF visit at which  
questionnaires should be completed, the study visits should be re- scheduled.  The Medpac e and 
uniQure Medical Directors  should be contacted to discuss how to proceed in case the visit would 
need to be pushed out beyond the protocol allowed visit window. 
6.1.6 Additional Visits  
The subject may be called in for additional visits, at the discretion of the Investigator. The 
subject may also contact the clinical trial site for an additional visit.  
An additional visit may include additional assessments, as deemed necessary by the Investigator, 
such as  (but not limited to) physical examination, AE assessment, bleeding assessment and/or 
repetition of instructions to the subject regarding subject e- diaries ( Section  6.1.1), additional 
blood and/or semen sampling, repetition of blood sampling due to erroneous results 
(Section  6.2.5), or conduct of measurements that were missed at the p revious visit.  
6.1.7 Additional C are of S ubjects a fter the Trial  
No after care (i.e. , after the long- term follow -up) is planned for this trial. 
6.2 Trial Evaluations 
6.2.1 Demographic and Other Baseline Characteristics  
6.2.1.1 Demographics  
Demographics collected at screening include birth year  (i.e., age at screening visit), race, ethnic 
group, and gender according to local regulations. CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 79 of 146 
6.2.1.2 Medical History and Concomitant Illnesses  
Medi cal history is any previous medical condition or surgical event, i.e., a condition/event that 
started prior to the screening visit, but is not ongoing at the screening visit. A concomitant illness 
is a medical condition that is ongoing at the screening vis it. Medical history pertaining to 
metabolic disorders (diabetes, pre-diabetes, metabolic syndrome), liver disease and hepatitis 
(metabolic associated fatty liver disease, non -alcoholic fatty  liver disease, non -alcoholic 
steatohepatitis; hepatitis B status,  history, and vaccination status; hepatitis C status, history, and 
eradication details; alcohol use), cancer/tumors (including any family medical history of cancer and specifically hepatocellular carcinoma), will be collected.  
Collection of historical medical information regarding hemophilia B is described in 
Section  6.2.1.4. Information  to determine if a subject has liver fibrosis and steatosis will be 
collected by means of a FibroScan (preferable during s creening or at an alternative time point, 
however at Visit L -Final at the lates t). Liver fibrosis scores and steatosis (CAP) scores will be 
collected during FibroScan assessment. A screening FibroScan assessment is not needed if either 1.) a FibroScan assessment has been performed in the year prior to screening for which CAP 
scores are available in the source documentation , or 2.) a liver biopsy has been performed within 
the 2 years prior to the screening for which fibrosis grade is documented and available in the source documentation. 
At screening, information on relevant medical history will be obtained and recorded. The 
following conditions and events will be considered relevant (bleeding events excluded): 
- Any surgical event or any chronic or ongoing medical condition, regardless if it 
requires/required therapy or not 
- Any medical condition or surgical event that has resulted in sequelae 
- Any isolated or one-off medical condition or surgical event that has occurred within 1 year prior to screening irrespective of the outcome of the event.  
- Any isolated or one-off medical condition or surgical event that has resolved without sequelae and occurred more than 1 year prior to screening if judged relevant by the Investigator (for example conditions that the Investigator evaluates could re- emerge over 
time, e.g., cancers).  
6.2.1.3 Prior and Concomitant Medication/Therapy  
For the definition of prior medication/therapy, refer to Section  5.6.1. For the definition of 
concomitant medication/therapy, refer to Section  5.6.2. At e very visit the Investigator or a 
qualified designee will ask the subject about concomitant medication. The Investigator should 
record the use of all medication (including over the counter medication, vitamin and/or mineral 
supplements, homeopathic remedies and herbal preparations) used and changes in the use of 
medication . Refer to Section  6.2.2.1 for instructions on recording of factor IX  replacemen t 
therapy . The Investigator should also record other concomitant treatments/therapy, e.g., 
physiotherapy. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 80 of 146 
The following information will be recorded on concomitant medications: 
- Drug /therapy  name (generic name preferred)  
- Indication 
- Dosing regimen (dose, unit, frequency, route) 
- Start date (if started ≥3 months prior to s creening , then this can be stated instead of 
recording the specific start date)  
- Stop date (or ongoing, if ongoing at end trial participation). 
6.2.1.4 Hemophilia B Status and History  
At screening, t he following medical history  data related to hemophilia B will be recorded:  
- Date of initial diagnosis  
- Date symptoms were first observed  
- Date and value of endogenous factor IX  activity assessment demonstrating factor IX 
activity of ≤ 2% or sufficient documentation within source documents of severity 
- Severity of Hemophilia B 
- Family members with a history of factor IX  inhibitors 
- Arthropathy 
-  version 2.1 (see Section  6.2.2.5).  
- Number and location of target joints, defined as three or more spontaneous bleeds into a 
single joint within a consecutive six -month peri od. Where there have been ≤2 bleeds into 
the joint within a consecutive 12-month period the joint is no longer considered a target 
joint  
- Registered name and dosage regimen of current continuous prophylactic factor IX  
replacement therapy (if applicable)  
- Hemophilia B related Surgical History  
o Date of surgery  
o Surgical event  
6.2.1.5 History  of Bleeding and Factor IX  Use 
During screening the following historical information regarding bleeding and factor IX  use will 
be collected and recorded in specific modules of the eCRF:  
Factor IX  use data from one year prior to screening:  
- Factor IX  product used (registered drug name) 
- Type of fa ctor IX  replacement therapy (on -demand or prophylaxis) 
- Start and stop date 
- Dose and frequency of dosing CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 81 of 146 
Bleeding data from one year prior to screening: 
- Number of spontaneous bleeding episodes 
- Number of traumatic bleeding episodes 
- Number of bleeding episodes for which it is unknown if they were spontaneous or 
traumatic  
- Number of joint bleeds 
Information on invasive procedures requiring factor IX  use in the year prior to screening: 
- Date of procedure  
- Type of procedure  
- Factor IX  product used (Registered drug name)  
- Total factor IX  dose (in International Unites [ IU]) used for each procedure 
6.2.1.6 Factor IX  Gene Sequencing  
For those subjects who have given their consent, a blood sample for the purpose of factor IX  
gene sequencing analysi s will be collected (preferably at s creening, but otherwise at a later time 
point during the subject’s trial participation). Factor IX  gene sequence analyses will be 
performed for all subjects that provide consent, even if they already have factor IX  gene 
mutation information.  
Gene sequencing analysis will be performed at a central laboratory.  
6.2.2 Efficacy  Evaluations 
For details on the timing and frequency of the assessments refer to Table 1 through Table 4. 
The name and address of each laboratory used in this trial will be maintained in the 
Investigator ’s files at each site. 
Details for the laboratory processing instruction will be provided in the laboratory manual. 
6.2.2.1 Factor IX Replacement Therapy  
From s creening (Visit S) until Week 52 of the post- treatment follow -up (Visit F- Final) , subjects 
will be asked to record all use of prophylactic and on-demand factor IX  replacement therapy in 
an e-diary. If a subject is not able to enter the details into the e -diary, the site will be able to e nter 
the information in the eCRF as long as the subject provides sufficient source documentation. The 
subject  e-diary will include questions with respect to: 
- Reason for factor IX  use (i.e., continuous routine prophylaxis, selective prevention of 
a bleed [e.g., because of upcoming physical activity, sports, etc.], prophylaxis for invasive procedures, or other) 
- Date and time of factor IX  infusion CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 82 of 146 
- Factor IX  product used (Registered drug name) 
- Total factor IX  dose in IU 
The Investigator/study nurse will review the e- diary entries for completeness and accuracy 
against the subject ’s medical/hospital records.  
Information on actual factor IX  replacement therapy used will be recorded by the subject in the 
e-diary. In addition, the prescribed factor IX  replacement therapy regimen will be recorded in the 
eCRF.  
During the long- term follow -up phase, subjects will be expected to continue documenting 
factor  IX replacement therapy  in their paper long- term follow -up factor IX use diary, whi ch they 
will bring  with them to all study visits . 
Factor IX infusions are not recommended for subject s with factor IX activity in the 
non-hemophilic ( ≥40% of normal) range especially in subjects with a confirmed COVID-19 
infection, as increased thrombogenic risk is a known complication of COVID-19. Subject s with 
factor IX activity in the non-hemophilic range post- treatment with AMT -061 and infected with 
COVID-19 may potentially be at the same risk of thrombosis as subject s without hemophilia ; 
antithrombotic therapy for these subject s should be considered under the same guidelines 
recommended for those without hemophilia. 
6.2.2.2 Bleeding Episodes  
From s creening (Visit S) until Week 52 of the post- treatment follow -up (Visit  F-Final) , subjects 
will recor d information of bleeding episodes in an e-diary. If a subject is not able to enter the 
details into the e -diary, the site will be able to enter the information in the eCRF  as long as the 
subject provides sufficient source documentation. The subject  e-diary will include questions 
regarding each bleeding episode with respect to:  
- Date and time of onset of bleed  (start and stop) 
- Location of bleed 
- Circumstances of bleed: spontaneous, traumatic, medical/dental /other procedure, 
unknown cause 
- Location and type of bleed  
- Symptoms associated with the bleed  
- Tests performed  
- Treatment of bleed with factor IX , and response to this treatment  
- Treatment other than factor IX  (e.g., pain medication, rest ) 
During the long- term follow -up phase, subjects will be expected to continue documenting 
bleeding episodes in their paper long- term follow -up bleed diary, which they will bring  with 
them to all study visits . CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 83 of 146 
In case of the occurrence of a bleeding as report ed by the subject  in the e-diary, the Investigator 
or designee needs to assess the bleeding as soon as possible but at least within 72 hours after it 
has been reported by the subject. In case the information entered in the e- diary is not sufficient to 
assess the bleeding, the subject  needs to  be called and/or visit the site.  
The Investigator will assess the bleed according to local standard of care (including potential 
imaging). The bleeding data and outcome should be recorded in source documents. 
Recurrent  bleed: A bleed is defined as a recurrent bleed when, after no or minimal response to 
treatment, the bleed is occurring within 72 hours after stopping treatment for the original bleed 
for which treatment was initiated.  
Persistent bleed : A bleed is defined as a persistent bleed when the same bleed continues for more 
than 72 hours in the same location, without stopping treatment for the original bleed for which treatment was initiated.  
6.2.2.3 Factor IX  Activity  Levels  and Factor IX  Protein Concentration  
Blood samples for determination of endogenous factor IX  activity and factor IX  protein will be 
collected and assessed at the central and /or local  laboratory as indicated in the schedule of event s 
(Table 2
 and Table 4). Central laboratory results for factor IX  activity will be used in the 
analyses  and local laboratory results for factor IX  activity will be used for local monitoring of 
subject s. 
Throughout the study, it will be the aim to draw blood samples at those time points when the 
subject’s factor IX  activity level is expected to be at its trough.  
For subjects on continuous routine prophylactic factor IX  replacement therapy:  
- The Investigator and/or study nurse will collaborate with the subject to schedule study 
visits to take place on days when continuous routine prophylactic factor IX  replacement 
treatment is due to be administered. At these visits, blood sampling will take place prior 
to administration of prophylactic factor IX  replacement therapy.  
- If a subject uses  additional on-demand factor IX  replacement treatment, his upcoming 
study visit may need to be re-scheduled (to the extent the visit window allows) so that the 
visit takes place at the time the subject resumes his continuous routine prophylaxis schedule.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 84 of 146 
For subjects only using on-demand factor IX  replacement therapy (only applicable after 
AMT -061 administration):  
- If a subject uses on -demand factor IX  replacement treatment, his upcoming study visit 
may need to be re- scheduled (to the extent the visit wind ow allows) so that the visit does 
not take place within 5 half -lives of exogenous Factor IX product use ( Table 8) . In case 
the 5  half-lives washout extends beyond the protocol allowed visit window, the Medpace 
and uniQure Medical Directors  should be contacted to discuss how to proceed. 
Contamination due to infused exogenous factor IX use begins at the date/time of infusion 
start and ends immediately after the date/time that is 5 times the half -life (of the factor IX 
medication) after the infusion start date/time. In case the infused factor IX medication is 
not listed in Table 8, the Medpace and uniQure Medical Directors  should be contacted to 
discuss.  
Factor IX  activity will be assessed by using the one- stage aPTT assay  
(local and central 
laboratory) and a chromogenic assay (central laboratory). 
 CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 85 of 146 
 
 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 86 of 146 
 
 
6.2.2.6
 Patient Reported Outcomes, Burdens, and Experiences ( PROBE ) Questionnaire  
The following information applies only to subjects who have volunteered to participate in the 
optional PROBE Questionnair e Sub -Study. 
It is recommended that the PROBE questionnaire will be completed by the subject, after signed 
informed consent has been obtained and prior to any other visit procedure is initiated (when 
possible). The Short Form PROBE will be completed  at screening  (Visit S) , Visit L -Final, and 
Visit LTF8  (Month 60) . The PROBE Follow- up Form  will be completed at Visit L3,  Visit F15 
(Month 6), and every year post- baseline (Visits F -Final, LTF2, LTF4, and LTF6  [Months 12, 24, 
36, and 48]). The PROBE questionnaire should be completed after the other . 
The PROBE questionnaire is to be completed under the supervision of a qualified and delegated 
study team member and is not to be given or sent to a subject to complete at home.  CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 87 of 146 
For those subjects where Visit F15 (Month 6), Visit F-Final (Month 12), and/or a long- term 
follow-up visit are impacted by COVID-19, the PROBE questionnaire may be conducted at the 
site within the following window: 
- Up to -1 month prior to the target visit 
- Up to +2 months after the target visit 
- And at least 4 months after the last PROBE questionnaires assessment.  
Adjustments to this visit schedule will be documented.  
The PROBE Questionnaire is a novel, patient-developed,  tool specific to hemophilia and 
intended to capture clinical outcomes that are considered relevant by patients. The Short Form is 
the full PROBE questionnaire minus the . The Follow-up Short Form includes select 
questions from the Short Form (without the ). 
The objective of this sub-study is to provide data complementary to the compendium of 
established  tools regarding the impact of gene therapy on patient-relevant outcomes and 
 over time.  
6.2.2.7 Musculoskeletal Ultrasound  (MSKUS)  
The following information applies only to subjects who have volunteered to participate in the 
optional MSKUS Sub-Study. 
MSKUS  will occur, after signed informed consent has been obtained, at scree ning (Visit S), Visit 
L-Final, during the post- treatment follow -up at Visit F15 (Month 6) and Visit F- Final ( Month 
12), and during the long- term follow -up at Visits LTF2 ( Month 24), LTF4 ( Month 36), LTF6 
(Month 48), and LTF8 ( Month 60). If it is not possible to obtain the MSKUS  at screening (Visit 
S), it is allowed to obtain this first MSKUS  at a later time point (preferably as soon as possible 
during one of the lead- in visits ). Additional ultrasounds may be collected at the Investigator’ s 
discretion. For those subjects where Visit F15 (Month 6), Visit F-Final (Month 12), and/or a 
long- term follow -up visit are impacted by COVID -19, scans may be conducted within the 
following window: 
- Up to -1 month prior to the target visit 
- Up to +2 months after the target visit 
- And at least 4 months after the last MUSKUS . 
Adjustments to this visit schedule will be documented . CSL Behring 
CCI
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 88 of 146 
Repeated bleeds into the joints can result in progressive damage to the joints, culminating in 
hemophilic arthropathy, mobility restrictions, and possible requirement for surgical repair. This sub-study will provide objective assessment of the effects of receiving gene therapy on the 
progression of physiological joint damage over time. 
Methodology for MSKUS plus scoring of MSKUS will be performed according to the J.A.D.E. 
protocol. The MSKUS s will be centrally analyzed and results assessed by subject  over the course 
of the study. Full details can be found in the Musculoskeletal Ultrasound Manual. 
6.2.3 Safety  Evaluations 
6.2.3.1 Adverse Events  
All AEs will be collected from signing of the informed consent form until the end of the five-
year follow-up. 
At each trial  visit, subjects will be questioned in a general way to ascertain if AEs have occurred 
since the previous visit (e.g., “Have you had any health problems since your last visit?”). During 
the long- term follow -up, AEs should be assessed at least quarterly by means of an additional 
contact between site staff and subject in between the scheduled visits. AE s are collected from the 
time informed consent is signed. 
For definitions of (S)AEs, and procedures regarding reporting of (S) AEs refer to Section  7. 
6.2.3.2 Vital Signs  
Vital signs (b lood pressure, pulse, and body temperature) will be measured at screening  (Visit S) , 
Visit L- Final , at pre -IMP and post-IMP (3 hours) on Visit D, and at all visits during the post-
treatment phase. Before measurement of blood pressure and pulse, the subject  should rest for at 
least 5 minutes. For the individual subject , all measurements should be performed while the 
subject  is in the same position (i.e. , sitting or lying) throughout the trial. 
Body temperature should be measured using the same method (e.g., an ear thermometer) for the 
individual subject  throughout the trial. 
Abnormalities  (e.g., high blood pressure) iden tified at the screening will be documented in the 
subject’s source documents and on the medical history eCRF. Changes after the s creening Visit 
will be captured as AEs on the AE eCRF page, as deemed clinically significant in the opinion of 
the Investigator. These abnormalities are to be followed until they reached “final outcome” (refer 
to Section  7.9).  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 89 of 146 
6.2.3.3 Physical Examination (I ncluding Height and Weight)  
A physical examination will be performed at screening ( Visit S ), L-Final, Visit D (pre -IMP), 
during the post- treatment follow -up at Visits F1, F2, F4, F6, F12, F13, F15, F17, F19, and 
F-Final  (Weeks 1, 2, 4, 6, 12 and Months 4, 6, 8, 10, and 12), and during the long- term follow -up 
at Visits LTF1, LTF2, LTF3, LTF4, LTF6, and LTF8 (Months 18, 24, 30, 36, 48, and 60). 
Height will only be measured at screening  and weight will only be measured at screening an d 
Visit L- Final . 
Height (without shoes) will be measured and recorded, rounded to the nearest centimeter. Body weight (without overcoat and shoes) will be measured and recorded, rounded to the nearest kilogram. 
The physical examination will include general appearance and bedside examination of the 
following body systems: Lymph nodes, eyes and ears, mouth and throat, lungs, abdomen, 
extremities, musculoskeletal system, neurolo gical system, cardiovascular system , and skin. 
The evaluation of each body system will be recorded as “normal” or “abnormal”. Abnormalities 
will need to be specified and  recorded.  
Abnormalities (e.g., scar at the left side at knee following total knee replacement, or arthropathy of left ankle due to hemophilia B) identified at screening will be documented in the subject’s source documents and on the medical history eCRF . Changes after the screening visit will be 
captured as AEs on the AE eCRF  page, as deemed clinically significant in the opinion of the 
Investigator. These abnormalities are to be followed until they reached “final outcome” (refer to Section  7.9).  
6.2.3.4 Abdominal Ultrasound 
To monitor subjects for liver fibrosis and potential occurrences of liver malignancies, abdominal ultrasounds will be performed. These ultrasounds will occur at Visit L -Final at the latest (to 
establish basel ine status) , Visit F -Final, and then every 6 months thereafter as specified  in 
Table 1 and Table 3. For those subjects where Visit F -Final (Month 12), and/or a long- term 
follow-up visit are impacted by COVID-19, abdominal ultrasounds may be conducted within the 
following window: 
- Up to -1 month prior to the target visit 
- Up to +1 month after the target visit 
Adjustments to this visit schedule will be documented.  
Ultrasounds will be evaluated by qualified personnel at each site for fibrosis and malignancy. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 90 of 146 
Abnormalities identified on the baseline abdominal ultrasound will be documented in the 
subject’s source documents and on the medical history eCRF. Changes after baseline will be 
captured as AEs on the AE eCRF page, as deemed clinically significant in the opinion of the 
Investigator. These abnormalities are to be followed until they reached “final outcome” (refer to 
Section  7.9).  
6.2.3.5 Anti -Factor IX  Antibodies  
Anti-factor IX  antibodies will be measured at the central  laboratory, at baseline and  at specific 
time points after IMP administration a s specified in  Table 2 and  Table 4. 
6.2.3.6 Factor IX  Inhibitors  
Factor IX  inhibitors will be measured at the central laboratory with the Nijmegen modified 
Bethesda assay, and at the local laboratory with the Bethesda assay or Nijmegen modified Bethesda assay  as specified in  Table 2 and  Table 4 . Preferably, the same type of assay is applied 
consistently for the individual subject  throughout the entire trial period. 
The Investigator (or designee) should ente r analysis results  from the local laboratory, as well as 
related reference ranges and analysis method applied (if applicable) in the eCRF. In addition, the local laboratory result reports should be kept in the subject’s medical record. 
A subject is said to  suffer from factor IX  inhibitors if he tested positive for factor IX  inhibitors at 
two consecutive tests, performed preferably within two  weeks.  
If a subject is tested positive for factor IX  inhibitors, a re-test should be performed preferably 
within two  weeks to confirm the positive test. The subject should be called in for an additional 
visit in case no routine visit is scheduled within this 2- week timeframe. The subject should 
remain in the trial as per the clinical judgement of the Investigator. If a subject has confirmed factor IX  inhibitors and continues with no change to treatment type for 
six weeks and the factor IX  inhibitor test is negative after that time, the factor IX  inhibitor is 
classified as transient.  
6.2.3.7 Factor IX  Recovery  
Measurement of factor IX  recovery (maximum concentration [C
max]) and incremental recovery , 
measured as increase in activity per unit infused (IU/ml per U/kg) at 30 min after infusion (timed 
from end of infusion) of a dose of factor IX , will be performed at Visit L -Final . Additionally, 
measurement of factor IX  recovery and incremental recovery should be done at suspicion of 
factor IX  inhibitor (see also Section  6.2.3.6) or at increase in bleeding frequency, as judged by 
the Investigator. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 91 of 146 
At each occasion, the subject’s continuous routine factor IX  product/dose should be administered 
while at the clinical trial site. A blood sample should be drawn prior to administering the factor 
IX dose and at 30 minutes after the factor IX  dose was administered. The blood sample should 
preferably be drawn from a vein different from the vein used for factor IX  infusion. 
The continuous routine factor IX  product/dose used for the baseline recovery assay should also 
be used when the assessment is repeated.  
Date of sampling, times of blood sampling (pre- and post- factor IX  administr ation) , time of 
subject’s continuous routine factor IX  product/dose and identity of subject’s continuous routine 
factor IX  product/dose will be recorded.  
Factor IX  activity  for the factor IX  Recovery Assessment  will be measured at a central 
laboratory using the one- stage aPTT assay.  
6.2.3.8 Total (IgG and IgM) and Neutralizing Antibodies to AAV5  
Sampling for total (IgG and IgM) and NABs  to AAV5 will be performed at s creening  (Visit S) , 
Visits L2 through LX, Visit L -Final , Visit D pre -IMP, during the post- treatment follow -up at 
Visits F3, F6, F9, F12, F15 and F- Final  (Weeks 3, 6, 9, 12 and Months 6 and 12), and every year 
post-baseline (Visits LTF2, LTF4, LTF6, and LTF8 [Months 24, 36, 48, and 60]) as specified in Table 2 and Table 4. Total IgG and IgM antibodies will be assessed using an enzyme-linked immunosorbent assay (ELISA) and a luciferase based bio-assay will be used for NABs  to AAV5. 
The measurements will be performed at the central laboratory . Further details of the assays will 
be provided in the laboratory manual. 
6.2.3.9 AAV5 capsid -specific T cells  
Sampling for AAV5 capsid -specific T cells will be  performed at baseline (Visit D, pre -IMP) and 
all visits during the post- treatment phase. 
AAV5 capsid -specific T cells will be measured at  the central laboratory.  
6.2.3.10 Vector Genome Detection  
Samp ling of blood and semen  to determine vector DNA levels  will be performed at baseline and 
at specific time points post- baseline,  as specified in  Table 2 and  Table 4, by means of 
quantitative (real -time) polymerase chain reaction (qPCR) . Sampling should continue for the 
individual subject  and for a specific matrix until three  consecutive negative samples have been 
detected for the subject  for that particular type of matrix.  The sampling schedule may be 
increased (in frequency) as agreed between the Investigator and subject following the 
notification of a first negative result on blood and/or semen, expediting the opportunity to reach 
three consecutive negative samples on the specific matrix.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 92 of 146 
Based on the wish of the subject  semen samples can be collected at home prior to attending the 
visit ( on the visit day or on the day before the visit day). The  sampling schedule may be reduced 
as agreed between the Investigator and subject. As per the inclusion criteria ( Section  4.1), the 
subject must use a condom during sexual intercourse until three consecutive negative samples for 
AAV5 have been detected.  In case a subject is not able to provide semen samples due to a 
medical condition, this should be recorded by the Investigator in the subjects’ medical record. 
6.2.3.11 Inflammatory Markers  
Blood samples will be taken at baseline (Visit D) and at specific time poi nts post- baseline, as 
specified in Table 2 and Table 4 to assess IL -1β, IL -2, IL -6, IFNγ , and MCP-1 using ELISA. All 
assessments will be performed at the central laboratory.  
6.2.3.12 Other Safety Laboratory Evaluations 
All clinical laboratory assays will be performed according to the laboratory’s normal procedures. 
Reference ranges are supplied by the laboratory and used to assess the clinical laboratory data for clinical significance and out -of-range pathological change s. The Investigator should assess out-
of-range clinical laboratory values for clinical significance, indicating if the value(s) is/are not 
clinically significant or clinically significant. Abnormal clinical laboratory values, which are unexpected or not explained by the subject’s clinical condition may be, at the discretion of the Investigator or Sponsor, repeated until confirmed, explained, or resolved as soon as possible. 
The safety laboratory assessments that will be performed  at the central  and/ or local  laboratory 
are specified in  Table 9, and as indicated in the schedule of events ( Table 2
 and Table 4). 
 
Table  9 Safety Laboratory Parameters  Assessed at the Central and/or Local Laboratory  
Central Laboratory   
Serum Chemistry  Serum electrolytes (sodium, potassium), creatinine, creatine kinase, gamma -
glutamyltransferase , AST, ALT, ALP, CRP, albumin, total bilirubin, glucose (non-
fasting)  
Hematology  Hemoglobin, hematocrit, platelet count, red blood cells, white blood cells with 
differential count, CD4+ count (all expressed in % as well as in absolute numbers)  
Coagulation  aPTT, PT (or INR [International Normalized Ratio])  
Serology  HIV viral load, HBsAg, HBV DNA and HCV RNA  
Alpha -fetoprotein   Alpha -fetoprotein (AFP)   
Local Laboratory  AST and ALT  
Abbreviations: ALP : alkaline phosphatase; ALT : alanine aminotransferase; aPTT : activated partial thromboplastin time; 
AST : aspartate aminotransferase; CRP : c-reactive protein; DNA : deoxyribonucleic acid; HBsAg : hepatitis B surface antigen; 
HBV: hepatitis B virus; HCB : hepatitis C virus; HIV : human immunodeficiency virus; PT: prothrombin time; 
RNA: ribonucleic acid . 
 
The Investigator should attempt to arrange with the local laboratory that analysis results are 
provided on the same day, or the day after, blood sampling has taken place. Local laboratory 
results should be provided as soon as possible to the Investigator. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 93 of 146 
The Investigator (or designee)  should enter analysis results from the local laboratory, as well as 
related reference ranges and analysis method applied (if applicable) in the eCRF. In addition, the 
local laboratory result reports should be kept in the subject’s medical record.  
Abnormalities identified at screening will be documented in the subject’s source documents and on the medical history eCRF. Changes after screening will be captured as AEs on the AE eCRF 
page, as deemed clinically significant in the opinion of the I nvestigator. These abnormalities are 
to be followed until they reached “final outcome” (refer to Section  7.9).  
6.2.4 Others  
6.2.4.1 Blood Sample for Future Research  
Four additional blood samples for the purpose of potential future research in the hemophilia B disease area (including development and validation of assays to support efficacy assessments) 
will be drawn ( at screening  [Visit S] , baseline [ Visit D  pre-IMP] , Visi t F12 [W eek 12 ], and Visit 
F-Final [ Month 12/W eek 52 ]). 
These additional blood samples will only be drawn if separate informed consent is given by the subject. Subjects who do not wish to donate blood samples for the purpose of potential future research may still participate in the trial and will not be required to withdraw from the trial if they withdraw consent for the potential future research. 
The procedures for the collection, processing, storage, and shipment of these blood samples are 
described in the Laboratory Manual.  
6.2.4.2 Liver Sample for Future Research  
The Sponsor will also provide an optional consent to ask subjects to agree with providing a tissue sample from their liver in case of death , or if the liver becomes available for any other reason 
(e.g., liver transplantation  or resection ) during the long- term follow -up phase of this study. Liver 
samples will be analyzed to investigate how the gene therapy sequences are maintained within 
the cel ls of the liver over time, tolerance and/or stress within the cells of the liver, and/or how the 
gene therapy is expressed in different parts of the liver and across the liver cells. This is entirely 
voluntary, and subjects may still participate in the stu dy if they do not wish to agree to donate a 
liver tissue sample.  
6.2.5 General Information Regarding Laboratory Sampling and Results 
All laboratory assessments will be conducted at a central laboratory, except the factor IX  activity 
assay for local monitoring of subjects ( Section  6.2.2.3), Factor IX  inhibitor assay for local  
monitoring of subjects, and evaluation of subject eligibility ( Section  6.2.3.6), and  local 
monitoring of live r enzymes (AST and ALT ; Section  6.2.3.12; also see the schedule of events 
[Table 2
 and Table 4] ). CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 94 of 146 
Dates and times of sampling will be recorded.  
Detailed procedures for the collection, processing, storage, and shipment of central laborator y 
samples are described in the Laboratory Manual. This manual as well as all material such as test 
tubes and labels will be provided by the coordinating central laboratory. 
After the laboratory samples have been analyzed , they will remain stored for potent ial re -analysis 
at any time during the trial to a maximum of up to one year after the trial has been completed, 
before being destroyed. Where allowed by local regulations, l eft over material of these samples 
may be used throughout the study to support studies in hemophilia B and/or gene therapy 
research, as well as related assay development to support such research. At m aximum 1 year 
after the study has been completed, all sample material will be destroyed. Exceptions are the 
future research blood samples, which will be stored and used for medical research until there is 
no sample remaining. 
The Investigator will be provided with those laboratory results needed for treatment decision-
making (i.e., laboratory results that inform safety monitoring or management of an individual 
subject at a site). The Investigator will receive serum chemistry, hematology, coagulation, 
serology, AFP, inflammatory markers, and gene sequencing results. Laboratory results will be 
provided at regular intervals for review and sign -off. Note that inflammatory markers will be 
analyzed by the central laboratory in batches and therefore reporting of these results to the Investigator is delayed. Any abnormality, judged by the I nvestigator as a clinically relevant 
worsening since the first measurement, should be reported as an AE, unless the laboratory abnormality is associated with an already reported AE.  
Any report of erroneous results from Visit F -Final ( Month 12/ Week  52) and onwards should 
prompt that the subject is called in for an Additional Visit to have blood sample(s) drawn for the purpose of re- measurement . 
The Additional Visit should preferably take place within 1 week after the report of the erroneous 
result(s).  
The Investigator will not be provided with results for one- stage aPTT for factor IX activity, 
chromogenic assay for factor IX activity, factor IX protein concentration, anti- factor IX 
antibodies, factor IX inhibitors, factor IX recovery, total (IgM and IgG) antibodies to AAV5, 
neutralizing antibodies to AAV5, AAV5 capsid- specific T cells, or vector genome detection.  
Once there have been three consecutive negative results for vector genome detection (in blood and semen), the Investigator will be informed that these samples no longer need to be collected.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 95 of 146 
6.2.6 Volume of Blood to be D rawn F rom E ach S ubject  
Overall, a total of approximately  2370 mL blood will be drawn from each subject during this 
trial (excluding additional visits) . A maximum of 120 mL will be taken per visit. A maximum 
amou nt of 110 mL will be drawn per additional visit.  
A minimum of a pproximately 2000 mL blood will be drawn between screening and the end of 
the post- treatment follow -up (Visit F- Final  [Month 12/Week 52 ]). During the long-t erm follow -
up, approximately 450 mL blood will be drawn. 
The amount of blood to be taken for each assessment  may vary according to the instructions 
given in the laboratory manual. The overall total amount of blood that will be drawn from each 
subject may vary  according to the number of additional visits needed for the individual subject . 
When multiple assessment s need to  be done at the same time point/visit, and they require the 
same type of tube, the assessments may be combined.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 96 of 146 
7 SAFETY DEFINITIONS, REPORTING AND FOLLOW- UP 
7.1 Adverse Event Definitions 
An AE, an adverse d rug r eaction (ADR) , and a SAE are defined according to 
ICH Guideline  E2A . 
An AE is any untoward medical occurrence in a subject administered the IMP and which does 
not necessarily have a causal relationship with this IMP or the IMP administration procedure. An 
AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of the IMP including the IMP administration procedure. The definition also covers medication errors and uses outside what is 
foreseen in the protocol, including misuse and abuse of the product. 
An ADR is an untoward and unintended response to the IMP related to any dose administered. A 
causal relationship between the IMP and the AE  is at least a reasonable possibility.  
An SAE is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life -threatening (this refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused 
death if it was more severe)  
• Requires in -subject  hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly or birth defect 
• Is judged medically important by the Investigator (this refers to an event, not resulting in any of the outcomes listed above, but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed) 
A Suspected U nexpected Serious A dverse R eaction  (SUSAR ) is an unexpected adverse reaction 
that at any dose results in death, is life -threatening, requires hospitalization  or prolongation of 
existing hospitalization, results in persistent or significant disability or incapacity, or is a 
congenital anomaly or birth defect. 
In the following situations events are not defined as an AE:  
• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads 
to the procedure is an AE 
• Anticipated day -to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the trial that do not w orsen  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 97 of 146 
• Condition(s) for which pre-planned procedure(s) have been recorded at s creening , 
including hospitalization(s), unless the condition(s) for which the procedure and/or 
hospitalization was planned has worsened from the first trial related activity after  the 
subject has signed the informed consent form 
• Concomitant illness identified during the screening procedures will be recorded as medical history. However, whenever symptoms for these condition(s) worsen and/or become serious, then these events must be reported as an AE or SAE, as applicable.  
7.2 Adverse Events Qualifying for Special Notification  
In addition, the following (S)AEs qualify for special notification as they are seen as safety issues of particular concern for Advanced Therapy Medicinal Product (A TMP) (ENTR/F/2/SF/dn 
D(2009) 35810. Brussels, 03/12/2009) and gene therapy medicinal products 
(EMA/CHMP/GTWP/60436/2007):  
• AEs related to the IMP administration procedure  
• Suspected or confirmed cases of opportunistic or serious infections that in the Investigator’s opinion might be related to the IMP 
• Unexpected reactions (e.g. , hypersensitivity, immunological, toxic or other as 
consequence of a change in the construction or function of the viral vector [e.g., 
generation of replication competent virus]) 
• AEs related to product failure (including lack of efficacy) 
• AEs related to mandatory concomitant medication (e.g., immunosuppression) 
• AEs related to medical devices which form part of the product or are used for application 
of the product 
• Development of any new/recurrent cancer.  
These AEs should be reported and followed in the same manner as SAEs. Note that the AEs may be serious or non-serious by definition (see Section  7.1).  
7.3 Adverse Event Assessment Definitions 
7.3.1 Severity  
The Investigator should assess the severity of all AEs according to the following definitions: 
• Mild:  A type of AE that is usually transient and may require only minimal treatmen t or 
therapeutic intervention. The event does not generally interfere with usual activities of daily living. 
• Moderate:  A type of AE that is usually alleviated with spec ific therapeutic intervention. 
The event interferes with usual activities of dai ly living, causing discomfort but poses no 
significant or permanent risk of harm to the research subject. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 98 of 146 
• Severe:  A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. 
For reporting of S(AE) related laboratory abnormalities, the severity (intensity) needs to be 
evaluated in accordance with the defined criteria for assessment of laboratory value abnormalities.  
Note the distinction between seriousness and severity: The term severe is used to describe the intensity of the event and a severe event is not necessarily serious (e.g., a severe headache would probably not constitute an SAE; however, a mild myocardial infarction could constitute an SAE). 
The seriousness criteria serve as a guide for defining regulatory reporting obligations. 
If an AE changes severity over time, the severity of maximum intensity should be reported. 
7.3.2 Relationship to  IMP  
The Investigator must assess the causal  relationship of the IMP for e ach (S) AE. The Investigator 
should decide whether, in his or her medical judgement , there is a reasonable possibility that the 
event may have been caused by the IMP according to the following guidelines and must 
document the causality assessment in the source document.  
Term  Relationship  Definition  
Related  Yes The temporal relationship between the event and the administration of the 
IMP is compelling and follows a known or suspected response pattern to 
that product; the response disappears or decreases on cessation or 
reduction of the IMP dose and/or it reappear s or worsens when the IMP  is 
administered.  
Possibly Related  Yes The temporal relationship between the event and the administration of the IMP is compelling and/or follows a known or suspected response pattern to 
that product, but the event could reasonably be explained by the subject’s medical condition, other therapies, or accident.  
Unlikely Related  No The temporal relationship between the event and the administration of the IMP is less  compelling and/or does not follow  a known or suspected 
response pattern to that product ; the event could plausibly  be explained by 
the subject’s medical condition, other therapies, or accident.   
Not Related  No The event can be readily explained by other factors such as the subject’s underlying medical condition, concomitant therapy, or accident and no plausible temporal or biologic relationship exists between the IMP  and the 
event. In addition, this assessment can be used in cases where the subject did not receive any treatment with IMP . 
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 99 of 146 
7.4 Reporting of Adverse Events 
All events meeting the definition of an AE must be reported in the period starting at the first visit 
during which any trial related activity takes place (i.e., as of ICF signature date) until the end of 
trial participation. Only medically qualifie d personnel (I nvestigators) must assess AEs.  
AEs must be reported in the source data and the eCRF. The diagnosis will be recorded, if available and applicable. If no diagnosis is available, each sign and symptom will be recorded as 
individual AEs. 
Recurrin g AEs should be reported separately, i.e., with separate start date and time and stop date 
and time.  
7.5 Prompt Reporting of SAEs and Other Events to CSL  Behring  
SAEs , AEs qualifying for special notification, and pregnancies  must be reported as described in 
Table 10 (once the Investigator determines that the event meets the protocol definition for that 
event ). 
Table  10 Timing of Reporting and Follow -up for (Serious) Adverse Events, Adverse Events for Special 
Notification , and Pregnancies  
 Initial Reports  Follow -up Information on a Previous 
Report  
Type of Event  Time Frame  Documents  Time Frame  Documents  
All SAEs  24 hours  SAE form  72 hours a SAE form  
All AEs qualifying for special 
notification as defined in 
Section  7.2 24 hours  SAE form  72 hours  a SAE form  
All pregnancies  24 hours  Pregnancy 
reporting form  Once separate 
informed consent is given by the 
subject and 
pregnant  partner, 
within 72 hours  a Pregnancy 
reporting form  
a. If however, in the opinion of the I nvestigator, the follow -up information may have implications for the safety of 
other subjects, the follow -up information is to be reported immediately (i.e. , within 24 hours  after initial report).  
 
The information will be reported on the respective  form and will include assessment of 
seriousness, severity, causal relationship to the IMP or trial procedures, outcome, and a narrative 
description of the course of the event , as applicable. Additional information may be subsequently 
provided. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 100 of 146 
The reporting form and all other relevant documents supporting the reported SAE, AE qualifying 
for speci al notification , and pregnancy must be reported to CSL  Behring. 
The IECs/IRBs and regulatory authorities will be notified of (S)AEs according to current 
regulation and local requirements. 
SAEs occurring to a subject after the subject has completed the clin ical trial and for which a 
reasonable possibility of a causal relationship is assessed by the Investigator, should be reported 
by the Investigator to the Sponsor if the I nvestigator becomes aware of them regardless of the 
time that has elapsed (post -trial events).  
7.6 Regulatory Reporting Requirements for SAEs and Other Events 
Prompt notification by the Investigator to CSL Behring of SAEs and AEs qualifying for special notification , and pregnancy is essential, so that legal obligations and ethical responsibilities 
towards the safety of subjects are met.  
CSL Behring has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a product under clinical investigation. CSL Behring will comply with ICH/FDA/EMA and country- specific regulatory requirements relating to safety 
reporting to the regulatory authority, IECs/IRBs and Investigator s. 
An Investigator who receives a SUSAR describing ( an) SAE(s) or other specific safety 
information (e.g., sum mary or listing of SAEs) from CSL  Behring will acknowledge and file it in 
the appropriate section of the ISF and will notify the IECs/IRB s, if appropriate, according to 
local requirements  (this information will also  be filed in the appropriate ISF section by the 
Investigator). 
In addition to submission of SAEs, an annual development safety update report will be prepared 
and submitted to the EMA, FDA, and locally if applicable, according to the development international birth date.  
7.7 Reporting of Pregnancies 
Should a pregnancy occur in a female partner of male subject, it will be recorded separately from AEs, but will be reported in a manner identical to the reporting of SAEs, how ever via the use of 
a pregnancy reporting form instead of a SAE  form.  
All attempts will be made to follow the pregnancy until the outcome of the pregnancy has been determined , and to capture information on the development of the infant in the period up until 
and including the age of 1 year. This information will only be collected if separate informed consent is given by the subject and the pregnant partner/infant’s mother. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 101 of 146 
Any report of a congenital abnormality/birth defect is an SAE and should be reported as such. 
Any complication of a pregnancy occurring during this trial, including elective termination for medical reasons, must be reported with the pregnancy reporting form.  
7.8 Reporting of Occupational Exposure 
Occupational exposure refers to the exposure to the IMP  as a result of one’s professional or non-
professional occupation. Any events of occupational exposure should be reported by the site according to local regulations and procedures. 
7.9 Follow-up on Adverse  Events 
All S(AE)s should be followed until resolved or they have reached a “final outcome” or the subject’s participation in the trial ends, whichever comes first.  
Severe, non- serious AEs assessed as “Related” to IMP and all SAEs and AEs qualifying for 
special notification (regardless of their relationship to IMP) still ongoing after ended trial participation, should be followed on a regular basis according to the I nvestigator’s clinical 
judgement until a “final outcome” h as been established.  
The outcome “recovering” can be used as the “final outcome” for events that are stabilized (i.e. , 
no further worsening is expected) and expected by the I nvestigator to resolve over time.  
The outcome “not recovered” can be used as the “final outcome” for events that are not expected to resolve over time (e.g., cancer).  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 102 of 146 
8 DATA MANAGEMENT  
8.1 Data Collection 
The Investigators’ authorized site personnel must enter the required information as per  the 
protocol on the e CRF  (note that authorized personnel from the data management vendor will 
enter the  and  summary data) . A trial monitor will visit each site or 
perform virtual monitoring in accordance with the monitoring plan and review the eCRF data 
against the source data for completeness and accuracy. Discrepancies between source data and 
data entered by the site on the eCRF will be addressed by qualified site personnel or the data 
management vendor for  and  summary data. When a data discrepancy 
warrants correction, the correction will be made by authorized site personnel or by authorized 
personnel from the data management vendor , where applicable. Data collection procedures will 
be discussed with the site personnel at the site initiation visit and/or at the Investigator ’s 
Meeting. It is expected that site personnel will complete the eCRF entry within 5 business days 
of the subject’s visit.  
The subject reported e -diary data will be directly loaded from the application into the eCRF up to 
Week 5 2, without source documentation. All other data will have separate source documentation; 
this data will not be recorded directly onto the eCRF. 
8.2 Clinical Data Management 
Data are to be entered into  the eCRF  as specified in data entry instruction. Quality control and 
data validation procedures are applied to ensure the validity and accuracy of the clinical 
database.   
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual pr ocedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.  
To aid in CSR reporting of missed visits due to COVID -19, the eCRFs will capture if a visit is  
missed and reason (s) why . 
8.3 Study Data 
Study data identified in this protocol are collected, and source verified, on eCRF. All study data 
will be formulated into data sets to provide transparency, traceability, and integrity of trial 
analysis results from collection source to meet regulatory obligations for standardized study data. 
Observed study data will be mapped to the Clinical Data Interchange Standards Consortium 
(CDISC ) Study Data Tabulation Model (SDTM) and serve as the source data from the trial. All 
study analyses will be completed using analysis data sets that are derived from the SDTM and 
follow the CDISC Analysis Data Model (ADaM) architecture.  CSL Behring 
CCI
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT-061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 103 of 146 
8.3.1 Clinical Data – CDISC Study Data Tabulation Model (SDTM)  
Domains will be mapped to CDISC SDTM (current version at the time of mapping). No derived 
data required for analysis are included in the SDTM domains. All SDTM domains will be fully 
documented with define documents (DEFINE.XML) and a reviewer’s guide after database lock 
and final analyses are completed.  
8.3.2 Analysis Data – CDISC Analysis Data Model (ADaM)  
All planned and  will be completed using the ADaM data sets derived from 
the SDTM domains for this study. Analysis data sets will contain all derived study endpoints 
required for analysis. All analysis data sets will be fully documented with define documents 
(DEFINE.XML) and a reviewer’s guide after database lock and final analyses are completed.  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 104 of 146 
9 STATISTICAL METH ODS  
9.1 Statistical Analysis  
Details regarding the statistical methods and definitions  for all study endpoints will be provided 
in the SAP , which will be finalized prior to database lock. The SAP will include a full 
description of the availability of data, timing of analyses and reporting, and will include 
templates for the tables, figures , and listings to be provided. 
Any agreed deviations from the SAP will be  justified in the CSR.  
Statistical analyses will be performed using SAS  Version 9.4 or higher (SAS Institute, Cary, 
NC 27513). 
9.2 Interim Analyses 
The first secondary  endpoint, endogenous factor IX  activity at 6 months after AMT -061 dosing, 
will be assessed once the last subject has achieved 6 months after AMT -061 treatment . This 
assessment will be based on clean data and a partially locked database.  
The second  secondary endpoint, endogenous factor IX activity at 12 months after AMT -061 
dosing, will be assessed once the last subject has achieved 12 months after AMT-061 treatment. 
This assessment will be based on clean data and a partially locked database.  
9.3 Final Analysis 
Factor IX expression is anticipated to be stable within 6 months post-dose. A fter 52 weeks 
following stable factor IX expression,  
 
. Data up to that point will be considered locked and will not be 
changed  (with the exception of ending dates and outcomes for continuing events and treatments) 
without explicit authorization  from the Sponsor. 
Following the 18 months post-dose assessments, subjects will be followed for another 3.5 years 
for evaluation of efficacy parameters and safety. A t the end of that 3.5-year period, all safety and 
efficacy data will be reported in a CSR addendum covering the entire study duration, including 
the later 3.5 -year period . 
The CSR and CSR addendum will summarize contingency measures implemented to manage 
study conduct due to COVID-19 control measures, protocol deviations due to COVID-19, and 
the impact COVID -19 had on visit schedules, missed visits, and missing information. CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 105 of 146 
9.4 Selection of Subjects to be Included in the Analyses 
The FAS (Full Analysis Set) will include all subjects who are enrolled, entered the lead -in phase, 
are dosed with AMT-061, and provide at least one efficacy endpoint assessment subsequent to 
AMT -061 dosing. The FAS population will be the primary population for all efficacy statistical 
analyses . 
The PP population will include all subjects from the FAS population who adhere to a stable and 
adequate prophylaxis use during the lead-in phase, who complete at least 18 months of efficacy 
assessments (52 weeks after achieving stable factor IX expression) for the 18 -month (data cut) 
analysis , who complete at least a full year of efficacy assessments for the 12 month (data cut) 
analysis, or who complete at least 6 months of efficacy assessments for the 6 month (data cut) 
analysis , and who have no major protocol deviations that impact the interpretation of efficacy. 
The PP population will be used for sensitivity analyses. Protocol deviations that impact the 
interpretation of efficacy include unwillingness to stop continuous routine factor IX  prophylactic 
treatment after receipt of AMT -061. Detailed rules for exclusion of data from the PP analysis 
will be established . 
The l ead-in safety population will consist of all subjects enrolled into the l ead-in period. The 
post-t reatment s afety population will consist of all subjects who receive AMT-061, irrespective 
of any protocol deviations. Period- specific safety tabulations will use the period -specific safety 
population for the “N” and denominator (for percentages). The s afety population will consist of 
all subjects who are in either the l ead-in safety population or the post-t reatment s afety 
population. 
The s creen failure population will include all subjects who were screened but never entered the 
lead-in period. 
The l ead-in discontinuers population will include all subjects who entered the lead-in period but 
discontinued from the study prior to AMT-061 dosing. 
9.5 Subje ct Disposition 
A disposition table for CT- AMT -061-02 for all subjects will be provided. This tabulation will 
include the number of subjects who were not treated, who received the study treatment, who 
discontinued from the study, and who completed the study. The number and percentage of 
subjects included in the FAS, PP, and Safety populations will also be tabulated. The reason for exclusion from the FAS, PP, and Safety populations will be summarized. Reasons for premature discontinuation from study treatment (i.e., being treated with only a partial dose of AMT-061) 
will be summarized for the Safety population. 
The data on subject disposition, protocol deviations (including those related to COVID-19), and 
informed consent will be listed.  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 106 of 146 
9.6 Demographic and Baseline Characteristics 
Descriptive summaries of demographics and other baseline characteristics will be presented for 
the FAS , PP, and S afety  populations. For quantitative variables, all summaries will include the 
number of non-missing observations, mean, median, SD, minimum, and maximum. For the qualitative variables, the summaries will include the number and percentage of subjects in each category or level. All data will be included in listings.  
Medical history will be coded using the most recent version of t he Medical Dictionary for 
Regulatory Activities ( MedDRA ), summarized using the number of observations and 
percentages of subjects reporting each category , and listed for each subject. 
A full description of demographic variables will be included in the SAP.  
9.7 Investigational Product Exposure 
Listings for exposure to IMP will be provided showing the date of exposure and dose received.  
The time of subject’s routine factor IX product/dose, incremental recovery, maximum concentration, and identity of subject’s routine factor IX product/dose will be listed. 
9.8 Prior and Concomitant Medication 
Prior and concomitant medication s will be collected and  will be coded using the most recent 
World Health Organization drug dictionary. Prior and concomitant medications will be listed  
separately . 
9.9 Efficacy Analyses 
All efficacy analyses will be performed for the FAS and PP populations.  Statistical analysis will 
be performed and plots and tabular displays will be created, visualizing individual effect s for the 
selected efficacy measures as specified in the following sections. Analyses will be based on central laboratory measurements if results are available from both local and central laboratories.  
The primary efficacy analysis will be completed using the FAS population. The analysis using the PP population is considered to be a sensitivity analysis. 
9.9.1 Primary Efficacy Endpoint s 
The primary efficacy endpoint i s as follows :  
- ABR comparison between AMT-061 and prophylaxis for non- inferiority between the 
lead-in phase and the 52 week s following stable factor IX expression (months 6-18 
post- treatment)  CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 107 of 146 
Primary efficacy analysis  for ABR 
ABR will be determined for the lead -in period and post- treatment period  (for the 52 weeks 
following stable factor IX expression [months 6-18 post- treatment ]). Analysis of the number of 
reported bleeding events will be performed using a repeated measures (RM) generalized 
estimating equations (GEE) negative binomial regression model accounting for the paired design 
of the trial with an offset parameter to account for the differential collection periods . An 
unstructured covariance matrix will be employed. If the model fails to converge, then a 
compound symmetry covariance structure will be used. The model will include the treatment (i.e., period) as a categorical variable. If convergence is not attained, then initial parameter estimates will be provided. The estimated rate ratio, one-sided 97.5% Wald confidence interval, 
and the corresponding p-value will be determined. The upper limit of the resultant confidence 
interval of the rate ratio will be compared to the non -inferiority margin of 1.8. If the upper limit 
is less than 1.8, then non- inferiority will be declared.  
For the data cut at 52 weeks following stable factor IX expression (18 months post- treatment), 
ABR counts over the 52 weeks following stable factor IX expression (months 6-18 
post- treatment ) will be used in the analysis. For data cuts prior to the post- treatment 18 -month 
data cut, to  allow time for AMT -061 to become active and to allow the subject the opportunity to 
stop the lead -in prophylactic Factor IX therapy, ABR counts beginning at Day 21 (of the 
post- treatment period) will be used in the analysis.  
The post- AMT -administration time at risk of (having) a bleeding event is the subject’s time on 
the study between stable factor IX expression (Month 6; between Day 21 for pre -Month 18 data 
cuts) and the time that is 52 weeks following stable factor IX expression (18 months; that is one year for the 12 -month data cut), the time of study completion, or the time of early withdrawal 
from the study, whichever is earlier. Any bleeds prior to stable factor IX expression (Month 6; to 
Day 21 for pre-Month 18 data cuts) of the post-treatment period are not considered in the 
analysis. Events from the entire lead-in period will be counted, and the entire lead-in period is considered to be time at risk.  
In the analysis, any person-time during the post- treatment period with in 5 half-lives subsequent 
to exogenous factor IX use will not be counted in the time at risk of (having) a bleeding event. 
Any bleeds occurring on or after stable factor  IX expression (post- treatment Month 6; on or after 
Day 21 for pre-Month 18 data cuts) should still be counted as events, even if they occurred 
during a time interval of “contamination”.  
The main population for analysis will be the FAS. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 108 of 146 
9.9.2 Secondary Efficacy Endpoints  and Order of Testing of Primary and Secondary 
Endpoints  
Secondary endpoints of the trial will focus on investigating the effect of 2 × 1013 gc/kg AMT-061 
on endogenous factor IX activity, assessment of annualized consumption (and infusion rate) of 
factor IX replacement therapy, remaining free of previous continuous routine prophylaxis, 
assessment of trough factor IX activity, bleeding events, estimated  ABR as a function of pre- IMP 
anti-AAV5 antibody titers using the luciferase based NAB assay (as a “correlation” analysis) , 
correlation of factor IX activity levels and observed anti-AAV5 antibody titers using the 
luciferase based NAB assay after AMT -061 dosing, occurrence and resolution of target joints, 
, and .  
Secondary efficacy endpoints are presented in Section  3.3.2. 
Efficacy analys es for factor IX activity  
For the factor IX activity analyses , the change in uncontaminated endogenous factor IX activity 
levels (by the one- stage aPTT assay) at 6 months, 12 months, and 18 months following a single 
treatment with AMT -061 will be assessed once the last subject has achieved 6 months, 12 
months, and 18 months after AMT -061 treatment , respectively . The methodology, as described 
below for assessment after 18 months, will also be used for the 6 month and 12 month analyses.  
The change from baseline in factor IX activity (factor IX DIFF) will be tested:  
o Ho: factor IX DIFF = 0 (no effect of treatment)  
o H1: factor IX DIFF > 0 
The hypothesis that factor IX DIFF = 0 (i.e., that the change from baseline is zero) will be tested 
and a one- sided p -value ≤ 0.025 will be regarded as statistically significant.  
The change from baseline in factor IX activity (percent of normal) at Month 18 will be analyzed 
using a RM linear mixed model. The baseline factor IX activity will be imputed as descri bed in 
the SAP. If a subject has zero uncontaminated central -laboratory post- AMT -061 factor IX 
activity values, the factor IX activity at Month 18 (and at any other post-AMT planned 
assessment time point that is to be used in the analysis) will be imputed based on the subject ’s 
historical hemophilia B severity as  documented on the CRF  in a manner identical to that used for 
baseline factor IX acti vity. The model will include visit as a categorical covariate. A Toeplitz 
covariance matrix will be used to model correlation within a subject. If the Toeplitz model fails 
to converge, then a first -order autoregressive (AR(1)) structure will be used instead. In the AR(1) 
model, subject will be included as a random effect. If the AR(1) model also fails to converge, 
then subject will be modeled as a random effect in the absence of an AR(1)  model. If 
convergence is still not attained, then initial parameter estimates will be provided. A contrast will 
be used to carry out the comparison at Month 18. The change from imputed baseline at CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 109 of 146 
Month 18, the two-sided 95% confidence interval for the mean change, and the corresponding 
p-value for the comparison to zero will be obtained from the model and provided in a table. 
To allow time for AMT -061 to become active and to allow the subject the opportunity to stop the 
lead-in prophylactic factor IX therapy, factor IX levels beginning with the Week 3 assessment 
will be used in the analysis. Visits post -AMT -061 that are within 5 half- lives  of exogenous factor 
IX use are considered contaminated and will also be excluded from this analysis. For the 
6-month analyses, a less refined contamination rule was used, whereby the date of exogenous factor IX infusion and the subsequent 9 days (10 discrete calendar days in total) were considered to be days of contamination with factor IX. The 12 month and 18 month analyses will use the more refined definition of contamination, based on 5 half- lives.  
The main efficacy analysis for factor IX activity will be completed using the FAS population. 
The analysis using the PP population is considered to be a sensitivity analysis. Sensitivity 
analyses will be conducted to account for missing data and will be specified in the SAP. 
Testing of Efficacy Endpoints 
Formal statistical testing of the efficacy endpoints will be performed using the closed testing 
principle (for Type I error control for multiple testing). Due to the closed testing principle, no 
correction for multiplicity is necessary.  All endpoints will be tested for superiority at a one-sided 
alpha level of 0.025 (except as otherwise noted) . Superiority and non- inferiority  testing will be 
accomplished using the FAS population. Fixed sequential testing will be performed using a hierarchical approach and will be continued until a non- significant result is obtained  (except as 
otherwise noted). 
The primary and secondary endpoints will be analyzed in the following order: 
1. ABR comparison between AMT-061 and prophylaxis for non- inferiority  between lead -in 
phase and the 52 weeks following stable factor IX expression (months 6-18 
post- treatment ; primary efficacy endpoint) 
2. Endogenous f actor IX a ctivity at 6 months after AMT -061 ( first secondary  efficacy  
endpoint) 
3. Endogenous f actor IX a ctivity at 12 months after AMT -061 (second secondary efficacy 
endpoint) 
4. Endogenous factor IX activity at 18 months after AMT -061 (third secondary efficacy 
endpoint) 
5. Annualized consumption of factor IX replacement therapy during the 52 weeks following stable factor IX expression (months 6-18 post- treatment) , excluding replacement for 
invasive procedures, compared to the lead -in phase (secondary efficacy endpoint)
 
6. Annualized infusion rate of factor IX replacement therapy during the 52 weeks following stable factor IX expression (months 6-18 post- treatment) , excluding replacement for 
invasive procedures, compared to  the lead -in phase (secondary efficacy endpoint) CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 110 of 146 
7. Comparison of the percentage of subjects with trough factor IX activity <12% of 
normal between the lead -in phase and after treatment with AMT -061 over the 
52 weeks following stable factor IX expression (months 6-18 post- treatment ; 
secondary efficacy endpoint)  
8. ABR comparison between AMT-061 and prophylaxis for superiority betwe en the 
lead-in phase and the 52 weeks following stable factor IX expression (months 6-18 
post- treatment; secondary efficacy endpoint) 
9. Rate of spontaneous bleeding events during the 52 weeks following stable factor IX 
expression (months 6- 18 post -treatment)  compared to the lead -in phase (secondary 
efficacy endpoint) 
10. Rate of joint bleeding events during the 52 weeks following stable factor IX 
expression (months 6- 18 post -treatment)  compared to the lead -in phase (secondary 
efficacy endpoint) 
11.  during the 
12 months following AMT-061 dosing compared with the lead -in phase (secondary 
efficacy endpoint) 
12.  during the 12 months  
following AMT-061 dosing compared with the lead -in phase (secondary efficacy 
endpoint) 
 
Simultaneous one-sided 97.5% confidence intervals based on a graphical approach to multiple 
testing will be provided for the Type I error controlled efficacy endpoints as a supportive 
analysis. For endpoints for which an increase is favorable, the lower one-sided 97.5% confidence 
bound will be provided; for endpoints for which an increase is unfavorable, the upper one-sided 
97.5% confidence bound will be provided. For any data cuts (i.e. , analysis times) that are not the 
main data cut for a given endpoint, the p-values and CIs will be considered to be descriptive 
rather than inferential.  
All data will be listed.  
A full description of the secondary analyses will be included in the SAP. 
 CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 111 of 146 
9.9.4 Optional Sub -study Endpoints  
Optional sub-study endpoints are presented in Section  3.3.3. 
The analysis for the optional PROBE Questionnaire sub-study will be described in the SAP. 
There will be a separate SAP document for the statistical analysis of the optional MSKUS  sub-
study results.  
Analysis will be based on the FAS population for the set of subjects participating in the respective sub -study. Any subject with at least one assessment of the sub-study endpoint will be 
considered to be participating in the respective sub -study. 
9.10 Safety Analyses 
Secondary safety endpoints to be analyzed are presented in Section  3.3.2.  
All TEAEs are tabulated by SOC and preferred terms within each SOC according to the MedDRA terminology list. TEAEs will also be tabulated by severity (mild/moderate/severe) and by relationship (related/not related)  to trial medication, using frequency counts (number of 
subjects  with event and number of events) and percentages. Similar tables will be created for 
TEAEs leading to premature discontinuation, deaths, and SAEs, if applicable.  
These summary tables will be presented by decreasing frequency of occurrence based on SOC 
and Preferred Term.  
An AE overview table will be created displaying the number of subjects (and percentage) 
experiencing an event and the number of events for: Any TEAE, m ild/moderate/s evere TEAE, 
definitely r elated/ probably r elated/ possibly r elated/ unrelated  TEAE, Serious TEAE, TEAE for 
special notification,  and TEAE leading to discontinuation. 
The summary tables will be accompanied by individual subject  listings of all AEs , including 
information on AE number, actual AE description, date/time of start and end of AE, preferred term (MedDRA), SOC (MedDRA), severity, relationship/causality, type of AE, seriousness, and outcome. Pre -existing AEs will be flagged. Pre -existing AEs are not considered to be treatment-
emergent, except in case of worsening during/after trial treatment (to be collected as separate 
AE). Separate listings will be created for TEAEs for special notification, deaths, and SAEs, if 
applicable.  
Other  safety data will be presented using graphical displays, as applicable, descriptive statistics 
(including change from baseline, if applicable), and/or individual data listing.  
The number of days until vector DNA can no longer be detected in semen and blood will be tabulated. The number of days is calculated using the date of collection of the first of three 
consecutive negative sample for each matrix.  
All safety analyses will be based on the Safety population. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 112 of 146 
9.11 Sample Size Justification 
The study sample size is constrained by the non- inferiority analysis of the primary  endpoint, 
ABR.  
Based on a literature search of trials in a similar clinical setting and the same underlying disease, 
as well as the previous AMT -060 Phase I/II trial, a non- inferiority margin o f 1.8 is assessed for 
the rate ratio of ABR between AMT -061 (post- treatment) and factor IX  prophylaxis (lead-in). 
For establishing the non-inferiority margin, an ABR of 2.4 between factor IX  prophylaxis and 
placebo treatment has been assumed . Via simulatio n of ABR under a negative binomial 
distribution with a yearly rate of 2.4 events for lead-in and 1.9 for post- treatment, with a Pearson 
correlation of 0.05 for the number of events between the two periods, and with a common negative binomial dispersion par ameter of 1.5, a sample size of N=50 will demonstrate non-
inferiority with a non-inferiority margin of 1.8 and a power of 82.0%. Therefore, the study should consist of at least 50 analyzable subjects.  
Given the sample size needed for AB R, this will produce a power >95 % for the secondary 
statistical analysis of endogenous factor IX activity . 
9.12 Data Monitoring Committee 
A DMC will be involved in the management of the  overall AMT -061 program including this 
clinical trial.  The purpose of the DMC in this trial, CT -AMT -061-02, is to monitor the safety of 
the subjects throughout the trial. 
The DMC will also be involved in monitoring the safety of the subjects in the dose confirmation 
trial, CT -AMT -061- 01, as well as to evaluate response to the treatment in t erms of factor IX  
activity levels. The DMC has assessed  whether observed factor IX  activity levels in the subjects 
treated with AMT -061 in the dose confirmation trial are within an expected range (as  defined in 
the DMC charter) to determine if the administered dose in the dose confirmation trial is suitable for administration in this trial. If the DMC had determined that the observed response was not within the expected range, or they did not observe enough consistency of effect, to proceed to dosing in thi s trial, they could have elected  to recommend up to three more subjects be treated at 
the same dose or recommend a second dose be studied  in the dose confirmation trial. T he DMC 
reviewed the 6- weeks post -treatment  interim analysis results f rom the dose confirmation trial and 
confirmed that the dose of 2 × 10
13 gc/kg for AMT -061 met  the intended safety and efficacy 
profile and that the same dose should be used in the treatment phase of this trial. 
In addition, the DMC will assess whether there is an impact of pre- existing NAB titers on 
clinical outcome following AMT-061 (per criteria defined in the DMC charter). Should the DMC 
determine that there is a recognizable impact of a certain titer and above, they can recommend institution of an exclusion criterion based on these titers for further enrollment in the study. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 113 of 146 
DMC meetings will be held at set times during the trial as outlined in the DMC charter. Further 
details regarding the DMC can be found in the DMC charter, which will be available prior to the administration of IMP . CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 114 of 146 
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES  
This trial is conducted in accordance with current applicable regulations, ICH GCP (E6[R2]), 
EU Directive 2001/20/EC, EU Directive 2005/28/EC, FDA guidelines, ATMP guidelines and its 
upda tes, and loca
l ethical and l egal requirements. 
10.1 Sponsor’s Responsibilities 
10.1.1  Good C linical P ractice C ompliance  
The t rial spons or and any third party to w hom a spect s of t he trial manageme nt or m onitoring 
have be en delegated wil l unde rtake their assigne d role s for this trial  in complianc e with the ICH 
GCP Guideli ne E6(R2), and
 related d etailed gui deli nes s pecific to ATMPs ( ENTR/F/2/SF/dn 
D(2009) 35810) , as w ell as w it h appl icable r egulatory requirement s in the countrie s where the 
trial will take pl ace. 
Representa
tives of t he trial sponsor, and/ or the company organizing/managing t he research on 
behal f of t he Sponsor , conduc t visits to s ites to in spect trial data, s ubjects’ medical re cords, a nd 
eCRF s in acco rdance wi th cur rent ICH GCP and t he respective l ocal and i nter /national 
governme nt re
gulati ons a nd guidelines. Recor ds and dat a may additionally be reviewed by 
auditor s or by regulator y authorities. 
The Spons or ensure s that Local Regulatory Authority requirement s are met before the start of t he 
trial. T he Spons or (or a n ominated designee ) is respons ible for the pr eparation, submission, and 
confirmation of receipt of any Regulatory Authority and IRB/I EC approval s required prio r to 
release of IMP f or shipme nt to the site. 
10.1.2  Indemnity/Liability an d Insurance 
The Spons or ensure s that a fully executed contrac t is in plac e prior to initiation of the trial, 
including appropriat e wording on indemnification of the Investigator/t he institution a gainst 
claims a rising 
from the tr ial, a s per applicable r egula tions . 
The Spons or ensure s that suita ble clinica l trial insuranc e covera ge is in plac e prior to the start of 
the tr ial. An insuranc e certifi cate is supplied to t he Investigat or as ne cessary. 
10.1.3  Public P osting of Trial Information 
The Spons or will assure that key design element s of t his protocol will be pos te d in a publicly 
accessible database such as Clinical T rials.gov, pri or to the start of t he trial. In addition, upon 
trial
 completion a nd finalization of the tr ial report the r esults of thi s trial w ill be e ither submitted  
for publ ication and/ or po st
ed in a publicly acce ssible databas e of clinica l trial results. 
Information inc luded in c linical trial registries ma y include pa rticipating Investigator s’ names 
and c
ontac t information. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 115 of 146 
The Sponsor will retain ownership of all data. 
10.1.4  Submission of Summary of Clinical Trial Report to Competent  Authori ties of 
Member S tates
 Concerned an d Independent E t hics C ommittees 
The Spons or will provide a s umma
ry of the CSR within 1 yea r of t he end of t he trial complet ion 
date to the compete nt authority of the M embe r State(s ) concerned a s required by regulatory 
requirement(s ) and to comply with t he Communi ty guideli ne on I CH GCP . The Spons or will 
provi de the IRBs/ IECs with a copy of the same summary. 
10.1.5  Trial S uspension, T ermin ation, an d Completion 
The Spons or may suspend or terminat e the trial or pa rt of t he trial at any tim e for any reas on. If 
the trial is suspende
d or terminated, t he Spons or will ensure that the Investigator as w ell as 
applicabl
e regulatory ag encies and IRBs/IECs ar e notified a s appropriate. Additionally, the 
discontinuation of a registered clinica l trial w ill be publ ished on t he publ icly availabl e database 
(as appl icable). 
The Sponsor will make an end of trial declaration to the relevant competent authority as required 
by Directive 2001/20/EC .  
10.2 Investigator’s Responsibilities 
10.2.1  Good Clinical Practice Compliance 
The Investigator must agree to conduct the trial in accordance with ICH GCP Guideline E6, 
includi
ng related de tailed  guidelines s pecific to  ATMP s and appl icabl e regulat ory requirements 
and guidelines.  
It is the Investigator’ s responsibility to ensur e that adequat e time and appropriat e trained 
res
ources a re available a t the s ite pr ior to  commitment t o participate in  this  trial. T he Inves tigator 
should also be able to e
stimat e or de monstrat e a p otentia l for recruiting t he required numbe r of 
suitabl e subject s within t he agreed recruitme nt pe riod. 
The Investigat or will maintain a list of a ppropriately qualified pers ons t o whom t he Investigator 
has delegated significa nt trial- related t asks. Curricul um v itae for Investigator s and 
sub-investi
gator s are provided to t he trial S pons or (or de signee ) before starti ng the trial. 
If a pot ential r esearch s ubject ha s a pr imary ca re physician, t he Investigat or shoul d, with the 
s
ubject’ s consent, infor m him or her of the s ubject’s pa rticipation in the tr ial. 
A
n international c oordin ating I nvestigator is a ppointed to r eview the f inal Clinical T rial Report. 
Agreement with the final
 Clinical Trial Report is d ocumented by the signed and dated signature 
of the coordinating Investigator, in compliance with Directive 2001/83/EC  as amended by 
Directive 2003/63/EC and
 ICH Guidance E3 ( 1995) . CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 116 of 146 
10.2.2 Protocol A dherence and Investigator A greement  
The Investigator and any sub-investigators must adhere to the protocol as detailed in this 
document. The Investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are  required to sign an Investigator Agreement to 
confirm acceptance and willingness to comply with the trial protocol. 
If the Investigator suspends or terminates the trial at his or her site, the Investigator will promptly 
inform the Sponsor, the IEC/IRB, and, where applicable, the regulatory authority, and provide 
them with a detailed written explanation . If the trial is prematurely terminated or suspended for 
any reason, the I nvestigator will promptly inform the trial subject(s) and will assure appropriate 
medical care and follow -up for the subjects. The Investigator will also return all IMPs, 
containers, and other trial materials to the Sponsor. Upon trial completion, the Investigator will 
provide the Sponsor, IEC/IRB , and regulatory agency with final reports and summaries as 
required by (inter)national regulations.  
Communication with local IECs/IRBs , to ensure accurate and timely information is provided at 
all phases during the trial , may be done by the Sponsor, applicable Contract Research 
Organization ( CRO ), Investigator, or for multi-s ite trials , the coordinating Investigator according 
to national provisions and will be documented in the Investigator Agreement. 
10.2.3 Documentation and Retention of R ecords  
10.2.3.1 Electronic Case Report Forms  
Access to the eCRF system and data capture by the Sponsor/C RO should be supported,  and 
should be handled in accordance with instructions from the Sponsor. 
The Investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Electronic CRF s must be 
completed by the Investigator or designee as stated in the site delegation log (note that 
authorized personnel from the data management vendor will enter  and  
summary data on the appropriate eCRF pages) . 
The subject reported e -diary data will be directly loaded from the application into the eCRF, 
without source documentation. All other data will have separate source documentation; this data 
will not be recorded directly onto the e CRF.  
All data sent to the Sponsor must be endorsed by the Investigator. 
The clinical research associate ( CRA )/Trial Monitor will verify the contents against the source 
data per the Monitoring Plan. If the data are unclear or contradictory, queries are sent for 
corrections or verifi cation of data.  CSL Behring 
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 117 of 146 
 
10.2.3.3  Recording,  Access , and Retention  of Source Data and Trial  Documents 
Original source data to be reviewed during this trial will include, but are no t limited  to: subject’s
 
medical file, or iginal clinical laboratory
 requisition forms 
and reports ,  
,  and da ta available from t he subjects
 e-diary device. 
All key data must be recorded in the subject’s medical records. 
The Investigator must permit authorized representatives of the Sponsor, the respective national, 
local, or foreign regulatory authorities, the IEC/IRB , and auditors to inspect facilities and to have 
direct ac cess t o
 original s ource records  relevant  to this trial, r egardless o f media. 
The CRA/Trial Monitor (and auditors , 
IEC/IRB 
or regulatory inspectors) may check the e CRF 
entries aga inst the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the Sponsor or its representatives, national or local 
regulatory authorities, or the IEC/IRB
 having access to source data (e.g., subje ct’s me dical file, 
appointment books , original laboratory reports, X- rays etc.). 
Non- trial site p ersonnel will not 
disclose any personal information or personal medical information. 
These records  must
 be made available within r
easonable times for inspection, if required, by a 
properly authorized representative of any regulatory agency (e.g., the US FDA, 
EMA, UK 
Medicines and Healthcare products Regulatory Agency [MHRA]) or other) . 
Essential documents must be maintained according to local regulations or ICH GCP (E6[R2])  
requirements , whichever is longer. Essential documents may not be destroyed without written 
permission from the Sponsor. N ote tha t traceabi lity records should be kept for a
 mini mum of 30 
years after the expiry date of the product, or longer if required by the terms of the clinical trial 
authorization or by the agreement with the Sponsor. 
10.2.3.4  Audit/Inspection  
To ensure compliance with relevant regulations, data generated by this trial must be available for 
inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory authorities), the EMA, the MHRA, other regulatory authorities, the 
Sponsor or its representatives, and the IEC/IRB for each s ite. 
10.2.3.5  Financial D isclosure 
The Investigator is required t o disclose any financial arrangement  prior  to participating  in the 
trial
 and for one year af ter, w hereby  the value of the compensation for conducting the trial could 
be influenced by the outcome of the trial. CSL Behring 
CCI
CCI
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 118 of 146 
The Investigator shoul d provide the following information: any significant payments from the 
Sponsor or subsidiaries such as a grant to fund ongoing research, compensation in the form of 
equipment, retainer for ongoing consultation or honoraria; any proprietary interest in IMP; any 
significant equity interest in the Sponsor or subsidiaries as defined in 21 Code of Federal 
Regulations (CFR) 54 2(b) (1998).  
In consideration of participation in the trial, the Sponsor pays the Investigator or nominated 
payee the sums set out in the payment schedule attached to the Inv estigator  agreement. 
10.2.4  Compliance t o all Regional, Local, State, and National C ontrolled -substance , 
Biohazard and Infectious D isease R egulations and Legislation 
When using controlled substances, biohazardous material, or substances for infectious diseases, 
the Investigator must at all times c omply w ith all regional, l ocal, s tate, and  national l aws 
pertaining  to registration, reporting w ith the appropriate regulatory body and control and 
handling of such substances. 
10.3 Ethical Considerations 
10.3.1  Informed C onsent 
It is the responsibility of the Investi gator, or designee, to obtain voluntary written inf ormed 
consent from all trial subjects pr ior to any trial related p roc edures inc l uding screening 
assessments. All consent documentation must be in accordance with applicable regulations, the 
GCP specific to AT MPs (ENTR/F/2/SF/dn D(2009) 35810) and ICH GCP (E6[R2]). In 
accordance wi
th the ATMP guideline, the informed consent form and a ny other written 
informati
on should include an explanation of particular issues associated with ATMPs, e.g., 
inconveniences of long-term follow -up, specific risks such as shedding and the irreversible 
nature of the ATMP and other issues as further lis ted in the guideline. 
Each subject is requested to sign the Subject Informed Consent Form in their local language after 
the subject has receive d and read (or been read) the written subject information and received an 
explanation of what the trial involves, t he particular is sues a rising  with ATMP s, including but 
not limited to:  the objective
s, potential benefits and r isk, inconveniences, and the subject’s rights 
and responsibilities. 
If the ICF i s revised with important ne w inf orma tion that must be shared with t he study subjects, 
the amended ICF w ill be  presented, as required by the IRB/IEC f or review and consideration by 
the subject, and s
igned re-consent is to be obtained.  
Separate written informed consents are to be obtained for the factor  IX gene sequenci ng and 
future r
esearch s amples p rior to col lection  of the sam ples ( as de tailed i n Secti on 6.2.1.6  and 
Section  6.2.4.1 , respectively) , the PROBE Questionnaire Sub-study ( Section 6.2.2.6), and the 
MSKUS Sub-study ( Section  6.2.2.7 ). CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 119 of 146 
A copy of all informed consent documentation (i.e., a complete set of subject information sheets 
and fully executed signature pages) must be given to the subject. If applicable, it is provided in a 
certified translation of the local languag e. Signed consent forms must remain in each subject’s 
trial file and must be available for verification at any time.  
The principal Investigator provides the Sponsor with a copy of the local  consent form which was 
reviewed by the IEC/IRB  and which received their favorable opinion/appro val. A copy of the 
IEC/IRB ’s written favorable opinion/approval of these documents must be provided to the 
Sponsor, prior to the start of the trial unless it is agreed to and documented (abiding by regulatory guidelines and national provisions) prior to tr ial start that a nother party (i.e., Sponsor 
or coordinating Investigator) is responsible for this action. Additionally, if the IEC/IRB requires 
modification of the sample Subject Information and Consent document provided by the Sponsor, the documentation supporting this requirement must be provided to the Sponsor. 
The Sponsor will also provide an optional consent to ask subjects to agree with providing a tissue 
sample from their liver in case of death, or if the liver becomes available for any other reason (e.g., liver transplantation or resection) during the long- term follow -up phase of this study. Liver 
samples will be analyzed to investigate how the gene therapy sequences are maintained within the cells of the liver over time, tolerance and/or stress with in the cells of the liver, and/or how the 
gene therapy is expressed in different parts of the liver and across the liver cells . This is entirely 
voluntary, and subjects may still participate in the study if they do not wish to agree to donate a liver tissu e sample.  
10.3.2 Institutional Review Board or Independent Ethics Committee  
For sites outside the EU, it is the responsibility of the Investigator to submit this protocol, the informed consent document (approved by the Sponsor or its  designee), relevant supporting 
information and all types of subject recruitment information to the IECs/IRB s for review, and all 
must be approved prior to site initiation. 
For sites within the EU, the applicant for an IEC opinion can be the Sponsor, the Investigator, or 
for multi- site trials the coordinating Investigator or Sponsor, according to national provisions. 
Responsibility for coordinating with IECs/IRBs  is defined in the Investigator Agreement. 
Prior to implementing changes in the trial, the Sponsor and the IECs/IRB s must approve any 
revisions of any revised informed consent documents and amendments to the protocol unless there is a subject safety issue (in that case approval can be after implementation) . 
IMP supplies will not be released until the Sponsor has received written IECs/IRB s approval of 
and copies of revised documents. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 120 of 146 
For sites outside the EU, the Investigator is responsible for keeping the IECs/IRB s appr aised of 
the progress of the trial and of any changes made to the protocol, but in any case at least once a 
year. For sites within the EU, this can be done by the Sponsor, the Investigator or for multi -site 
trials the c oordinating Investigator, according to national provisions. The Investigator must also 
keep the local IECs/IRB s informed of any serious and significant AEs. 
The names of the IECs/IRB s chairperson  and the members of the IECs/IRB s will be collected as 
well as a statement that the IECs/IRB s works in accordance with the principles of ICH GCP.  
10.3.3 Subject Treatment Cards  
All subjects will receive a subject treatment card, which has been approved by the Sponsor and the IEC/IRB, containing at a minimum:  
-The name of the subject
-The Investigator’s contact number
-Information regarding the IMP received
Treatment cards  will be  handed out  at Visit D. I f a subject is tr aveling  to a d ifferent site f or 
Visit D, this card should be handed out at the L-Final visit and the subject should be instructed to 
bring  it with hi m to V isit D.  
10.4 Privacy and Confidentiality 
Al
l US-based sites and labor atories or entities providing support for this trial, must, where 
applicable, comply with the Health Insurance Porta bility and Accountability Act of 1996 
(HIPAA) . A site that is not a Covered Entity as defined by HIPAA, must provide documentation 
of this fact to the S ponsor. 
All EU-based sites and laboratories or entities providing support 
for this trial, must, where 
applicable, comply with the Data Protection Directive 95/46/EC  (24 Oct 1995), E U data 
protection regulations No. 45/2001 (18 Dec 2001),  and EU General Data Protection Regulation 
(GDPR) 2016/679 (27 Apr 2016). 
The confidentiality of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, a nd guidelines. CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)  
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 121 of 146 
After subjects have consented to take part in the trial, the Sponsor and/or its representative 
reviews t heir m edical r ecords  and data collected d uring  the trial . These records and data may, in 
addition, be reviewed by others including the following: independent auditors who validate the 
data on behalf of the Sponsor; third parties with whom the Sponsor may develop, register, or 
market AMT -061; national or local regulatory authorities; and the IRBs /IEC s, which gave 
approval f or the trial t o proceed. The Sponsor and/or its representatives accessing the records and 
data will t ake all reasonable precaut ions in accordance with applicable laws, regulations, and 
guidelines to ma intain the  confidentiality of  subjects' ide ntities. 
Subjects are assigne d a unique identifying number. H owever, birth year may be collected and  
used to assis
t the Sponsor to verify t he accuracy o f the data, f or ex ample, t o conf irm t hat 
laborator
y results ha ve been as signed to the correct subject. 
The results of  trials – containing subjects’ unique ident ifying number, relevant medical data, and 
possibly birth year – w ill be  recorded. T hey may be transferred t o, and used in, othe r countries 
that may not  afford the  same le vel of  protection  that applies w ithin the  countries w here thi s trial 
is conduc
ted. The purpos
e of any such transfer would include: to support regulatory submissions, 
to conduct new data analyses to publish or present the trial results, or to answer questions asked 
by regulatory or health authorities. 
10.5 Publication Policy 
All manuscripts, abstracts, or other modes of presentation arising from the results of the trial 
must be reviewe d and approved in writing by the Sponsor, in advance of submission. T he  review 
is aimed at protecting the Sponsor’s proprietary information e ither existi ng at the date of the 
commencement of the tr
ial, or generated during the trial. Authorship will follow guidelines 
established by the International Committee o
f Medical Journal Editors (ICMJE, 2015). The 
publication poli
cy with respect to the Investigator and clinical trial site will be  further d etailed  in 
a separate docum
ent.
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 122 of 146 
11 ADMINISTRATIVE ASPECTS  
11.1 Investigator(s) 
One principal Investigator and one or more sub- investigators will be appointed for each clinical 
trial site. Name and title of the Investigator(s) who is (are) responsible for conducting the trial, 
and the address and telephone number(s) of the trial site will be contained in other documents 
such as the Trial Procedures Manual and Clinical Trial Application forms.  
One National Coordinating Investigator will be appointed for each participating country. This 
Investigato r will be responsible for national issues relating to the trial.  
Responsibilities of the I nvestigator are described in Section  10.2. 
11.2 International Coordinating Investigator 
The International Coordinating Investigator is responsible for approval of the clinical trial report 
on behalf of all trial Investigators. 
11.3 Clinical Trial Site s 
Clinical trial sites should have adequate resources and facilities to conduct the study 
11.4 Vendors  
Trial management, vendor oversight, and medical monitoring oversight will be provided by 
uniQure biopharma B.V. The Sponsor will engage vendors to perform the following services: 
- Laboratory analysis  
o Individual central laboratories will be applied for speci fic laboratory analyses.  
o One coordinating central laboratory will prepare the Laboratory Manual, sampling 
kits, perform training of clinical trial site personnel, arrange for courier shipments, 
and manage central preparation and storage of samples.  
- Storage, secondary packaging, shipping, and EU Q ualified P erson (QP) release of IMP  
- Clinical monitoring  and project management  
- Regulatory 
- Medical Monitoring 
- Data M anagement  
- DMC Administration  
- Statistics  
- Medical Writing  
- The provision of the  
- The provision of the e- diaries  
- eTMF  
- Investigator Meeting organization  
- Subject  Travel organization and reimbursement CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 123 of 146 
12 REFERENCE  LIST 
Publications 
Bolton-Maggs P and Pasi K. Haemophilias A and B. Lancet 2003;361:1801-09 
Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al. Prevalence of 
serum IgG and neutralizing factors against adeno -associated virus (AAV) types 1, 2, 5, 6, 8, and 
9 in the healthy population: implications for gene therapy using AAV vectors. H um Gene Ther . 
2010;21:704-12 
Cantore A, Nair N, Della Valle P, Di Matteo M, Màtrai J, Sanvito F et al. Hyperfunctional 
coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. The American Society of Hematology. 2012;120:4517-4520 
Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list 
ranked by the risk for developing drug-induced liver injury in humans. Drug Discov today. 
2016;21:648-653 
Crudele JM, Finn JD, Siner JI, Martin NB, Niemeyer GP, Zhou S, et al.  AAV liver expression of 
FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in 
hemophilia B dogs and mice. The American Society of Hematology. 2015;125:1553-1561 Darby S, Kan S, Spooner R, Giangrande P, Hill F, Hay C et al.  Mortality rates, life expectancy, 
and causes of death in people with hemophilia A or B in the United Kingdom who were not 
infected with HIV. Blood 2007;110:815-25 
D’Avola, D, López-Franco, E, Sangro, B, Pañeda, A, Grossios, N., Gil- Farina, I et al.  Phase I 
open label liver- directed gene therapy clinical trial for acute intermitten t porphyria. J Hepatol. 
2016;65(4):776-83 Gater A, Thomson T, Strandberg-Larsen M. Haemophilia B: impact on patients and economic 
burden of disease. Thromb Haemost. 2011;1:1349-55 
George L, Sullivan S, Giermasz A, Ducore J, Rasko J, Teitel J et al. Hemophilia B Gene Therapy 
with a High -Specific-Activity Factor IX Variant. N Engl J Med. 2017;377 (23):2215-2227. 
Jiang H, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, Smit h P et al.  Evidence of multiyear 
factor IX expression by AAV- mediated gene transfer to skeletal muscle in an individual with 
sever e hemophilia B. Mol Ther. 2006;14(3):452-5 
Kao CY, Yang SJ, Tao MH, Jeng YM, Yu IS, Lin SW. Incorporation of the factor IX Padua mutation into FIX -Triple improves clotting activity in vitro and in vivo . Thromb Haemost. 
2013;110: 244–56 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 124 of 146 
Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A e t al. Evidence for gene 
transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat 
Genet . 2000;24(3):257- 61 
Kessler C  and Mariani G. Clinical manifestations and therapy of the haemophilias.  In: Colman 
R, Hirsh J, Marder V, Clowes A, George J, eds. Hemostasis and Thrombosis: Basic Principles 
and Clinical Practice. 5th ed. Philadelphia: Lippincott-Raven; 2006. p 887-904 
Leebeek F, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R et al. Reduction in 
annualized bleeding and factor IX consumption for up to 2.5 years in adults with severe or 
moderate- severe hemophilia B treated with AMT -060 (AAV5 -hFIX) gene therapy. The 
American Society for Hematology, 2018. 
Lu DR, Zhou JM, Zheng B, Qiu XF, Xue JL, Wang JM et al.  Stage I  clinical trial of gene therapy 
for hemophilia B. Sci China B. 1993 Nov;36(11):1342-51 Manno C, Chew A, Hutchison S, et al.  AAV- mediated factor IX gene transfer to skeletal muscle 
in patients with severe haemophilia B. Blood 2003;101:2963-72 
Manno C, Pie rce G, Arruda V, et al. Successful transduction of liver in haemophilia by AAV 
factor IX and limitations imposed by the host immune response. Nat Med .2006;12:342-47 
Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno -associated virus vector 5 -
human factor IX in adults with hemophilia B. Blood 2018;131:1022-1031: doi.10.1182/blood-
2017-09-804419 
Monahan P.E. Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb 
Haemost . 2015;13(Suppl. 1):S151–60 
Nathwani A, Tuddenham E, Rangarajan S, et al.  Adenovirus- associated virus vector mediated 
gene transfer in haemophilia B. N Engl J Med. 2011;365:2357-2365 
Nathwani A, Reiss U, Tuddenham E, et al. Long- term safety and efficacy of factor IX gene 
therapy in haemophilia B. N Engl J Med. 2014;371:1994-2004 Nathwani AC, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, et al. Adeno-
associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing 
“empty viral particles” on safety and efficacy of gene transfer. Blood. 2018; 132:491. 
O’Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS 
study. Orphanet J Rare Dis. 2017;12:106 
Osooli M, Steen Carlsson K, Astermark J, Bertorp E. Surgery and survival in birth cohorts with 
severe haemophilia and differences in access to replacement therapy: The Malmö experience. 
Haemophilia 2017:1-6 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 125 of 146 
Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with 
hemophilia, 1992- 2001: a prospective cohort study. J Thromb Haemost. 2006;4:510-6 
Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5- Factor VIII Gene 
Transfer in Severe Hemophilia A. N Engl J Med. 2017;377(26):2519-2530. 
Reilly M, Zbrozek A, and Dukes EM. The validity and reproducibility of a work productivity 
and activity impairment instrument. PharmacoEconomics 1993; 4(5):353-65. 
Schramm W and  Berger K. Economics of prophylactic treatment. Haemophilia  2003;9(suppl 
s1):111-6 
Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP et al.  X-Linked 
Thrombophilia with a Mutant Factor IX (Factor IX Padua). N Engl J Med. 2009; 1671-5 
Srivastava A, Brewer AK, Mauser -Bunschoten EP, Key NS, Kitchen S, Llina A et al. Guidelines 
for the management of hemophilia. Haemophilia 2013;19:e1-47 
Stonebraker S, Bolton-Maggs H, Brooker M, Farrugia A, Srivastava A.  A study of reported 
factor IX use around the world. Haemophilia 2011;17:446-55 
Taylor JA, Kruse- Jarres R. A new era for hemophilia B treatment. Blood 2016 Apr 
7;127(14):1734-6 
Witkop M, Neff A, Buckner TW, Wang M, Batt K., et al. Self -reported prevalence, description 
and management of pain in adults with haemophilia: methods, demographics and results from the 
Pain, Functional Impairment, and  (P-FiQ) study. Haemophilia 2017;23(4):556-65 
World Federation of Haemophilia. World Federation of Haemophilia report on the annual global 
survey 2017. dated October 2018. http://www1.wfh.org/publicat ions/files/pdf -1714.pdf date 
accessed: 23  November 2018 
 
Guidelines 
Committee for Medicinal Products for Human Use (CHMP). Guideline on Follow-up of Patients 
Administered with Gene Therapy Medicinal Products. EMA/CHMP/GTWP/60436/2007. 
London, 22 October 2009. 
Detailed guidelines on good clinical practice specific to advanced therapy medicinal products. 
ENTR/F/2/SF/dn D(2009) 35810. Brussels, 03/12/2009. Available from: 
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/2009_11_03_guideline.pdf CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 126 of 146 
ICH Guideline E2A: Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting. Finalised under Step 4 in October 1994. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effic acy/E2A/Step4/E
2A_Guideline.pdf 
ICH Guideline E3: Structure and Content of Clinical Study Reports. Finalised under Step 4 in 
November 1995. Available from: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf 
Integrated Addendum to ICH Guideline E6(R1):  Guideline for Good Clinical Practice  E6(R2). 
Finalised under Step 4 in Nov 2016. Available from: 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4.pdf 
Other  
Investigator’s Brochure AAV5- hFIX and AAV5 -hFIXco -Padua (AMT -060 and AMT-061 
[etranacogene dezaparvovec]) . Current Edition. 
National Institute on Alcohol Abuse and Alcoholism. Available from http://www.niaaa.nih.gov/ Responsible Drinking EU. Available from https://www.responsibledrinking.eu  
Treatment Guidelines Working Group, on behalf of the World Federation of Hemophilia (WFH). 
Guidelines for the management of hemophilia. 2nd ed., originally published in Haemophilia; 
Epub 6 Jul 2012. Available from: http://www.wfh.org/.  
U.S. Food and Drug Administration (FDA). Drug Induced Liver Injury Rank (DILIrank) Dataset. 
Available from: 
https://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/ucm604985.htm date accessed: 06 December 2018.  
World Federation of Haemophilia. Available from http://www.wfh.org/. 
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 127 of 146 
13 APPENDICES  
13.1 Laboratory Information 
Laboratory  Test/Profile  
 
 Central Laboratory:  
Coagulation  
Chemistry  
Inflammatory markers/cytokines  
Serology  
Hematology  
CD4 counts  
PBMC isolation for 
AAV5 -capsid specific T -cell response (up 
until June 2019)  
 
 
 Referral testing: 
Vector genome detection (blood and semen)  
 
 
 Referral Testing:  
Factor IX Activity: one -stage aPTT, chromogenic assay  
Factor IX protein concentration  
Factor IX inhibitors  
Anti- factor IX antibodies  
IgG antibodies AAV5/IgM antibodies AAV5 
 
 Referral Testing:  
PBMC isolation for AAV5 -capsid specific T- cell response 
(starting July 2019)  
AAV5 -capsid  specific T -cell  
NABs  to AAV5  
 
 
 Referral Testing:  
Factor IX genetic sequencing  
 
 
 Confirmation Testing:  
HIV- 1/2 Antibody differentiation test 
 CSL Behring 
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 128 of 146 
13.2 Summary of Changes in Current Amendment 
Protocol Amendments  
Summary of Changes Since Last Version of Approved Protocol  
Amendment Number:  
7.0 (Version 8.0)  Amendment Date:  
07 Feb  2022 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
The Sponsor was changed from uniQure to CSL Behring.  All 
Minor administrative text and formatting updates.  All 
It was clarified that uniQure will provide oversight to 
Medpace, the Monitoring CRO. Title Page  
Administrative changes to the identified Sponsor 
representative.  Signature Page  
The entity responsibile for safety oversight including 
SAE/AESI/pregnancy reporting was updated to CSL 
Behring, with details provided for contacting CSL Global 
Clinical Safety & Pharmacovigilance.  Emergency Contact 
Information  
Section 7.5 
Section 7.6 
The identity and  details for the uniQure Medical Director 
were updated.  Emergency Contact 
Information  
It was clarified that for subjects only using on -demand 
Factor IX replacement therapy, study visits may need to be 
re-scheduled so that the visit does not take place within 5 
half-lives of exogenous Factor IX product use. Table 8 
“Half -Life for Infused Exogenous Factor IX Medical by 
Name” was also added to clarify half -lives for infused 
exogenous factor IX medications. Table 1  
Table 2  
Table 3  
Table 4  
Section 6.2.2.3 
Table 8  
Footnote notation was adjusted  for clarity in Table 4 
“Schedule of Events for Laboratory Parameters, for Long-
Term Follow -up (Visit LTF1 to LTF8)” for sampling for 
vector genome detection  blood and semen. Table 4  
It was clarified that in case of a bleed occurring within 2 
weeks of a scheduled LTF visit at which  
should be completed, the study visits should be rescheduled. Section 6.1.5  
Section 6.2.2.4 
Optional consent to ask subjects to agree with providing a 
tissue sample from their liver  in case of death, or if the liver 
becomes available for any other reason (e.g., liver 
transplantation or resection) during the long- term follow -up 
phase of this study was added. Section 6.2.4.2  
Section 10.3.1 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 129 of 146 
Due to the addition of Table 8, the previous Table 8 is now 
Table 9. Due to the addition of Table 8, the previous Table 9 
is now Table 10. Table 9  
Table 10  
The phrase “using the Common Terminology Criteria for 
Adverse Events severity grades” was removed from Section  9.10 Section 9.10  
It was clarified that t rial management, vendor ov ersight, and 
medical monitoring oversight will be provided by uniQure. 
Pharmacovigilance was removed from the list of services 
that the sponsor will engage vendors to perform. Section 11.4  
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 130 of 146 
13.3 Previous Amendments 
Protocol Amendments  
Summary of Changes  
Amendment Number:  
6.0 (Version 7.0)  Amendment Date:  
28 Jun 2021 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
Study objectives and endpoints were updated, based on input 
from the FDA.  
The primary objective and endpoint was updated to focus on 
ABR, 52 weeks following establishment of stable factor IX 
expression (months 6 to 18 post- treatment).  
The previously primary objectives and endpoints related to 
endogenous factor IX activity at 6 months and 12 months 
were moved to be the first and second secondary efficacy 
endpoints. Endogenous factor IX activity at 18 months after 
AMT -061 dosing was added as the third second ary efficacy 
endpoint. Estimated ABR as a function of pre- IMP anti -
AAV5 antibody titers using the luciferase based NAB assay 
was added as a secondary efficacy endpoint (as a 
“correlation” analysis).  
 
 
 
 
 Synopsis  
Section 2  
Section 3.3 
Section 9.9 
Section 9.10 
It was clarified that the FAS population would be used for all 
efficacy statistical analyses, with the PP population used for 
sensitivity analyses. The definition of the PP population was 
updated to clarify the timepoints used to identify the 
population for various data cuts. Synopsis  
Section 9.4 
To align with the updated endpoints, the statistical analyses 
were also reordered and timing clarified, including the order 
of endpoints for the fixed sequential testing of the primary 
and secondary efficacy endpoints. Synopsis  
Section 9.9.1 
Section 9.9.2 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 131 of 146 
As the primary objective was adjusted to focus on ABR, the 
description of the number of subjects, the sample size, and 
sample size justification, was similarly updated; the sample 
size remained at 50 subjects.  Synopsis  
Section 3.4 
Section 9.11 
Details on the interm and final analyses were updated. The 
timing of the CSR was clarified to occur after 18 months 
post- treatment with AMT -061, instead of after 12 months. 
An interim analysis would still occur after 12 months to assess endogenous factor IX activity. The study period included in the CSR addendum was also clarified. Synopsis  
Section 3  
Section 9.2 Section 9.3 
Clarification that duri ng the long -term follow up, quarterly 
contact ( ±2 weeks) should occur to monitor for AEs, proper 
completion of study-specific patper diaries, and proper 
reporting of factor IX usage and bleeding episodes Synopsis  
Table 3  
Section 3  
Section 6.1.5 
It was cla rified that the calculation for the number of days 
until vector DNA can no longer be detected in blood and 
semen would be based on the first of three consecutive 
negative samples.  Synopsis  
Additional detail on medical history to be specifically 
collected was added.  Section 6.2.1.2  
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 132 of 146 
Summary of Changes  
Amendment Number:  
5.0 (Version 6.0)  Amendment Date:  
04 Feb 2021 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
Update to uniQure Clinical Development and 
Pharmacovigilance signee.  Clinical Trial Protocol 
Signature Page 
Update to uniQure Medical Director details.  Emergency Contact 
Information  
The frequency of abdominal ultrasounds in the long -term 
follow- up phase was increased from  yearly to every 
6 months. The abdominal ultrasound was added as a 
procedure that could be performed at an unscheduled visit 
during the long- term follow -up, if judged relevant by the 
Investigator. The permitted visit window for abdominal 
ultrasounds conduc ted at Visit F -Final and in the long- term 
follow-up phase when the visit is impacted by COVID-19 
was adjusted to be up to -1 month prior to the target visit and 
up to +1 month (previously up to +2 months) after the target 
visit.  Synopsis  
Table 1  
Table 3  
Section 6.1.5 
Section 6.2.3.4 
Clarification was added that s ubjects who are on continuous 
routine factor IX prophylaxis during the long- term follow -up 
phase of the trial are required to contact the site staff 
immediately in case of a bleed and/or factor IX use different 
from their routine factor IX prophylaxis, in addition to 
completing the questions/information requested on the paper 
diaries to capture all information.  Synopsis  
Table 3  
Section 6.1.5 
For , the option to be considered a 
missed assessment if the questionnaires cannot be completed 
within the allowed visit window when a visit is impacted by 
COVID-19, was removed. It was clarified that adjustments 
to the visit timing within the allowed visit window are to be 
documented.  Table 1  
Table 3  
Section 6.2.2.4 
For the PROBE questionnaire sub -study, the option to be 
considered a missed assessment if the PROBE questionnaire 
cannot be completed within the allowed visit window when a 
visit is impacted by COVID -19, was removed. It was 
clarified that adjustments to the visit timing within the 
allowed visit window are to be documented. Table 1  
Table 3  
Section 6.2.2.6 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 133 of 146 
For the MSKUS sub -study, the option to be considered a 
missed assessment if the scans cannot be completed within 
the allowed visit window when a visit is impacted by 
COVID- 1, was removed. It was clarified that adjustments to 
the visit timing within the allowed visit window are to be documented. Table 1  
Table 3  
Section 6.2.2.7 
Local laboratory assessments of factor IX (one -stage aPTT 
for factor IX activity) and transaminases (AST/ALT) for local monitoring were added to the long- term follow -up. 
Reference to the schedule of events for laboratory 
parameters (Table 2 and Table 4) was added to the following 
section s, for clarity on the timing of these assessments 
during the study: Section 6.2.3.12 (Other Safety Laboratory Evaluations) 
Section 6.2.5 (General Information Regarding Laboratory 
Sampling and Results). Table 4  
Section 6.2.3.12 Section 6.2.5 
To align with the eCRFs, the possible options for causality 
assessments for AEs were updated, with options being related, possibly related, unlikely related, and not related. Section 7.3.2  
 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 134 of 146 
Summary of Changes  
Amendment Number:  
4.0 (Version 5.0)  Amendment Date:  
15 Oct 2020 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
The primary objective and endpoints were updated to include 
factor IX activity after 12 months (52 weeks) of AMT-061 
treatment and the non- inferiority assessment of AMT -061 
during the post- treatment follow -up compared to standard of 
care continuous routine factor IX prophylaxis treatment 
during the lead-in period, which were both previously 
secondary objectives/endpoints. Text references to the 
objectives throughout the protocol were updated as needed. 
 
 
Safety endpoints were updated for alignment and 
completeness.  Synopsis  
Section 2  
Section 3.3 
Section 9.9 
Addition of comment that a djustments to the visit location 
and/or schedule may be made to accommodate safety 
concerns and restrictions due to the COVID-19 pandemic 
was added in discussion of the post- treatment follow -up 
phase, long- term follow -up phase, and PROBE and MSKUS 
sub-study. Synopsis  
Clarification that paper diaries are to be used  during the long 
term follow for bleeds (long- term follow -up bleed diary) and 
factor IX use (long -term follow -up factor IX use diary) and 
brought to all clinic visits in this phase for reporting. Synopsis  
Table 3  
Section 6.1.5 
Section 6.2.2.1, 6.2.2.2 
Addition of a visit window for the PROBE questionnaire to 
be completed for Visit F15 (Month 6) and Visit F- Final 
(Month 12) and during the long- term follow -up period if 
those visits are impacted by COVID-19. Synopsis  
Section 6.2.2.6 
Addition of a visit windo w for MSKUS to be completed for 
Visit F15 (Month 6) and Visit F-Final (Month 12) and 
during the long- term follow -up period if those visits are 
impacted by COVID-19. Synopsis  
Section 6.2.2.7 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 135 of 146 
The label for the event of “Hematology parameters” was 
updated to “Hematology and coagulation parameters” to be 
more representative of the parameters being collected, as 
specified in the associated footnote. Table 2, Table 4  
Clarification that the sampling schedule for vector genome 
detection assessments can be increased as agreed between 
the Investigator and subject following the notification of a 
first negative result on blood and/or semen. Table 2, Table 4  
Section 6.2.3.10 
Section 1.6 “Accomodations Due to the COVID -19 
Pandemic” was added as an introductio n to the COVID-19 
pandemic and its impact on clinical trial procedures.  Section 1.6 (new)  
Section 3.1.1 “Considerations Due to the COVID -19 
Pandemic” was added to discuss potential adjustments to the 
meeting schedule or visit location/method due to the 
COVID-19 pandemic and to indicate that all deviations from 
the protocol due to the pandemic are to be documented. Section 3.1.1 (new)  
Recommendations on use of antithrombotic treatment was 
added for patients with factor IX activity in the 
non-hemophilic (≥40% of normal) range and wit h a 
confirmed COVID -19 infection. Section 5.6.2, 5.6.3  
Section 6.2.2.1 
Additional clarification and recommendations on 
transaminase elevation management was added including 
discussions on steroid tapering, considerations with 
prolonged high dose steroid use, and considerations with 
potential and confirmed COVID-19 infections. Section 5.6.4  
Addition of a visit window for  to be 
completed for Visit F15 (Month 6) and Visit F-Final (Month 
12) and during the long- term follow -up period if those visits 
are impacted by COVID -19. Section 6.2.2.4  
Addition of a visit window for abdominal ultrasounds to be 
completed for Visit F -Final (Month 12) and during the long-
term follow -up period if those visits are impacted by 
COVID-19. Section 6.2.3.4  
Removal of use of international criteria for assessment of 
laboratory value abnormalities. Section 7.3.1  
Clarification that trial monitor visits may be virtual.  Section 8.1  
Mention of update to eCRFs to include COVID -19 reasons 
for missed visits.  Section 8.2  
Specification that the protocol deviations includes those 
related to COVID -19. Section 9.5  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 136 of 146 
Summary of Changes  
Amendment Number:  
3.0 (Version 4.0)  Amendment Date:  
30-Aug-2019 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
Contact details for Medpace Clinical Safety were updated.  Emergency Contact 
Information  
Under Trial Period (Planning), the timing of last subject last 
visit was updated to Q2 2025. Synopsis  
Details on sponsor -preapproved alternatives that may be 
used to collect liver fibrosis scores were added.  Synopsis  
Table 1  
Section 6.1.1, 6.1.2 
An abdominal ultrasound to screen for liver malignancy was 
added at Visit L -Final  at the latest (to establish baseline) , 
Visit F -Final, and Visits LTF2, LTF4, LTF6, and LTF8. 
Section 6.2.3.4 Abdominal Ultrasound was added. Synopsis  
Table 1 and Table 3  
Section 6.1.2 and 6.1.4 
Section 6.2.3.4 
Vital signs (blood pressure, pulse, body tem perature) was 
removed from the list of safety endpoints. Synopsis  
Section 3.3.2 
Exclusion criterion #3 was updated to allow subjects with 
total bilirubin >2 times upper normal limit if this elevation is 
caused by Gilbert disease. 
Assessment of exclusion criterion #5 was updated to occur at screening (Visit S). Additionally, positivity for hepatitis B extracellular antigen (HBeAg) was removed as an additional criterion to Hepatitis B or C infection.  Synopsis  
Section 4.2 
Description of study endp oints and statisticial analyses were 
updated to align with the current plans described in the SAP, including addition of sub-study endpoints and clarification of 
the study populations to be analyzed. Synopsis  
Section 3.3.2, 3.3.3 
Section 9.4, 9.5, 9.6, 9.7, 9.9 
It was clarified that blood sampling occurs prior to Factor IX 
administration, and the requirement that this occurs at the clinic was removed.  Table 1, Table 2, Table 3, 
Table 4  
Section 6.2.2.3 
The visit window for Visit S was updated to -28 days Table 1 and Table 2  
The visit window for Visit L -Final was updated to -28 days 
(±7 days) from Visit D and it was specified that the time 
period between Visit LX and Visit L -Final can be less than 2 
months as long as the total lead-in period is a minimum of 26 weeks. Table 1 and Table 2  
Section 3.1 Section 6.1.2 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 137 of 146 
For recommended alcohol use, it was recommended that the 
daily alcohol limit in grams be adhered to most strictly 
during the first 12 weeks post-IMP and that the importance 
of abstaining from binge-drinking be reinforced at every 
visit.  Table 1  
Section 6.1.1 
For subjects travelling to a different site for Visit D, it was 
clarified that they would receive their treatment card at the 
L-Final visit and instructed to bring it with them to Visit D.  
Subjects travelling for Visit D may provide their semen 
sample at Visit L -Final.  Table 1  
Section 3.1 
Section 6.1.3.3 
Section 10.3 
The end of the clinical trial was defined as the point in time 
the last patient has completed the long -term follow-up 
observation period of 5 years after administration of the 
investigational medicinal product. Section 3.1  
Text was added explaining that Subjects who withdraw from 
the trial after enrolling in the Lead -in Phase but who are not 
dosed will be required to return their e-diary device and will 
not be requested to complete any final evaluations. Section 4.5  
It was clarified that each vial of AMT -061 will contain an 
extractable volume of at least 10 mL.  Section 5.2  
It was clarified that subjects can receive their dose of 
continuous routine factor IX on the day of AMT-061 dosing. Section 5.6.2  
Section 6.1.3.3 
Section 5.6.3 Guidelines for Use of Factor IX for Patients 
Undergoing Major Surgery was added. Section 5.6.3  
It was clarified that visits during the post -treatment follow -
up period (from Week 1 up until Week 52) that do not 
include physical examination and/or  
may be performed at the subject’s home by an appropriately 
qualified and trained nurse, with agreement from the 
Investigator and Sponsor.  Section 6.1.4  
The details on type of medical history data related to 
hemophilia B recorded were updated. Section 6.2.1.4  
It was clarified that for subjects who are not able to enter the 
details of their factor  IX replacement therapy into the e-
diary, the site can enter the information in the CRF as long 
as the subject provides sufficient source documentation. Section 6.2.2.1  
It was clarified that for subjects who are not able to enter the 
details of their blee ding episodes into the e- diary, the site can 
enter the information in the CRF as long as the subject 
provides sufficient source documentation. Section 6.2.2.2  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 138 of 146 
The description of  was updated, to include mention 
that this includes an assessment of the time sitting.  Section 6.2.2.4  
It was specified that the methodology for MSKUS plus 
scoring of MSKUS will be performed according to the 
J.A.D.E. protocol. Section 6.2.2.7  
It was clarified that the Investigator  will be provided with 
those laboratory results needed for treatment decision-
making (i.e., laboratory results that inform safety monitoring 
or management of an individual subject at a site). The 
Investigator will receive chemistry, hematology, serology, 
coagulation, and gene sequenc ing results at regular intervals 
for review and sign- off. Once there have been three 
consecutive negative results for vector genome detection (in 
blood and semen), the Investigator will be informed that 
these samples no longer need to be collected. Section  6.2.5  
The approximately volume of blood to be drawn from each 
subject during the trial was lowered to 2370 mL. Section 6.2.6  
Pharmacovigilance Department was updated to Medpace 
Clinical Safety.  Section 7.5  
It was clarified that for clinical data, domai ns will be 
mapped to the current version of CDISC SDTM at the time 
of mapping. Section 8.3.1  
Storage, secondary packaging, shipping, and EU Qualified 
Person (QP) release of IMP was added to the list of services 
vendors are engaged for in this trial Section 11.4  
Laboratory details for testing of PBMC isolation for AAV5 -
capsid specific T -cell response, and of NABs, were updated. Section 13.1  
Appendix 13.2 Drug Induced Liver Injury Dataset was 
removed and reference to the source added in the protocol 
body. Section 5.6.2  
Section 13.2 (previous) 
 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 139 of 146 
Summary of Changes  
Amendment Number:  
2.0 (Version 3.0)  Amendment Date:  
07 Dec 2018 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
The title page was updated to show the name of the 
Monitoring CRO in place of the monitor’s name. Title Page  
Contact information for Medpace Clinical Safety was added.  
The Medpace Monitor was updated to the Medpace Medical 
Director and contact information for the uniQure Medical 
Director was added, with clarification and protocol- or 
safety -related issues must be sent to both of these 
individuals. Emergency Contact 
Information  
FIX was changed to factor IX throughout except in the name 
of the IMP. Throughout  
The planned n umber of sites was increased to approximately 
50. Synopsis  
Section 3.5 
The dose of 2 × 1013 gc/kg AMT -061 will be the dose used 
in this study, as confirmed in the interim results from the 
CT-AMT -061-01 dose confirmation study. Text throughout 
the protocol was updated to reflect this.  Synopsis  
Section 1.3.2.3 Section 1.4 Section 3.2 
Section 9.12  
Interim analysis results from the Phase IIb study CT -AMT -
061-01 was added and sections updated to highlight CT-AMT -061-01 data and focus on AMT-061. Synopsis  
Section 1.3 Section 1.4 
Section 1.5 
FibroScan ™ was added as an assessment at screening to 
deterimine if a subject has liver fibrosis and steatosis. A screening FibroScan assessment is not needed if either a 
FibroScan assessment has been performed  in the year prior 
to screening for which CAP scores are available or if a liver biopsy has been performed within the 2 years prior to the 
screening for which fibrosis grade is documented. Synopsis  
Trial Schedules  
Section 6.1.1 
A discussion between the Investigator  or designee with the 
subject on the importance of a healthy liver before and after 
receiving a liver directed gene therapy, and factors that 
might impact liver health was added as a continuous 
assessment from screening onwards.  Synopsis  
Trial Schedules  
Section 6.1.4 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 140 of 146 
It was clarified that the lead -in phase will last for a minimum 
of 6 months ending at or before Visit D. Subjects will remain 
in the lead -in phase until a minimum of 6 months of lead-in 
data have been collected and it is confirmed t hat the subjects 
still meet all eligibility criteria, with the final visist occuring 
approximately four weeks (6 weeks maximum) prior to the 
planned data of IMP dose administration (Visit D). Synopsis  
Trial Schedules  
Section 3.1 
Section 6.1.2 
Criteria for IMP dose administration was removed as the 
interim results of the dose confirmation trial are now 
available.  Synopsis  
Figure 2 
Trial Schedules  
Section 3.1 
Section 6.1.2 
It was clarified that at Visit L -Final, re -evaluation of 
subject’s eligib ility will be based on assessments during both 
the lead -in period and this visit. Synopsis  
Section 6.1.2 
It was clarified that the wash out period will be 3 days for 
regular -acting factor IX products and 10 days for extended 
half-life factor IX products. Synopsis  
Trial Schedules  
Section 3.1 
It was specified that if the ICF is revised during the lead -in 
pahse with lead -in phase with important new information 
that must be shared with the study subjects, the amended ICF 
will be presented, as required by the Institutional Review 
Board (IRB)/Independent Ethics Committee (IEC), for 
review and consideration by the subject, and signed re-
consent is to be obtained prior to IMP dose administration. Synopsis  
Section 3.1 
Section 6.1.2 
Section 10.3.1 
During the post -treatment follow -up, visits that do not 
include physical examination or  may be 
performed at the subject’s home by an appropriately 
qualified and trained nurse, with agreement from the 
investigator and the Sponsor. Each home nursing visit is 
expected to be supplemented by a phone call from the 
Investigator or designee to the subject to discuss AEs, 
concomitant medications, and e-diary compliance. Synopsis  
Trial Schedules  
Section 6.1.4 
Text describing management of endogeneous factor IX 
activity was updated to always present what should be done 
if endogenous factor IX activity is ≥ 5% followed by if it is 
between 2 and 5% and then <2%. Synopsis  
Section 5.6.2 
Section 6.1.4 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 141 of 146 
It was clarified tht for ALT level increments of at least 2 -
fold baseline and > ULN, and for AST level increments of at 
least 2 -fold ULN, the Investigator should contact the 
Medpace and uniQure Medical Directors to discuss a clinical 
management plan on a case-by- case basis , including 
potential re -tests and/or initiation of corticosteroid treatment.  
Section 5.6.3 was created as the section for Guidelines for 
ALT Elevations.  Synopsis  
Section 5.6.3 
It was clarified that assessment of blood pressure, pulse, and 
body temperature was assessment of vital signs.  Synopsis  
Trial Schedules  
Section 3.3.2 
Section 6.2.3.2 
Assessment of Exclusion Criterion #5 was clarified to occur 
at Visit L -Final only. Exclusion criteria 5 and 6 were 
combined into a single criterion. 
Exclusion Criterion #9 was updated to include advanced 
liver fibrosis (suggestive of or equal to METAVIR Stage 3 
disease; a FibroScan ™ score of >9 kPa was considered 
equivalent). 
Exclusion Criterion #11 related to known history of allergy 
to corticosteroids was ad ded. Synopsis  
Section 4.2 
Descriptions of statistical analyses were expanded, including 
update of the Full Analysis Set and Per Protocol population 
definitions, specification that the primary analysis will be 
performed using a repeated measures linear mix ed model, 
adjusting the order the secondary endpoints will be analyzed 
in,  
 Synopsis  
Section 2.2 
Section 3.3.2 
Section 9  
Alpha -fetoprotein was added as an assessment (measured at 
Visit L -Final, Visit F15, Visit F -Final, and all LTF visits) 
and as a safety endpoint. Synopsis  
Trial Schedules  
Section 3.3.2 
Table 8  
Section 9.10 
Definition of gc was updated to genome copies from gene 
copies in the List of Abbreviations. List of Abbreviations  
It was clarified that study visits should be scheduled to 
ensure they take place when factor IX activity is at its 
trough, on the day that routine prophylactic factor IX 
replacement treatment is planned to be administe red. Trial Schedules  
Section 6.2.2.3 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 142 of 146 
Dose of routine factor IX and its associated footnote was 
removed from the Trial Schedules. Trial Schedules  
It was clarified that  being completed by 
the subject prior to other assessments are performed was a 
recommendation. Trial Schedules  
Section 6.1.2 
Section 6.1.4 
Section 6.1.5 
Section 6.2.2.4 
Section 6.2.2.6 
For the optional musculoskeletal ultrasound sub -study, it 
was clarified that if it is not possible to obtain the 
musculoskeletal ultrasound at screening (Visit S), it is 
allowed to obtain this first musculoskeletal ultrasound at a 
later time point (preferably as soon as possible thereafter 
during one of the lead- in visits).  Trial Schedules  
Section 6.2.2.7 
Details fo r the second and last reference listed in Table 5 
were updated.  Table 5  
The title for Section 1.3.2.1 was updated to “Preliminary 
Clinical Evidence for Efficacy and Safety of Components of 
AMT -061”, instead of AMT-060. Section 1.3.2.1  
Preliminary results  from a Phase I/II trial of an AAV5 -B-
domain- deleted factor VIII construct was updated with initial 
results.  
Preliminary results from a single study showing sustained 
factor IX expression driven by a gene cassette encoding a 
Padua variant factor IX was upd ated with initial results.  Section 1.3.2.1  
In discussion of the results from trial AMT -060-01, 
clarification was made regarding how many subjects shifted 
to a moderate or severely moderate hemophilia phenotype 
during the study. Section 1.3.2.2  
Clarificat ion that transaminase increase alone may warrant 
the initiation of a corticosteroid was made in Section 1.5.3, 
for consistency with Section 5.6.2. Section 1.5.3  
The study population was clarified to include subjects with 
more than 150 exposure days to a factor IX product in 
Section  1.5.8 for consistency with the inclusion/exclusion 
criteria.  Section 1.5.8  
It was clarified in Section 1.5.9 that subjects will be 
administered a dose of their usual factor IX product/dose for 
their factor IX recovery assessment at Visit L -Final, not also 
at the screening visit.  Section 1.5.9  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 143 of 146 
It was clarified that during the lead -in phase, an email 
communication is acceptable as an alternative to a follow -up 
phone call if the subject cannot be reached, though 
reasonable efforts for a phone call should be made. Section 3.1  
Section 6.1.2 
Clarifications were added surrounding concomitant 
medication/therapy. Section 5.6.2  
It was clarified that factor IX gene sequence analyses will be 
performed for all subjects that provide consent, even those 
that already have factor IX gene mutation information. Section 6.1.1  
Section 6.2.1.6 
For assessment of endogenous factor IX activity, the upper 
factor IX activity limit was set to >5% for consistency with 
the other limits of  2-5% and <2%. Section 6.1.4  
Collection at screening of on -demand factor IX replacement 
therapy at trial entry was removed from the list of medical 
history data related to hemophilia B being collected. Section 6.2.1.4  
Definitions for joint and muscle bleeds were removed.  
The definition for persistent bleed was added. Section 6.2.2.2  
It was clarified that the short form of the  
 will be used in this 
study. Section 6.2.2.4  
 CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 144 of 146 
Summary of Changes  
Amendment Number:  
1.0 Amendment Date:  
29 Mar 2018 Global/Country/Site -
Specific:  
Global 
Description of Change  Section(s) Affected by 
Change 
The title of the trial was updated, changing “an serotype” to 
“a serotype.”  
Current: Phase III, open-label, single-dose, multi- center 
multinational trial investigating a serotype 5 adeno -
associated viral vector containing the Padua variant of a 
codon- optimized human factor IX gene (AAV5 -hFIXco -
Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B Previous: Phase III, open-label, single-dose, multi- center 
multinational trial investigating an  serotype 5 adeno-
associated viral vector containing the Padua variant of a 
codon-optimized human factor IX gene (AAV5 -hFIXco -
Padua, AMT-061) administered to adult subjects with severe 
or moderately severe hemophilia B Title  
Administrative change to the identity of the study monitor.  Title Page  
Inclusion Criterion #4 updated.  
Current: >150 previous exposure days of treatment with FIX protein. 
Previous: >20 previous exposure days of treatment with FIX 
protein. Synopsis  
Section 4.1 
Specification that Exclusion Criterion #2 will be based on 
local laboratory results. Specification that Exclusion Criteria #3, 4, 5, and 8 will be based on central laboratory results. Synopsis  
Section 4.2  
Rewording of visit descriptions to improve clarity of 
assessments and their order.  Synopsis  
Section 3.1 Section 6.1 
Specification that subjects are expected to document factor 
IX usage and bleeding episode during the long- term follow -
up, but not in the e-diary. Synopsis  
Section 6.1.5 Section 6.2.2.1 Section 6.2.2.2 CSL Behring 
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 145 of 146 
Update to language stating that Investigator s will assess each 
bleeding episode, not adjudicate each bleeding episode. Synopsis  
Schedule of Events Table 1 
Section 6.1.2 
Section 6.1.6 
Section 6.2.2.2 
Clarification that analyses will be based on central laboratory 
measurements if results are available from both local and 
central laboratories.  Synopsis  
Section 6.2.2.3 
Section 9.9 
Removal of the  
assessment at Visit L3.  Schedule of Events Table 1  
Adjustment of t iming of physical examination assessments. 
Physcial examination assessments will occur at screening 
(Visit S), Visit L -Final, Visit D (pre -IMP), Visits F1, F2, F4, 
F6, F12, f13, F15, F17, F19, F-Final, LTF1, LTF2, LTF3, 
LTF4, LTF6, and LTF8. Schedule of Ev ents Table 1  
Section 6.1.4 
Section 6.1.5 
Section 6.2.3.3 
Addition of a chromogenic assay for FIX activity with 
assesments at Visits L1 to L -Final, Visit D, pre -IMP, Visits 
F1 to F-Final, and Visits LTF1 to LTF8. Schedule of Events Table 2 
and Table 4  
Section 6.2.2.3 
Section 6.2.3.6 
Clarification of the duration of trial participation.  
Current: The overall trial participation will be approximately 
five and a half years.  
Previous: The overall trial participation will be a minimum 
of five and a half year s. Section 3.1  
Addition of “Withdrawal by principal Investigator ” as a 
possible reason for discontinuation. Section 4.5.1  
The fill volume of IMP vials provided was clarified to be 
approximately10 mL. Section 5.2 and Table 7  
Update of the names of the 2  PROBE forms.  
Addition of a description of both the Short Form and the 
Follow-up Form. 
Clarification that the Follow -up Form will be completed at 
Visit L3.  Section 6.2.2.6  
Clarification that musculoskeletal ultrasounds will be 
centrally analyzed and results assessed by subject  over the 
course of the study. Full details can be found in the 
Musculoskeletal Ultrasound Manual. Section 6.2.2.7  
Removal of vendor information for v ector genome detection.  
Clarification of changes to the sampling schedule. Section 6.2.3.9  CSL Behring 
CCI
AMT -061 (AAV5 -hFIXco -Padua; etranacogene dezaparvovec)   
Protocol ID:  CT-AMT -061-02 
Version: 8.0 CONFIDENTIAL  Date:  07 Feb 2022  
Page 146 of 146 
Clarification that local laboratory results should be provided 
to the Investigator as soon as possible. Section 6.2.3.11  
The volume of blood to be drawn from each subject was 
updated due to the addition of the chromogenic assay for 
FIX activity.  
Current:  
• Approximately 2450 mL blood (excluding additional 
visits) total.  
• Maximum of 120 mL per visit and maximum of 110 mL 
per additional visit.  
• Approximately 2000 mL  between screening and the end 
of the post- treatment follow -up 
• Approximately 450 mL during the long- term follow -up. 
Previous:  • Approximately 2250 mL blood (excluding additional 
visits) total.  
• Maximum of 110 mL per visit and maximum of 100 mL 
per additional visit.  
• Approximately 1850 mL between screening and the end 
of the post- treatment follow -up 
• Approximately 400 mL during the long- term follow -up. Section 6.2.6  
 CSL Behring 
Version: 1.0
Signature Page 1 of 1
--- Do Not Detach This Signature Page ---
glbdctmp Print Date: 04-Mar-2022 11:40:34 GMT-05:00Signature Page
CT-AMT-061-02 - Protocol Amendment - AMD 7 CSP_V8_2022_02_07
Signed By Date (GMT)
Approved-Clinical Development Physician Approval 00:01:02
Approved-  Approval 16:23:02
Approved-  Approval 16:31:51
Approved-Clinical Safety Physician Approval 19:37:27
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD